<?xml version="1.0" encoding="UTF-8"?>
<?xml-stylesheet href="http://onlinelibrarystatic.wiley.com/xslt/wol-journal-rss.xsl"
            type="text/xsl"?><rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#"><channel rdf:about="http://onlinelibrary.wiley.com/rss/journal/10.1002/(ISSN)1097-0347" xmlns="http://purl.org/rss/1.0/"><title>Head &amp; Neck</title><description> Wiley Online Library : Head &amp; Neck</description><link>http://dx.doi.org/10.1002%2F%28ISSN%291097-0347</link><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc</dc:publisher><dc:language xmlns:dc="http://purl.org/dc/elements/1.1/">en</dc:language><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/">Copyright © 2012 Wiley Periodicals, Inc., A Wiley Company</dc:rights><prism:issn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1043-3074</prism:issn><prism:eIssn xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">1097-0347</prism:eIssn><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-03-01T00:00:00-05:00</dc:date><prism:coverDisplayDate xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">March 2012</prism:coverDisplayDate><prism:volume xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">34</prism:volume><prism:number xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">3</prism:number><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">305</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">458</prism:endingPage><image rdf:resource="http://onlinelibrary.wiley.com/store/10.1002/hed.v34.3/asset/cover.gif?v=1&amp;s=dadefb4abe7824a440274e3f6e227c258f1814f1"/><items><rdf:Seq><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21999"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22000"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22003"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22006"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22007"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22008"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22946"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22951"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22955"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22957"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22902"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22904"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22905"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22942"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22945"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21977"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22005"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22010"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22011"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22900"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21917"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22906"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22929"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21963"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21815"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22001"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22918"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22920"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22940"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22947"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22949"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22952"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22954"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22956"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22927"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22917"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22922"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22923"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21973"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21978"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21988"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21989"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21990"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21995"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22931"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22933"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22937"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22938"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22939"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22944"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22948"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21996"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22908"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22910"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22915"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22925"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21956"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21964"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21966"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21967"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21969"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21953"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21952"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21954"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21958"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21946"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21975"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21998"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22004"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22926"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22934"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22924"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22903"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22907"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22913"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22916"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22919"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22921"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21874"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21980"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21981"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21985"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22002"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22009"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22012"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22015"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21987"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21993"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21997"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22909"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22911"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21894"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21948"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21982"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21986"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21968"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21972"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21976"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21983"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21971"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21974"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21979"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22013"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21962"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21870"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21928"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21878"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21957"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21959"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21960"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21961"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21965"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21877"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21949"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21950"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.22016"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21784"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21859"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21868"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21880"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21890"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21905"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21930"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21933"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21920"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21916"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21914"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21912"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21911"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21944"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21942"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21938"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21935"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21927"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21886"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21889"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21892"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21893"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21895"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21896"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21876"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21879"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21881"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21882"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21884"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21897"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21915"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21931"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21932"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21934"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21941"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21936"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21945"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21853"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21857"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21888"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21937"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21860"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21939"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21867"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21923"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21943"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21910"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21929"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21940"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21887"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21869"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21864"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21852"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21847"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21898"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21899"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21909"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21918"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21922"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21947"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21866"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21913"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21926"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21872"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21891"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21885"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21906"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21924"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21849"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21861"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21862"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21783"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21848"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21854"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21925"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21858"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21883"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21846"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21844"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21863"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21842"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21833"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21826"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21819"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21865"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21856"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21836"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21831"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21830"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21829"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21828"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21824"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21823"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21821"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21817"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21816"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21814"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21752"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21850"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21822"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21825"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21835"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21843"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21791"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21801"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21813"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21820"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21767"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21839"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21855"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21851"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21834"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21832"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21818"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21810"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21808"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21773"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21811"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21812"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21809"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21806"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21805"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21804"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21802"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21807"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21803"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21797"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21793"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21789"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21780"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21779"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21796"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21795"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21790"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21787"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21785"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21777"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21794"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21792"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21781"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21776"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21782"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21778"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21763"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21757"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21772"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21765"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21764"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21751"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21759"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21771"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21760"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21755"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21770"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21769"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21768"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21758"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21766"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21762"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21761"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21739"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21722"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21731"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21712"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21724"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21690"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21677"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21674"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21651"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21575"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21568"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21626"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21608"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21735"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21725"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21723"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21736"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21732"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21734"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21733"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21744"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21743"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21742"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21741"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21740"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21738"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21737"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21746"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21745"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21754"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21753"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21706"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21705"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21538"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21562"/><rdf:li rdf:resource="http://dx.doi.org/10.1002%2Fhed.21837"/></rdf:Seq></items></channel><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21999" xmlns="http://purl.org/rss/1.0/"><title>Microsurgical reconstruction of composite scalp and calvarial defects in patients with cancer: A 10-year experience</title><link>http://dx.doi.org/10.1002%2Fhed.21999</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Microsurgical reconstruction of composite scalp and calvarial defects in patients with cancer: A 10-year experience</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Albert H. Chao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peirong Yu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roman J. Skoracki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Franco DeMonte</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthew M. Hanasono</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-13T05:08:49.208285-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21999</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21999</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21999</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>In scalp reconstruction, soft tissue and osseous defects frequently coexist. The purpose of this study was to compare outcomes of simultaneous scalp and calvarial reconstruction to scalp only reconstruction.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A review of microsurgical scalp reconstruction with or without cranioplasty over a 10-year period was performed.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>One hundred thirty-eight scalp reconstructions were performed, of which 48 involved concurrent cranioplasty. The overall rate of perioperative complications was 21.0%, whereas the rate of late recipient site complications was 11.6%. No significant differences in perioperative (<em>p</em> = .56) or late (<em>p</em> = .42) recipient site complications were observed between patients undergoing scalp and calvarial versus scalp only reconstruction. In terms of complications, muscle free flaps with skin grafts were as reliable as free flaps with skin paddles (<em>p</em> = .36).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Simultaneous scalp and calvarial reconstruction is associated with success rates equivalent to scalp only reconstruction. Muscle flaps covered with skin grafts and flaps with a skin paddle seem to be equally reliable. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundIn scalp reconstruction, soft tissue and osseous defects frequently coexist. The purpose of this study was to compare outcomes of simultaneous scalp and calvarial reconstruction to scalp only reconstruction.MethodsA review of microsurgical scalp reconstruction with or without cranioplasty over a 10-year period was performed.ResultsOne hundred thirty-eight scalp reconstructions were performed, of which 48 involved concurrent cranioplasty. The overall rate of perioperative complications was 21.0%, whereas the rate of late recipient site complications was 11.6%. No significant differences in perioperative (p = .56) or late (p = .42) recipient site complications were observed between patients undergoing scalp and calvarial versus scalp only reconstruction. In terms of complications, muscle free flaps with skin grafts were as reliable as free flaps with skin paddles (p = .36).ConclusionSimultaneous scalp and calvarial reconstruction is associated with success rates equivalent to scalp only reconstruction. Muscle flaps covered with skin grafts and flaps with a skin paddle seem to be equally reliable. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22000" xmlns="http://purl.org/rss/1.0/"><title>Medullary thyroid carcinoma and 2q37 deletion in a patient with nevoid basal cell carcinoma syndrome: Clinical description and genetic analysis</title><link>http://dx.doi.org/10.1002%2Fhed.22000</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Medullary thyroid carcinoma and 2q37 deletion in a patient with nevoid basal cell carcinoma syndrome: Clinical description and genetic analysis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrés Coca–Pelaz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jose Luis Llorente–Pendás</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jorge García–Martínez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Blanca Vivanco–Allende</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Milagros Balbín</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlos Suárez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mario Hermsen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-09T03:58:36.021837-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22000</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22000</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22000</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Nevoid basal cell carcinoma syndrome (NBCCS) is a rare, inheritable, multisystem disorder characterized by numerous basal cell carcinomas (BCCs), maxillary keratocyst, and musculoskeletal malformations. Occasionally, it is associated with malignancies like rhabdomyoma, melanoma, and sinonasal undifferentiated carcinoma, to name a few.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A patient presented with NBCCS with a medullary thyroid carcinoma. Clinical, surgical details, and germline genetic analysis are herein described.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>A 32-year-old woman was referred to our department with suspicion of medullary thyroid carcinoma, which was confirmed by histopathological examination. The patient was diagnosed as also having NBCCS. Germline mutation analysis indicated wild-type genes <em>PTCH1</em> and <em>RET</em>. DNA copy number analysis by high resolution microarray comparative genomic hybridization (CGH) revealed a small interstitial loss at chromosomal band 2q37.3.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>To our knowledge, this is the first described patient with NBCCS carrying a medullary thyroid carcinoma and a 2q37 deletion, which confirms that this syndrome can be associated with many different malignancies. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundNevoid basal cell carcinoma syndrome (NBCCS) is a rare, inheritable, multisystem disorder characterized by numerous basal cell carcinomas (BCCs), maxillary keratocyst, and musculoskeletal malformations. Occasionally, it is associated with malignancies like rhabdomyoma, melanoma, and sinonasal undifferentiated carcinoma, to name a few.MethodsA patient presented with NBCCS with a medullary thyroid carcinoma. Clinical, surgical details, and germline genetic analysis are herein described.ResultsA 32-year-old woman was referred to our department with suspicion of medullary thyroid carcinoma, which was confirmed by histopathological examination. The patient was diagnosed as also having NBCCS. Germline mutation analysis indicated wild-type genes PTCH1 and RET. DNA copy number analysis by high resolution microarray comparative genomic hybridization (CGH) revealed a small interstitial loss at chromosomal band 2q37.3.ConclusionTo our knowledge, this is the first described patient with NBCCS carrying a medullary thyroid carcinoma and a 2q37 deletion, which confirms that this syndrome can be associated with many different malignancies. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22003" xmlns="http://purl.org/rss/1.0/"><title>Voice outcomes after concurrent chemoradiotherapy for advanced nonlaryngeal head and neck cancer: A prospective study</title><link>http://dx.doi.org/10.1002%2Fhed.22003</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Voice outcomes after concurrent chemoradiotherapy for advanced nonlaryngeal head and neck cancer: A prospective study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vinidh Paleri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paul Carding</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sanjoy Chatterjee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Charles Kelly</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Janet Ann Wilson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrew Welch</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Drinnan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-09T03:58:22.93718-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22003</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22003</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22003</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The voice impact of treatment for nonlaryngeal head and neck primary sites remains unknown.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We conducted a prospective study of a consecutive sample of patients undergoing chemoradiation for nonlaryngeal head and neck cancer. The Voice Symptom Scale (VoiSS) was completed, and voice recordings were made at 3 time-points.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Of 42 recruited patients, 34 completed the measures before and in the early posttreatment phase (mean 16.5 weeks), while 21 patients were assessed at the final time-point (mean, 20.4 months). VoiSS scores showed statistically significant progressive deterioration in the total score (<em>p</em> = .02) and impairment subscale (<em>p</em> &lt; .0001) through to the final assessment. Acoustic measures and perceptual ratings deteriorated significantly (<em>p</em> &lt; .001) in the early posttreatment weeks and improved at the final assessment, but not to the baseline. Interrater agreement was excellent for expert measures.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>To the best of our knowledge, this is the first prospective study to show that chemoradiation therapy for nonlaryngeal head and neck cancer has a significant effect on the patients' self-reported voice quality, even in the long term. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe voice impact of treatment for nonlaryngeal head and neck primary sites remains unknown.MethodsWe conducted a prospective study of a consecutive sample of patients undergoing chemoradiation for nonlaryngeal head and neck cancer. The Voice Symptom Scale (VoiSS) was completed, and voice recordings were made at 3 time-points.ResultsOf 42 recruited patients, 34 completed the measures before and in the early posttreatment phase (mean 16.5 weeks), while 21 patients were assessed at the final time-point (mean, 20.4 months). VoiSS scores showed statistically significant progressive deterioration in the total score (p = .02) and impairment subscale (p &lt; .0001) through to the final assessment. Acoustic measures and perceptual ratings deteriorated significantly (p &lt; .001) in the early posttreatment weeks and improved at the final assessment, but not to the baseline. Interrater agreement was excellent for expert measures.ConclusionTo the best of our knowledge, this is the first prospective study to show that chemoradiation therapy for nonlaryngeal head and neck cancer has a significant effect on the patients' self-reported voice quality, even in the long term. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22006" xmlns="http://purl.org/rss/1.0/"><title>Second primary lung cancer after head and neck squamous cell cancer: Population-based study of risk factors</title><link>http://dx.doi.org/10.1002%2Fhed.22006</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Second primary lung cancer after head and neck squamous cell cancer: Population-based study of risk factors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael T. Milano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carl R. Peterson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hong Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Deepinder P. Singh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuhchyau Chen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-09T03:58:09.551874-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22006</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22006</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22006</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Patients with head and neck squamous cell cancer (HNSCC) are at risk of developing second primary lung cancer (SPLC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Among 61,883 patients with HNSCC from the Surveillance, Epidemiology and End Results (SEER) database, 4522 developed SPLC (any histology) ≥2 months after HNSCC. We correlated risk with demographic and tumor-related parameters.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The risk of SPLC after HNSCC was 5.8%, 11.4%, and 16.4% at 5, 10, and 15 years, respectively. From Cox regression, significantly adverse (<em>p</em> &lt; .0001) risk factors for SPLC included: regional versus localized HNSCC stage (hazard ratio [HR] = 1.16), hypopharyngeal or supraglottic laryngeal site (HR = 1.57), increased age (HR = 1.26/decade), black race (HR = 1.27), and male sex (HR = 1.26). Glottic (HR = 0.75) and tonsillar or oral cavity sites (HR = 0.80) were associated with significantly (<em>p</em> &lt; .0001) lower risks of SPLC.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>From population-based actuarial analyses, HNSCCs with more aggressive clinicopathologic features were more apt to develop SPLC, suggestive of similar environmental and/or host factors for these cancers. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundPatients with head and neck squamous cell cancer (HNSCC) are at risk of developing second primary lung cancer (SPLC).MethodsAmong 61,883 patients with HNSCC from the Surveillance, Epidemiology and End Results (SEER) database, 4522 developed SPLC (any histology) ≥2 months after HNSCC. We correlated risk with demographic and tumor-related parameters.ResultsThe risk of SPLC after HNSCC was 5.8%, 11.4%, and 16.4% at 5, 10, and 15 years, respectively. From Cox regression, significantly adverse (p &lt; .0001) risk factors for SPLC included: regional versus localized HNSCC stage (hazard ratio [HR] = 1.16), hypopharyngeal or supraglottic laryngeal site (HR = 1.57), increased age (HR = 1.26/decade), black race (HR = 1.27), and male sex (HR = 1.26). Glottic (HR = 0.75) and tonsillar or oral cavity sites (HR = 0.80) were associated with significantly (p &lt; .0001) lower risks of SPLC.ConclusionFrom population-based actuarial analyses, HNSCCs with more aggressive clinicopathologic features were more apt to develop SPLC, suggestive of similar environmental and/or host factors for these cancers. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22007" xmlns="http://purl.org/rss/1.0/"><title>Measurement of epithelial thickness within the oral cavity using optical coherence tomography</title><link>http://dx.doi.org/10.1002%2Fhed.22007</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Measurement of epithelial thickness within the oral cavity using optical coherence tomography</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sven Prestin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sacha I. Rothschild</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christian Stephan Betz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcel Kraft</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-09T03:57:58.058983-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22007</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22007</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22007</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of the present study was to determine normal values of epithelial thickness within the oral cavity by using optical coherence tomography (OCT).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>In a total of 143 healthy test persons, epithelial thickness of the oral mucosa was determined with the help of OCT separately for each side at 7 different locations. Special attention was directed to those sites having the highest incidence for the development of dysplasias and carcinomas.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The epithelium demonstrated a varying thickness depending on its location within the oral cavity. The highest values were found in the region of the buccal mucosa (294 μm) and the hard palate (239 μm), whereas the thinnest epithelium was measured at the floor of the mouth (99 μm).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Our data serve as reference values for detecting oral malignancy and determining the approximate grade of dysplasia. In this circumstance, a differentiated view of the different regions is important due to a variation in thickness of the epithelium within the oral cavity. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of the present study was to determine normal values of epithelial thickness within the oral cavity by using optical coherence tomography (OCT).MethodsIn a total of 143 healthy test persons, epithelial thickness of the oral mucosa was determined with the help of OCT separately for each side at 7 different locations. Special attention was directed to those sites having the highest incidence for the development of dysplasias and carcinomas.ResultsThe epithelium demonstrated a varying thickness depending on its location within the oral cavity. The highest values were found in the region of the buccal mucosa (294 μm) and the hard palate (239 μm), whereas the thinnest epithelium was measured at the floor of the mouth (99 μm).ConclusionOur data serve as reference values for detecting oral malignancy and determining the approximate grade of dysplasia. In this circumstance, a differentiated view of the different regions is important due to a variation in thickness of the epithelium within the oral cavity. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22008" xmlns="http://purl.org/rss/1.0/"><title>Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.22008</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pretreatment levels of peripheral neutrophils and lymphocytes as independent prognostic factors in patients with nasopharyngeal carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jian-Rong He</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guo-Ping Shen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ze-Fang Ren</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Han Qin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cui Cui</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ying Zhang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi-Xin Zeng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wei-Hua Jia</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-09T03:57:47.316301-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22008</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22008</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22008</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to evaluate the counts and percentages of differential leukocytes as prognostic indicators in patients with nasopharyngeal carcinoma (NPC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This study consisted of 1410 cases identified from an established prospective cohort of 1533 patients with NPC between October 2005 and October 2007 in the Sun Yat–Sen University Cancer Center. Multivariate Cox proportional hazards analyses were applied.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>A high percentage of lymphocyte was significantly associated with a favorable prognosis of NPC (highest vs lowest quartile, hazard ratio [HR], 95% confidence interval [CI] for overall and progression-free survival, HR, 0.71; 95% CI, 0.48–1.06; HR, 0.61; 95% CI, 0.43–0.86, respectively), whereas a high neutrophil percentage (HR, 1.62; 95% CI, 1.06–2.46; HR, 1.55; 95% CI, 1.10–2.18, respectively), and a neutrophil/lymphocyte ratio (NLR; HR, 1.57; 95% CI, 1.04–2.39; HR, 1.68; 95% CI, 1.19–2.38, respectively), were significantly related to a poor prognosis of NPC.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Pretreatment NLR and percentages of lymphocyte and neutrophil are independent prognostic factors and may serve as clinically convenient and useful biomarkers for survival of patients with NPC. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to evaluate the counts and percentages of differential leukocytes as prognostic indicators in patients with nasopharyngeal carcinoma (NPC).MethodsThis study consisted of 1410 cases identified from an established prospective cohort of 1533 patients with NPC between October 2005 and October 2007 in the Sun Yat–Sen University Cancer Center. Multivariate Cox proportional hazards analyses were applied.ResultsA high percentage of lymphocyte was significantly associated with a favorable prognosis of NPC (highest vs lowest quartile, hazard ratio [HR], 95% confidence interval [CI] for overall and progression-free survival, HR, 0.71; 95% CI, 0.48–1.06; HR, 0.61; 95% CI, 0.43–0.86, respectively), whereas a high neutrophil percentage (HR, 1.62; 95% CI, 1.06–2.46; HR, 1.55; 95% CI, 1.10–2.18, respectively), and a neutrophil/lymphocyte ratio (NLR; HR, 1.57; 95% CI, 1.04–2.39; HR, 1.68; 95% CI, 1.19–2.38, respectively), were significantly related to a poor prognosis of NPC.ConclusionPretreatment NLR and percentages of lymphocyte and neutrophil are independent prognostic factors and may serve as clinically convenient and useful biomarkers for survival of patients with NPC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22946" xmlns="http://purl.org/rss/1.0/"><title>Voice and swallowing after partial laryngectomy: Factors influencing outcome</title><link>http://dx.doi.org/10.1002%2Fhed.22946</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Voice and swallowing after partial laryngectomy: Factors influencing outcome</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matteo Alicandri–Ciufelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessia Piccinini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alberto Grammatica</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrea Chiesi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Bergamini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Pia Luppi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Federica Nizzoli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Angelo Ghidini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sauro Tassi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Livio Presutti</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T02:24:59.782346-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22946</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22946</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22946</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to assess the factors influencing swallowing and phonatory results after partial laryngectomy.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We carried out a medical chart review of patients who underwent partial laryngectomies between June 2003 and November 2010, focusing on functional outcomes.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Thirty-two patients were enrolled. No statistically significant difference was found in the comparison of phonatory outcomes of patients with preservation of both arytenoids; the results of the Yanagihara classification were significantly different (<em>p</em> = .015) in patients with an atypical neoglottis; radiotherapy statistically significantly influenced only the mean fundamental frequency (<em>p</em> = .035). The type of partial laryngectomy does not seem to affect the deglutition results; radiotherapy statistically significantly affected the dysphagia score (DS; <em>p</em> = .03), penetration aspiration (<em>p</em> = .02), and MD Anderson Dysphagia Inventory (MDADI; <em>p</em> = .02).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Horizontal supraglottic laryngectomy and supracricoid partial laryngectomy give the same swallowing results. The presence of both arytenoids does not influence the final outcome compared to patients in whom only 1 arytenoid is preserved. Postoperative radiotherapy only influences the swallowing function. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to assess the factors influencing swallowing and phonatory results after partial laryngectomy.MethodsWe carried out a medical chart review of patients who underwent partial laryngectomies between June 2003 and November 2010, focusing on functional outcomes.ResultsThirty-two patients were enrolled. No statistically significant difference was found in the comparison of phonatory outcomes of patients with preservation of both arytenoids; the results of the Yanagihara classification were significantly different (p = .015) in patients with an atypical neoglottis; radiotherapy statistically significantly influenced only the mean fundamental frequency (p = .035). The type of partial laryngectomy does not seem to affect the deglutition results; radiotherapy statistically significantly affected the dysphagia score (DS; p = .03), penetration aspiration (p = .02), and MD Anderson Dysphagia Inventory (MDADI; p = .02).ConclusionHorizontal supraglottic laryngectomy and supracricoid partial laryngectomy give the same swallowing results. The presence of both arytenoids does not influence the final outcome compared to patients in whom only 1 arytenoid is preserved. Postoperative radiotherapy only influences the swallowing function. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22951" xmlns="http://purl.org/rss/1.0/"><title>Stage grouping in tumors of the ethmoid sinuses and the nasal cavity using the sixth edition of the UICC classification of malignant tumors</title><link>http://dx.doi.org/10.1002%2Fhed.22951</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Stage grouping in tumors of the ethmoid sinuses and the nasal cavity using the sixth edition of the UICC classification of malignant tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthias Kreppel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin Scheer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dirk Beutner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Uta Drebber</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert Semrau</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joachim E. Zöller</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Orlando Guntinas–Lichius</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:31:18.055103-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22951</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22951</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22951</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to evaluate the prognostic impact of the sixth edition of the Union Internationale Contre le Cancer (UICC) classification and different TNM-based stage groupings for malignant tumors of the ethmoid sinuses and the nasal cavity.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We conducted a retrospective analysis of 98 patients with malignant tumors of the ethmoid sinuses and the nasal cavity between 1967 and 2003. The UICC classification of the sixth edition and the T and N Integer Score (TANIS) and Hart were tested for their prognostic significance.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>In univariate analysis, all stage groupings revealed discriminatory power for overall survival (OS; <em>p</em> &lt; .05), however, in multivariate analysis only the UICC-stage grouping (<em>p</em> = .033) and the TANIS-8 scheme (<em>p</em> = .044) predicted OS. The TANIS did not have a better prognostic quality than the sixth edition of the UICC classification.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The UICC-stage grouping of the sixth edition is a good prognostic index for malignant tumors of the ethmoid sinuses and the nasal cavity. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to evaluate the prognostic impact of the sixth edition of the Union Internationale Contre le Cancer (UICC) classification and different TNM-based stage groupings for malignant tumors of the ethmoid sinuses and the nasal cavity.MethodsWe conducted a retrospective analysis of 98 patients with malignant tumors of the ethmoid sinuses and the nasal cavity between 1967 and 2003. The UICC classification of the sixth edition and the T and N Integer Score (TANIS) and Hart were tested for their prognostic significance.ResultsIn univariate analysis, all stage groupings revealed discriminatory power for overall survival (OS; p &lt; .05), however, in multivariate analysis only the UICC-stage grouping (p = .033) and the TANIS-8 scheme (p = .044) predicted OS. The TANIS did not have a better prognostic quality than the sixth edition of the UICC classification.ConclusionThe UICC-stage grouping of the sixth edition is a good prognostic index for malignant tumors of the ethmoid sinuses and the nasal cavity. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22955" xmlns="http://purl.org/rss/1.0/"><title>Primary neuroendocrine neoplasms of the larynx. A series of 4 cases reported and a review of the literature</title><link>http://dx.doi.org/10.1002%2Fhed.22955</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Primary neuroendocrine neoplasms of the larynx. A series of 4 cases reported and a review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nikolaos Angouridakis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John Goudakos</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Georgia Karayannopoulou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefanos Triaridis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Angelos Nikolaou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Konstantinos Markou</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:31:09.991324-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22955</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22955</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22955</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Neuroendocrine tumors are rare neoplasms arising from neural and epithelial origin.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>The case records of 4 patients with the diagnosis of neuroendocrine laryngeal tumor were retrospectively reviewed. In this analysis of our medical records, we describe a series of 4 men with neuroendocrine laryngeal tumors treated in our department since 1994, including the first extremely aggressive and lethal laryngeal paraganglioma reported in the English-language literature. We also discuss the classification, the macro and microscopical characteristics, clinical and pathologic findings, and treatment of these neoplasms.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Although neuroendocrine laryngeal tumors account for approximately 1% of all neoplasms in the larynx, its majority represents very aggressive tumors showing a capacity for metastasis and portending poor outcome. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundNeuroendocrine tumors are rare neoplasms arising from neural and epithelial origin.Methods and ResultsThe case records of 4 patients with the diagnosis of neuroendocrine laryngeal tumor were retrospectively reviewed. In this analysis of our medical records, we describe a series of 4 men with neuroendocrine laryngeal tumors treated in our department since 1994, including the first extremely aggressive and lethal laryngeal paraganglioma reported in the English-language literature. We also discuss the classification, the macro and microscopical characteristics, clinical and pathologic findings, and treatment of these neoplasms.ConclusionAlthough neuroendocrine laryngeal tumors account for approximately 1% of all neoplasms in the larynx, its majority represents very aggressive tumors showing a capacity for metastasis and portending poor outcome. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22957" xmlns="http://purl.org/rss/1.0/"><title>Management of the neck and regional recurrence in squamous cell carcinoma of the maxillary alveolus and hard palate compared with other sites in the oral cavity</title><link>http://dx.doi.org/10.1002%2Fhed.22957</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Management of the neck and regional recurrence in squamous cell carcinoma of the maxillary alveolus and hard palate compared with other sites in the oral cavity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James S. Brown</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fazilet Bekiroglu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard J. Shaw</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia A. Woolgar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simon N. Rogers</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:30:55.926749-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22957</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22957</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22957</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The aim of this article was to assess the management of the neck and regional recurrence for squamous cell carcinoma of the maxillary alveolus and hard palate (<em>n</em> = 43) and compare that to the rest of the oral cancer sites (<em>n</em> = 465).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This is a retrospective report through database and case note review.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The incidence of nodal metastases (pathologic node–positive necks added to regional recurrence for clinical N0 and pathologic N0) was 37% (16/43) for maxillary alveolus and hard palate compared with 40% (187/465) for the oral cavity in general. Regional recurrence occurred in 26% (11/43) in the maxillary alveolus and hard palate compared with 7% (31/465) in the remaining oral cavity sites (<em>p</em> = .001).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Squamous cell carcinoma arising in the maxillary alveolus and hard palate has a similar risk of regional metastasis as the rest of the oral cavity, and a lower propensity for selective neck dissection is resulting in higher regional recurrence and lower survival rates. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe aim of this article was to assess the management of the neck and regional recurrence for squamous cell carcinoma of the maxillary alveolus and hard palate (n = 43) and compare that to the rest of the oral cancer sites (n = 465).MethodsThis is a retrospective report through database and case note review.ResultsThe incidence of nodal metastases (pathologic node–positive necks added to regional recurrence for clinical N0 and pathologic N0) was 37% (16/43) for maxillary alveolus and hard palate compared with 40% (187/465) for the oral cavity in general. Regional recurrence occurred in 26% (11/43) in the maxillary alveolus and hard palate compared with 7% (31/465) in the remaining oral cavity sites (p = .001).ConclusionsSquamous cell carcinoma arising in the maxillary alveolus and hard palate has a similar risk of regional metastasis as the rest of the oral cavity, and a lower propensity for selective neck dissection is resulting in higher regional recurrence and lower survival rates. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22902" xmlns="http://purl.org/rss/1.0/"><title>Proposal of landmarks for clamping neurovascular elements during endoscopic surgery of the supraglottic region</title><link>http://dx.doi.org/10.1002%2Fhed.22902</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Proposal of landmarks for clamping neurovascular elements during endoscopic surgery of the supraglottic region</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">R. Souvirón</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">E. Maranillo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">T. Vázquez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">N. Patel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. McHanwell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">I. Cobeta</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">B. Scola</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">J. Sañudo</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:30:34.699964-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22902</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22902</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22902</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Bleeding within the supraglottic region can be a lethal complication after CO<sub>2</sub> laser microsurgery. Our aim was to propose endoluminal anatomical landmarks to locate the superior laryngeal vessels resulting in a safer microsurgery.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Endoluminal dissections were made in 22 larynges without laryngeal disease.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The neurovascular structures were in the superior third of a triangle defined by the vocal process, the anterior commissure, and the epiglottic attachment of the aryepiglottic fold. They overlapped in 4 different ways: pattern I (70.4%): superior laryngeal vein (SLV), superior laryngeal artery (SLA), and internal laryngeal nerve (ILN); pattern II (13.6%): SLA, SLV, ILN; pattern III (4.6%): SLV, ILN, and SLA; pattern IV (4.6%): SLA, ILN, and SLV.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Microsurgery in the supraglottic region may be safer if surgeons are aware of the superior third of the above-defined triangle, “danger area”, where the vascular elements of this region are located. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundBleeding within the supraglottic region can be a lethal complication after CO2 laser microsurgery. Our aim was to propose endoluminal anatomical landmarks to locate the superior laryngeal vessels resulting in a safer microsurgery.MethodsEndoluminal dissections were made in 22 larynges without laryngeal disease.ResultsThe neurovascular structures were in the superior third of a triangle defined by the vocal process, the anterior commissure, and the epiglottic attachment of the aryepiglottic fold. They overlapped in 4 different ways: pattern I (70.4%): superior laryngeal vein (SLV), superior laryngeal artery (SLA), and internal laryngeal nerve (ILN); pattern II (13.6%): SLA, SLV, ILN; pattern III (4.6%): SLV, ILN, and SLA; pattern IV (4.6%): SLA, ILN, and SLV.ConclusionMicrosurgery in the supraglottic region may be safer if surgeons are aware of the superior third of the above-defined triangle, “danger area”, where the vascular elements of this region are located. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22904" xmlns="http://purl.org/rss/1.0/"><title>Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volume-based metabolic parameters</title><link>http://dx.doi.org/10.1002%2Fhed.22904</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prognostic value of 18F-FDG PET/CT in patients with squamous cell carcinoma of the tonsil: Comparisons of volume-based metabolic parameters</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Seung Hwan Moon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joon Young Choi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hwan Joo Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Young-Ik Son</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chung-Hwan Baek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yong Chan Ahn</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Keunchil Park</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kyung-Han Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Byung-Tae Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:30:01.193669-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22904</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22904</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22904</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The prognostic significance of volume-based metabolic parameters measured by <sup>18</sup>F-fluorodeoxyglucose positron emission tomography/CT (<sup>18</sup>F-FDG PET/CT) is not established. We evaluated the prognostic value of metabolic parameters in patients with squamous cell carcinoma (SCC) of the tonsil.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We enrolled a total of 69 patients with SCC of the tonsil who underwent pretreatment <sup>18</sup>F-FDG PET/CT. We measured maximum standardized uptake value (SUV<sub>max</sub>), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and asymmetry indices (of SUV<sub>max</sub>, MTV, and TLG). The prognostic significance of these parameters and clinical variables was assessed by Cox proportional hazards regression analysis.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Multivariate analyses with adjustments for age, sex, and American Joint Committee on Cancer stage showed that only TLG (hazard ratio = 1.020, 95% confidence interval 1.003–1.037, <em>p</em> = .023) was an independent predictive factor associated with decreased overall survival.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>TLG is a significant independent metabolic prognostic factor for overall survival in patients with SCC of the tonsil. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe prognostic significance of volume-based metabolic parameters measured by 18F-fluorodeoxyglucose positron emission tomography/CT (18F-FDG PET/CT) is not established. We evaluated the prognostic value of metabolic parameters in patients with squamous cell carcinoma (SCC) of the tonsil.MethodsWe enrolled a total of 69 patients with SCC of the tonsil who underwent pretreatment 18F-FDG PET/CT. We measured maximum standardized uptake value (SUVmax), metabolic tumor volume (MTV), total lesion glycolysis (TLG), and asymmetry indices (of SUVmax, MTV, and TLG). The prognostic significance of these parameters and clinical variables was assessed by Cox proportional hazards regression analysis.ResultsMultivariate analyses with adjustments for age, sex, and American Joint Committee on Cancer stage showed that only TLG (hazard ratio = 1.020, 95% confidence interval 1.003–1.037, p = .023) was an independent predictive factor associated with decreased overall survival.ConclusionTLG is a significant independent metabolic prognostic factor for overall survival in patients with SCC of the tonsil. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22905" xmlns="http://purl.org/rss/1.0/"><title>Lipoleiomyosarcoma of the larynx</title><link>http://dx.doi.org/10.1002%2Fhed.22905</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Lipoleiomyosarcoma of the larynx</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">J. P. Trijolet</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">E. Lescanne</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. Morinière</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">A. Robier</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">D. Bakhos</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:29:43.22848-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22905</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22905</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22905</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Lipoleiomyosarcoma is a rare tumor consisting of well-differentiated liposarcoma and leiomyosarcoma. The ear–nose–throat location of lipoleiomyosarcoma has not been previously described.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>A 37-year-old man with a dysphagia had a dyspnea after an endoscopy. A large tumor was exteriorized from the man's mouth. The lesion was pedicled to the epiglottis. A histologic examination determined that the tumor was a lipoleiomyosarcoma. MDM2 and CDK4 gene amplification were positive. Due to the risk of recurrence, a second intervention was performed to complete the excision.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>These tumors develop in cavities slowly and gradually. The treatment of this lesion is surgical with a sufficient resection margin. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundLipoleiomyosarcoma is a rare tumor consisting of well-differentiated liposarcoma and leiomyosarcoma. The ear–nose–throat location of lipoleiomyosarcoma has not been previously described.Methods and ResultsA 37-year-old man with a dysphagia had a dyspnea after an endoscopy. A large tumor was exteriorized from the man's mouth. The lesion was pedicled to the epiglottis. A histologic examination determined that the tumor was a lipoleiomyosarcoma. MDM2 and CDK4 gene amplification were positive. Due to the risk of recurrence, a second intervention was performed to complete the excision.ConclusionThese tumors develop in cavities slowly and gradually. The treatment of this lesion is surgical with a sufficient resection margin. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22942" xmlns="http://purl.org/rss/1.0/"><title>Significant overexpression of the Merkel cell polyomavirus (MCPyV) large T antigen in Merkel cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.22942</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Significant overexpression of the Merkel cell polyomavirus (MCPyV) large T antigen in Merkel cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Boban M. Erovic</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ayman Al Habeeb</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luke Harris</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David P. Goldstein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Danny Ghazarian</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan C. Irish</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:29:29.296186-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22942</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22942</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22942</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to determine the expression pattern of the Merkel cell polyomavirus (MCPyV) large T-protein antigen in patients with Merkel cell carcinoma.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A tissue microarray (TMA) containing 30 specimens was constructed and stained for the MCPyV large T protein. Immunohistochemical expression was determined semiquantitively and was compared to patients' outcome.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Nuclear expression of MCPyV large T protein was detected in 29 of 30 specimens (97%). In particular, 60% to 100%, 30% to 60%, and 10% to 30% of tumor cells were positive in 27 specimens (90%), 1 (3%), and 1 (3%), respectively. There was no difference in positivity between primary and metastatic lesions. Clinical data could not be correlated to MCPyV large T-protein expression.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>MCPyV large T protein was significantly overexpressed in 97% of all specimens. Although we could not demonstrate a predictive effect, MCPyV large T protein may represent a molecular marker with utility in pathological diagnosis as well as a potential new therapeutic target in patients with Merkel cell carcinoma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to determine the expression pattern of the Merkel cell polyomavirus (MCPyV) large T-protein antigen in patients with Merkel cell carcinoma.MethodsA tissue microarray (TMA) containing 30 specimens was constructed and stained for the MCPyV large T protein. Immunohistochemical expression was determined semiquantitively and was compared to patients' outcome.ResultsNuclear expression of MCPyV large T protein was detected in 29 of 30 specimens (97%). In particular, 60% to 100%, 30% to 60%, and 10% to 30% of tumor cells were positive in 27 specimens (90%), 1 (3%), and 1 (3%), respectively. There was no difference in positivity between primary and metastatic lesions. Clinical data could not be correlated to MCPyV large T-protein expression.ConclusionMCPyV large T protein was significantly overexpressed in 97% of all specimens. Although we could not demonstrate a predictive effect, MCPyV large T protein may represent a molecular marker with utility in pathological diagnosis as well as a potential new therapeutic target in patients with Merkel cell carcinoma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22945" xmlns="http://purl.org/rss/1.0/"><title>Ethmoid sinus osteoma: Diagnosis and management</title><link>http://dx.doi.org/10.1002%2Fhed.22945</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ethmoid sinus osteoma: Diagnosis and management</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yoann Pons</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jean–Philippe Blancal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benjamin Vérillaud</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elisabeth Sauvaget</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elsa Ukkola–Pons</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Romain Kania</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philippe Herman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:28:57.51775-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22945</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22945</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22945</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Ethmoid sinus osteomas are uncommon, benign, osteogenic tumors. The purpose of this retrospective study was to describe their usual clinical presentation and to discuss their surgical management.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>The medical records of 25 patients treated for ethmoid osteoma between March 2001 and December 2010 were retrospectively reviewed.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The average tumor size was 18.5 ± 14 mm. Only 3 patients were asymptomatic, 14 had a history of frontal sinusitis (complicated with orbital cellulitis in 4 cases), and 4 patients presented with diplopia. An endoscopic approach was performed in 19 cases, a coronal approach in 4 cases, and a combined approach (endoscopic + coronal) in 2 cases. No recurrence was reported.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Ethmoid sinus osteoma can be asymptomatic and detected incidentally on CT scans, but often causes frontal sinusitis and orbital complications. The endoscopic approach offers the possibility of safe removal with cosmetic advantages compared to coronal approach. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundEthmoid sinus osteomas are uncommon, benign, osteogenic tumors. The purpose of this retrospective study was to describe their usual clinical presentation and to discuss their surgical management.MethodsThe medical records of 25 patients treated for ethmoid osteoma between March 2001 and December 2010 were retrospectively reviewed.ResultsThe average tumor size was 18.5 ± 14 mm. Only 3 patients were asymptomatic, 14 had a history of frontal sinusitis (complicated with orbital cellulitis in 4 cases), and 4 patients presented with diplopia. An endoscopic approach was performed in 19 cases, a coronal approach in 4 cases, and a combined approach (endoscopic + coronal) in 2 cases. No recurrence was reported.ConclusionEthmoid sinus osteoma can be asymptomatic and detected incidentally on CT scans, but often causes frontal sinusitis and orbital complications. The endoscopic approach offers the possibility of safe removal with cosmetic advantages compared to coronal approach. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21977" xmlns="http://purl.org/rss/1.0/"><title>Second, third, and fourth head and neck tumors. A progressive decrease in survival</title><link>http://dx.doi.org/10.1002%2Fhed.21977</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Second, third, and fourth head and neck tumors. A progressive decrease in survival</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xavier León</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vicenç Martínez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Montserrat López</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jacinto García</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">María del Prado Venegas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eduard Esteller</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miquel Quer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:28:42.163102-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21977</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21977</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21977</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Patients with a first head and neck carcinoma have a high risk of successive neoplasms, many of which appear again in the head and neck. Second head and neck tumors have a poorer prognosis than first tumors, but data about the prognosis of third and fourth tumors in the head and neck are lacking.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We carried out a retrospective study of 4298 patients with a primary head and neck carcinoma. Survival and the characteristics of the first tumor, second tumor, and any successive tumors in the head and neck were analyzed.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Second and successive tumors showed a tendency to appear more frequently in the oral cavity and oropharynx and had a lower stage than that of index tumors. Five-year survival rates after a first, second, third, and fourth tumors in the head and neck were 67.6%, 56.1%, 45.0%, and 32.1%, respectively.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Survival decreased progressively with every new head and neck tumor. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundPatients with a first head and neck carcinoma have a high risk of successive neoplasms, many of which appear again in the head and neck. Second head and neck tumors have a poorer prognosis than first tumors, but data about the prognosis of third and fourth tumors in the head and neck are lacking.MethodsWe carried out a retrospective study of 4298 patients with a primary head and neck carcinoma. Survival and the characteristics of the first tumor, second tumor, and any successive tumors in the head and neck were analyzed.ResultsSecond and successive tumors showed a tendency to appear more frequently in the oral cavity and oropharynx and had a lower stage than that of index tumors. Five-year survival rates after a first, second, third, and fourth tumors in the head and neck were 67.6%, 56.1%, 45.0%, and 32.1%, respectively.ConclusionSurvival decreased progressively with every new head and neck tumor. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22005" xmlns="http://purl.org/rss/1.0/"><title>Parapharyngeal space tumors: Another consideration for otalgia and temporomandibular disorders</title><link>http://dx.doi.org/10.1002%2Fhed.22005</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Parapharyngeal space tumors: Another consideration for otalgia and temporomandibular disorders</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Courtney C. Grosskopf</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arthur S. Kuperstein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bert W. O'Malley</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas P. Sollecito</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:28:29.683482-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22005</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22005</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22005</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Parapharyngeal space (PPS) tumors are rare, accounting for 0.5% of all head and neck neoplasms. PPS tumors are difficult to diagnose due to limited presenting signs and symptoms and because of their location deep within the neck.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>A 60-year-old woman presented with complaints of otalgia, which appeared to be consistent with a temporomandibular disorder (TMD). Due to disproportionate symptoms, an MRI of the temporomandibular joints was ordered. The MRI revealed a mass within the PPS, which was later diagnosed as a mucoepidermoid carcinoma. A literature search failed to reveal otalgia, and facial pain, thought to be related to a TMD, as the primary presenting symptoms of a PPS neoplasm.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Patients presenting with disproportionate signs and symptoms of a TMD should be evaluated with advanced imaging to rule out occult pathology. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundParapharyngeal space (PPS) tumors are rare, accounting for 0.5% of all head and neck neoplasms. PPS tumors are difficult to diagnose due to limited presenting signs and symptoms and because of their location deep within the neck.Methods and ResultsA 60-year-old woman presented with complaints of otalgia, which appeared to be consistent with a temporomandibular disorder (TMD). Due to disproportionate symptoms, an MRI of the temporomandibular joints was ordered. The MRI revealed a mass within the PPS, which was later diagnosed as a mucoepidermoid carcinoma. A literature search failed to reveal otalgia, and facial pain, thought to be related to a TMD, as the primary presenting symptoms of a PPS neoplasm.ConclusionPatients presenting with disproportionate signs and symptoms of a TMD should be evaluated with advanced imaging to rule out occult pathology. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22010" xmlns="http://purl.org/rss/1.0/"><title>Serial suture ligation glossectomy for squamous cell carcinoma in the setting of a massive lymphovascular malformation</title><link>http://dx.doi.org/10.1002%2Fhed.22010</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Serial suture ligation glossectomy for squamous cell carcinoma in the setting of a massive lymphovascular malformation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wade Chien</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Harrison W. Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel G. Deschler</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:28:15.660023-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22010</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22010</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22010</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>We describe a novel surgical technique for resection of squamous cell carcinoma in the setting of a massive tongue lymphovascular malformation (LVM).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>A 75-year-old man with a history of long-standing massive LVM of the tongue presented with a 4-cm squamous cell carcinoma of the involved oral tongue. Given the aberrant vascular anatomy of this lesion, traditional surgical treatment could not be undertaken. Therefore, serial suture ligation was performed over a 2-week period, allowing complete excision of the squamous cell carcinoma and a large portion of the tongue LVM with minimal morbidity. Return to preoperative functional status was likewise achieved.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Serial suture ligation glossectomy is a simple and effective technique for treating the uncommon case of squamous cell carcinoma of the tongue in the setting of a massive LVM. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundWe describe a novel surgical technique for resection of squamous cell carcinoma in the setting of a massive tongue lymphovascular malformation (LVM).Methods and ResultsA 75-year-old man with a history of long-standing massive LVM of the tongue presented with a 4-cm squamous cell carcinoma of the involved oral tongue. Given the aberrant vascular anatomy of this lesion, traditional surgical treatment could not be undertaken. Therefore, serial suture ligation was performed over a 2-week period, allowing complete excision of the squamous cell carcinoma and a large portion of the tongue LVM with minimal morbidity. Return to preoperative functional status was likewise achieved.ConclusionSerial suture ligation glossectomy is a simple and effective technique for treating the uncommon case of squamous cell carcinoma of the tongue in the setting of a massive LVM. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22011" xmlns="http://purl.org/rss/1.0/"><title>Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer</title><link>http://dx.doi.org/10.1002%2Fhed.22011</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Up-front neck dissection followed by concurrent chemoradiation in patients with regionally advanced head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter A. Paximadis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael E. Christensen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Greg Dyson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dev P. Kamdar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ammar Sukari</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ho-Sheng Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">George H. Yoo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Harold E. Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:28:02.612277-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22011</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22011</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22011</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The appropriate management of the neck in patients with regionally advanced head and neck cancer remains controversial. The purpose of this study was to retrospectively analyze our institutional experience with up-front neck dissection followed by definitive chemoradiotherapy.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Fifty-five patients with radiographic evidence of large or necrotic lymph nodes underwent up-front neck dissection followed by definitive chemoradiation.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The 5-year overall survival (OS) and progression-free survival (PFS) rates were estimated at 71.3% and 64.7%, respectively. There were 2 failures in the dissected neck, for a control rate of 96.7%. There were 7 locoregional failures and 12 distant failures, for locoregional and distant control rates of 87.3% and 78.2%, respectively.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Up-front neck dissection followed by chemoradiotherapy resulted in excellent locoregional control, OS, and PFS. Utilization of this strategy should be considered in carefully selected patients with regionally advanced head and neck cancer. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe appropriate management of the neck in patients with regionally advanced head and neck cancer remains controversial. The purpose of this study was to retrospectively analyze our institutional experience with up-front neck dissection followed by definitive chemoradiotherapy.MethodsFifty-five patients with radiographic evidence of large or necrotic lymph nodes underwent up-front neck dissection followed by definitive chemoradiation.ResultsThe 5-year overall survival (OS) and progression-free survival (PFS) rates were estimated at 71.3% and 64.7%, respectively. There were 2 failures in the dissected neck, for a control rate of 96.7%. There were 7 locoregional failures and 12 distant failures, for locoregional and distant control rates of 87.3% and 78.2%, respectively.ConclusionUp-front neck dissection followed by chemoradiotherapy resulted in excellent locoregional control, OS, and PFS. Utilization of this strategy should be considered in carefully selected patients with regionally advanced head and neck cancer. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22900" xmlns="http://purl.org/rss/1.0/"><title>Carcinosarcoma de novo of the parotid gland: Case report</title><link>http://dx.doi.org/10.1002%2Fhed.22900</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Carcinosarcoma de novo of the parotid gland: Case report</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nizar H. Taki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nora Laver</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tobi Quinto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard O. Wein</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:27:49.233078-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22900</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22900</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22900</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Salivary gland carcinosarcoma is a rare and aggressive malignant mixed tumor in which carcinomatous and sarcomatous elements coexist and metastasize together. The tumor may occur in the background of a preexisting pleomorphic adenoma or may arise de novo. We report a case of a woman presenting with a carcinosarcoma de novo of the parotid gland.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>Our patient underwent surgical resection and adjuvant radiotherapy and demonstrates no evidence of recurrence at 14 months posttreatment.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Review of the literature supports combined modality, surgery with postoperative radiation, as the standard of care for this malignancy, although the long-term prognosis for these patients is unclear. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundSalivary gland carcinosarcoma is a rare and aggressive malignant mixed tumor in which carcinomatous and sarcomatous elements coexist and metastasize together. The tumor may occur in the background of a preexisting pleomorphic adenoma or may arise de novo. We report a case of a woman presenting with a carcinosarcoma de novo of the parotid gland.Methods and ResultsOur patient underwent surgical resection and adjuvant radiotherapy and demonstrates no evidence of recurrence at 14 months posttreatment.ConclusionsReview of the literature supports combined modality, surgery with postoperative radiation, as the standard of care for this malignancy, although the long-term prognosis for these patients is unclear. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21917" xmlns="http://purl.org/rss/1.0/"><title>Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21917</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Antitumor effect of vandetanib through EGFR inhibition in head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonah D. Klein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Apostolos Christopoulos</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sun M. Ahn</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William E. Gooding</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jennifer R. Grandis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Seungwon Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:27:25.478599-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21917</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21917</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21917</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) have been implicated as therapeutic targets for head and neck squamous cell carcinoma (HNSCC). Vandetanib is a small-molecule tyrosine kinase inhibitor (TKI) with dual specificity for EGFR and VEGFR. Here we characterize the phenotypic and biochemical effects of vandetanib on various HNSCC cell lines.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>In vitro models were used for studying tumor cell viability, invasion, and signaling as well as in vivo xenograft models.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Treatment with vandetanib reduced viability, invasion, and tumor growth of HNSCC cell lines. Phosphorylation levels of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) were reduced in vandetanib-treated HNSCC cells. Additionally, vandetanib abrogates EGF-induced STAT3 activity and STAT3 target gene expression.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>We demonstrated that vandetanib inhibits the growth of head and neck cancer cell lines. The antitumor effects of vandetanib appear to be exerted via the EGFR inhibitory effect of the compound. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe epidermal growth factor receptor (EGFR) and vascular endothelial growth factor receptor (VEGFR) have been implicated as therapeutic targets for head and neck squamous cell carcinoma (HNSCC). Vandetanib is a small-molecule tyrosine kinase inhibitor (TKI) with dual specificity for EGFR and VEGFR. Here we characterize the phenotypic and biochemical effects of vandetanib on various HNSCC cell lines.MethodsIn vitro models were used for studying tumor cell viability, invasion, and signaling as well as in vivo xenograft models.ResultsTreatment with vandetanib reduced viability, invasion, and tumor growth of HNSCC cell lines. Phosphorylation levels of mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription 3 (STAT3) were reduced in vandetanib-treated HNSCC cells. Additionally, vandetanib abrogates EGF-induced STAT3 activity and STAT3 target gene expression.ConclusionsWe demonstrated that vandetanib inhibits the growth of head and neck cancer cell lines. The antitumor effects of vandetanib appear to be exerted via the EGFR inhibitory effect of the compound. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22906" xmlns="http://purl.org/rss/1.0/"><title>Application of microfluidic systems in management of head and neck squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.22906</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Application of microfluidic systems in management of head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Faiz Tanweer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Victoria Louise Green</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nicholas David Stafford</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John Greenman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-06T01:26:53.449559-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22906</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22906</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22906</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Microfluidics is an emerging multidisciplinary field that has the potential to provide solutions to many of the current challenges in managing head and neck squamous cell carcinoma (HNSCC). Treatment strategies for this disease are often complex and associated with significant morbidity and mortality; furthermore, prediction of response to treatment remains inaccurate. Microfluidic technology allows a small sample of tumor to be maintained alive ex vivo within a microenvironment that mimics the in vivo milieu; the response of this tumor biopsy to treatment regimens can subsequently be investigated. Microfluidics is the science and technology of systems that process or manipulate microliter to nanoliter volumes of fluids in purpose-built devices fabricated from glass or other biocompatible polymers. The technology also involves miniaturization and integration of various laboratory procedures into novel analysis devices. The purpose of this review is to provide an overview of microfluidic devices and discuss potential applications in HNSCC management. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>]]></content:encoded><description>Microfluidics is an emerging multidisciplinary field that has the potential to provide solutions to many of the current challenges in managing head and neck squamous cell carcinoma (HNSCC). Treatment strategies for this disease are often complex and associated with significant morbidity and mortality; furthermore, prediction of response to treatment remains inaccurate. Microfluidic technology allows a small sample of tumor to be maintained alive ex vivo within a microenvironment that mimics the in vivo milieu; the response of this tumor biopsy to treatment regimens can subsequently be investigated. Microfluidics is the science and technology of systems that process or manipulate microliter to nanoliter volumes of fluids in purpose-built devices fabricated from glass or other biocompatible polymers. The technology also involves miniaturization and integration of various laboratory procedures into novel analysis devices. The purpose of this review is to provide an overview of microfluidic devices and discuss potential applications in HNSCC management. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22929" xmlns="http://purl.org/rss/1.0/"><title>Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns</title><link>http://dx.doi.org/10.1002%2Fhed.22929</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Unilateral neck therapy in the human papillomavirus ERA: Accepted regional spread patterns</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas J. Galloway</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miriam N. Lango</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Barbara Burtness</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ranee Mehra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karen Ruth</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John A. Ridge</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:20:01.107952-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22929</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22929</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22929</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to determine whether the incidence of bilateral neck disease tonsillar cancer is rising.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We reviewed tonsillar cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The annual incidence of advanced neck disease (≥N2) with small primary tonsillar cancer is increasing (annual percent change [APC]; <em>p</em> &lt; .05) during 2 evaluable time frames (1988–2003 and 2004–2008). The increase for small primary tonsillar cancer from 2004 to 2008 is associated with increased ipsilateral disease (ie, T1-2N2a–b, APC 10.6%; <em>p</em> &lt; .05) rather than bilateral neck disease (T1-2N2c, APC 5.9%, APC = NS). The increase in bilateral neck disease is less than the overall rise in T1 to 2 tonsillar cancer (APC 7.2%; <em>p</em> &lt; .05).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>In the human papillomavirus (HPV) era, bilateral neck disease is increasingly common. This seems to be a consequence of the increasing incidence of tonsillar cancer rather than a new biologic behavior. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to determine whether the incidence of bilateral neck disease tonsillar cancer is rising.MethodsWe reviewed tonsillar cancer incidence data from the Surveillance, Epidemiology, and End Results (SEER) Program of the National Cancer Institute.ResultsThe annual incidence of advanced neck disease (≥N2) with small primary tonsillar cancer is increasing (annual percent change [APC]; p &lt; .05) during 2 evaluable time frames (1988–2003 and 2004–2008). The increase for small primary tonsillar cancer from 2004 to 2008 is associated with increased ipsilateral disease (ie, T1-2N2a–b, APC 10.6%; p &lt; .05) rather than bilateral neck disease (T1-2N2c, APC 5.9%, APC = NS). The increase in bilateral neck disease is less than the overall rise in T1 to 2 tonsillar cancer (APC 7.2%; p &lt; .05).ConclusionIn the human papillomavirus (HPV) era, bilateral neck disease is increasingly common. This seems to be a consequence of the increasing incidence of tonsillar cancer rather than a new biologic behavior. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21963" xmlns="http://purl.org/rss/1.0/"><title>Superficial temporal artery aneurysm: Diagnosis and treatment options</title><link>http://dx.doi.org/10.1002%2Fhed.21963</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Superficial temporal artery aneurysm: Diagnosis and treatment options</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dominique J. P. van Uden</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maarten Truijers</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ellis E. Schipper</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clark J. Zeebregts</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michel M.P.J. Reijnen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:19:20.112281-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21963</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21963</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21963</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Superficial temporal artery (STA) aneurysms are an uncommon entity and mostly described in case studies. The purpose of this review was to show the studied clinical presentation, diagnostic modalities, and treatment modalities of STA aneurysms.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A review was performed of reports on STA aneurysms published until December 2010, using the MEDLINE and Cochrane databases.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>One hundred sixty-six pseudoaneurysms and 20 true aneurysms were described. The majority of patients presented with a painless pulsatile mass. Historically, angiography was most often used, but ultrasound scan, CT, and MRI may be superior. Surgical resection was performed in 128 pseudoaneurysms and 20 true aneurysms with 1 recurrence and few complications. Endovascular approaches were used in 13% of pseudoaneurysms with an 80% success rate.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Pseudoaneurysms are mostly the result of blunt trauma as opposed to true aneurysms which usually occur spontaneously. Surgical resection is a safe treatment modality, but endovascular treatment might be considered in a selected group of patients. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundSuperficial temporal artery (STA) aneurysms are an uncommon entity and mostly described in case studies. The purpose of this review was to show the studied clinical presentation, diagnostic modalities, and treatment modalities of STA aneurysms.MethodsA review was performed of reports on STA aneurysms published until December 2010, using the MEDLINE and Cochrane databases.ResultsOne hundred sixty-six pseudoaneurysms and 20 true aneurysms were described. The majority of patients presented with a painless pulsatile mass. Historically, angiography was most often used, but ultrasound scan, CT, and MRI may be superior. Surgical resection was performed in 128 pseudoaneurysms and 20 true aneurysms with 1 recurrence and few complications. Endovascular approaches were used in 13% of pseudoaneurysms with an 80% success rate.ConclusionPseudoaneurysms are mostly the result of blunt trauma as opposed to true aneurysms which usually occur spontaneously. Surgical resection is a safe treatment modality, but endovascular treatment might be considered in a selected group of patients. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21815" xmlns="http://purl.org/rss/1.0/"><title>Total thyroidectomy with ultrasonic scalpel: A multicenter, randomized controlled trial</title><link>http://dx.doi.org/10.1002%2Fhed.21815</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Total thyroidectomy with ultrasonic scalpel: A multicenter, randomized controlled trial</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luiz P. Kowalski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alvaro Sanabria</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">José Guilherme Vartanian</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roberto Araujo Lima</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ullianov Bezerra Toscano de Mendonca</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlos Roberto dos Santos</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Domingos Boldrini Júnior</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luis Eduardo Barbalho de Mello</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fernando Paiva Pinto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlos Neutzling Lehn</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luiz Artur Costa Correa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rogério A. Dedivitis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">André Vicente Guimarães</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paola Andrea Galbiatti Pedruzzi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gyl Henrique Albrecht Ramos</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio José Gonçalves</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexandre Babá Suehara</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jossi Ledo Kanda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Renato de Castro Capuzzo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">José Carlos de Oliveira</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria Paula Curado</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">José Francisco de Góis Filho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Erica Fukuyama</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ivo Marquis Beserra Júnior</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paulo Bentes de Carvalho Neto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">André Lopes Carvalho</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:19:08.68981-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21815</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21815</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21815</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The ultrasonic scalpel is a recently introduced device in head and neck surgery. Total thyroidectomy is the most common endocrine procedure performed by surgeons.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This was an open, phase IV, multicenter, randomized controlled trial (RCT) that compared the use of an ultrasonic scalpel with a conventional technique in patients who underwent total thyroidectomy. The outcomes were surgical complication rate, operative time, drainage volume, postoperative pain, and costs.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>In all, 261 patients were included in 11 centers. There was a mean difference of 17% of operative time in favor of the ultrasonic scalpel group. There were no differences in postoperative complications. There was a difference in costs of 14% in favor of the ultrasonic scalpel group, but it was not statistically significant.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>The use of an ultrasonic scalpel was as safe as that of the conventional technique and had the advantage of a shorter operative time and lower postoperative drainage. Costs were not different between groups. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe ultrasonic scalpel is a recently introduced device in head and neck surgery. Total thyroidectomy is the most common endocrine procedure performed by surgeons.MethodsThis was an open, phase IV, multicenter, randomized controlled trial (RCT) that compared the use of an ultrasonic scalpel with a conventional technique in patients who underwent total thyroidectomy. The outcomes were surgical complication rate, operative time, drainage volume, postoperative pain, and costs.ResultsIn all, 261 patients were included in 11 centers. There was a mean difference of 17% of operative time in favor of the ultrasonic scalpel group. There were no differences in postoperative complications. There was a difference in costs of 14% in favor of the ultrasonic scalpel group, but it was not statistically significant.ConclusionsThe use of an ultrasonic scalpel was as safe as that of the conventional technique and had the advantage of a shorter operative time and lower postoperative drainage. Costs were not different between groups. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22001" xmlns="http://purl.org/rss/1.0/"><title>Life-threatening cervical spine collapse as a result of postradiation osteonecrosis—case report and review of the literature</title><link>http://dx.doi.org/10.1002%2Fhed.22001</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Life-threatening cervical spine collapse as a result of postradiation osteonecrosis—case report and review of the literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valerie A. Smith</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eric J. Lentsch</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:18:55.474563-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22001</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22001</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22001</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Mandibular osteoradionecrosis (ORN) is a well-known complication of head and neck radiotherapy; however, ORN of the cervical spine is rarely reported.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Herein, we present a patient with a history of tonsillar carcinoma treated with chemoradiation who developed acute, severe progressive neck pain due to cervical spine collapse as a result of ORN. We also discuss diagnosis and treatment of cervical ORN based on a review of the literature.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The patient was successfully treated with antibiotics and surgical debridement and fixation.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Delayed diagnosis of cervical ORN can result in marked disability and pain due to spinal cord compression, as well as serious deformity and instability requiring surgical intervention, and even death. It is important for otolaryngologists who treat head and neck malignancies to be aware of this potential complication so that patients may be diagnosed as early as possible and treated with conservative measures. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundMandibular osteoradionecrosis (ORN) is a well-known complication of head and neck radiotherapy; however, ORN of the cervical spine is rarely reported.MethodsHerein, we present a patient with a history of tonsillar carcinoma treated with chemoradiation who developed acute, severe progressive neck pain due to cervical spine collapse as a result of ORN. We also discuss diagnosis and treatment of cervical ORN based on a review of the literature.ResultsThe patient was successfully treated with antibiotics and surgical debridement and fixation.ConclusionDelayed diagnosis of cervical ORN can result in marked disability and pain due to spinal cord compression, as well as serious deformity and instability requiring surgical intervention, and even death. It is important for otolaryngologists who treat head and neck malignancies to be aware of this potential complication so that patients may be diagnosed as early as possible and treated with conservative measures. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22918" xmlns="http://purl.org/rss/1.0/"><title>Hyperparathyroidism–jaw tumor syndrome</title><link>http://dx.doi.org/10.1002%2Fhed.22918</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hyperparathyroidism–jaw tumor syndrome</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthew R. Kutcher</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthew H. Rigby</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin Bullock</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan Trites</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">S. Mark Taylor</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert D. Hart</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:18:33.239808-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22918</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22918</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22918</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Hyperparathyroidism–jaw tumor (HPT-JT) syndrome is a rare autosomal dominant multiple tumor syndrome characterized by hyperparathyroidism due to single or multiple-gland parathyroid tumor(s). Since it was first described in 1990, the genetics underlying the syndrome have been elucidated and typical clinical presentations are becoming clarified as literature describing this rare entity amasses.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>A 22-year-old man presented with a 2-year history of fatigue, weight loss, nausea, and vomiting. Anemia workup indicated severe hypercalcemia. Investigations were consistent with a diagnosis of HPT-JT. The patient underwent a total 4-gland parathyroidectomy with single gland reimplantation.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>HPT-JT is a complex syndrome with phenotypic manifestations that can seem physiologically and temporally unrelated. The risk of parathyroid carcinoma is elevated in patients with HPT-JT, necessitating rapid treatment and complete tumor resection to reduce the morbidity and mortality associated with intractable hypercalcemia due to local recurrence or metastatic disease. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundHyperparathyroidism–jaw tumor (HPT-JT) syndrome is a rare autosomal dominant multiple tumor syndrome characterized by hyperparathyroidism due to single or multiple-gland parathyroid tumor(s). Since it was first described in 1990, the genetics underlying the syndrome have been elucidated and typical clinical presentations are becoming clarified as literature describing this rare entity amasses.Methods and ResultsA 22-year-old man presented with a 2-year history of fatigue, weight loss, nausea, and vomiting. Anemia workup indicated severe hypercalcemia. Investigations were consistent with a diagnosis of HPT-JT. The patient underwent a total 4-gland parathyroidectomy with single gland reimplantation.ConclusionHPT-JT is a complex syndrome with phenotypic manifestations that can seem physiologically and temporally unrelated. The risk of parathyroid carcinoma is elevated in patients with HPT-JT, necessitating rapid treatment and complete tumor resection to reduce the morbidity and mortality associated with intractable hypercalcemia due to local recurrence or metastatic disease. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22920" xmlns="http://purl.org/rss/1.0/"><title>Venous thromboembolism in patients with head and neck cancer after surgery</title><link>http://dx.doi.org/10.1002%2Fhed.22920</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Venous thromboembolism in patients with head and neck cancer after surgery</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leo Thai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kate McCarn</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William Stott</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tammara Watts</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark K. Wax</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter E. Andersen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Neil D. Gross</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:18:20.031677-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22920</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22920</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22920</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to report the incidence of venous thromboembolism (VTE) in patients with head and neck cancer after surgery.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This was a single-institution, retrospective cohort: 134 patients underwent resection and simultaneous microvascular reconstruction. The primary endpoint was identification of confirmed or suspicious VTE within 30 days of surgery.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Two subjects (1.4%) with confirmed VTE (1 pulmonary embolism, 1 deep venous thrombosis) and 6 subjects (4.4%) with suspicious VTE (1 acute respiratory failure, 1 sudden cardiac arrest, and 4 cases of leg edema without imaging) were identified. The strongest predictors of possible VTE were prior VTE (<em>p</em> = .004; odds ratio [OR], 25.11; 95% confidence interval [CI], 1.13–556.40), red cell transfusion (<em>p</em> = .009; OR, 1.80; 95% CI, 1.16–2.80), high body mass index (<em>p</em> = .015, OR, 1.29, 95% CI, 1.05–1.58), and older age (<em>p</em> = .046; OR, 1.10; 95% CI, 1.00–1.19).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The incidence of VTE in patients with head and neck cancer after resection and microvascular reconstruction ranged from 1.4% to 5.8%. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to report the incidence of venous thromboembolism (VTE) in patients with head and neck cancer after surgery.MethodsThis was a single-institution, retrospective cohort: 134 patients underwent resection and simultaneous microvascular reconstruction. The primary endpoint was identification of confirmed or suspicious VTE within 30 days of surgery.ResultsTwo subjects (1.4%) with confirmed VTE (1 pulmonary embolism, 1 deep venous thrombosis) and 6 subjects (4.4%) with suspicious VTE (1 acute respiratory failure, 1 sudden cardiac arrest, and 4 cases of leg edema without imaging) were identified. The strongest predictors of possible VTE were prior VTE (p = .004; odds ratio [OR], 25.11; 95% confidence interval [CI], 1.13–556.40), red cell transfusion (p = .009; OR, 1.80; 95% CI, 1.16–2.80), high body mass index (p = .015, OR, 1.29, 95% CI, 1.05–1.58), and older age (p = .046; OR, 1.10; 95% CI, 1.00–1.19).ConclusionThe incidence of VTE in patients with head and neck cancer after resection and microvascular reconstruction ranged from 1.4% to 5.8%. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22940" xmlns="http://purl.org/rss/1.0/"><title>Hyalinizing clear cell adenocarcinoma of the oropharynx</title><link>http://dx.doi.org/10.1002%2Fhed.22940</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Hyalinizing clear cell adenocarcinoma of the oropharynx</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eelam Adil</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dhave Setabutr</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kael Mikesell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Goldenberg</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:18:07.56926-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22940</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22940</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22940</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Hyalinizing clear cell adenocarcinoma (HCCA) is a rare salivary gland malignancy. To our knowledge, there are no published reports of primary clear cell carcinoma of the vallecula.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A 59-year-old man with progressive dysphagia and otalgia underwent direct laryngoscopy with biopsy of a vallecular mass. The pathology results returned as clear cell adenocarcinoma. He underwent a wide local excision for his T<sub>2</sub>N<sub>0</sub>M<sub>0</sub> stage II tumor.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Clear cell adenocarcinoma of the oropharynx typically presents as a painless neck mass and it can be difficult to distinguish from other clear cell malignancies.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Immunohistochemical staining is essential for narrowing the differential diagnosis of these lesions. Treatment is controversial but usually consists of wide local excision and possibly a neck dissection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundHyalinizing clear cell adenocarcinoma (HCCA) is a rare salivary gland malignancy. To our knowledge, there are no published reports of primary clear cell carcinoma of the vallecula.MethodsA 59-year-old man with progressive dysphagia and otalgia underwent direct laryngoscopy with biopsy of a vallecular mass. The pathology results returned as clear cell adenocarcinoma. He underwent a wide local excision for his T2N0M0 stage II tumor.ResultsClear cell adenocarcinoma of the oropharynx typically presents as a painless neck mass and it can be difficult to distinguish from other clear cell malignancies.ConclusionImmunohistochemical staining is essential for narrowing the differential diagnosis of these lesions. Treatment is controversial but usually consists of wide local excision and possibly a neck dissection. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22947" xmlns="http://purl.org/rss/1.0/"><title>Multimodality approach for advanced-stage juvenile nasopharyngeal angiofibromas</title><link>http://dx.doi.org/10.1002%2Fhed.22947</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Multimodality approach for advanced-stage juvenile nasopharyngeal angiofibromas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fernando López Álvarez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vanessa Suárez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlos Suárez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">José L. Llorente</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:17:32.540802-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22947</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22947</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22947</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Juvenile nasopharyngeal angiofibromas (JNAs) with significant skull base involvement and intracranial extension are challenging tumors. We evaluated our experience in the treatment of extensive JNAs through resection followed by radiosurgery.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>From 1999 to 2007, 10 advanced JNAs (Andrews grade IV) were treated by primary surgical resection followed by gamma knife radiosurgery of residual tumor. Tumor control and treatment morbidity were evaluated.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Six months after radiosurgery and annually thereafter, an imaging study was done that revealed decrement in tumor size in 3 patients and no change in 7 patients, after a 3-year minimum follow-up. Clinically, patients are asymptomatic.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>An efficient strategy in the management of extensive JNAs is the use of a multimodality approach, in which surgical resection is followed by the treatment with radiosurgery in critical locations. These therapeutic schemes are safe and offer long-term tumor control. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundJuvenile nasopharyngeal angiofibromas (JNAs) with significant skull base involvement and intracranial extension are challenging tumors. We evaluated our experience in the treatment of extensive JNAs through resection followed by radiosurgery.MethodsFrom 1999 to 2007, 10 advanced JNAs (Andrews grade IV) were treated by primary surgical resection followed by gamma knife radiosurgery of residual tumor. Tumor control and treatment morbidity were evaluated.ResultsSix months after radiosurgery and annually thereafter, an imaging study was done that revealed decrement in tumor size in 3 patients and no change in 7 patients, after a 3-year minimum follow-up. Clinically, patients are asymptomatic.ConclusionAn efficient strategy in the management of extensive JNAs is the use of a multimodality approach, in which surgical resection is followed by the treatment with radiosurgery in critical locations. These therapeutic schemes are safe and offer long-term tumor control. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22949" xmlns="http://purl.org/rss/1.0/"><title>Clinical value of endosonography in the assessment of laryngeal cancer</title><link>http://dx.doi.org/10.1002%2Fhed.22949</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical value of endosonography in the assessment of laryngeal cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcel Kraft</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nina Bruns</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Monika Hügens-Penzel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christoph Arens</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:17:19.054021-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22949</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22949</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22949</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Endosonography has been successfully used in staging gastrointestinal cancer, but its value is as yet undetermined in laryngology.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This prospective study includes 84 patients undergoing microlaryngoscopy for laryngeal cancer. The results of endosonography were compared with those of CT and MRI in the 76 surgical cases.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>In the assessment of laryngal cancer, endosonography was superior to current imaging techniques, whereas CT and MRI showed similar results (accuracy of 89% vs 77% and 77%, respectively).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>This study confirms that endosonography is highly effective in staging laryngeal cancer. Therefore, the latter may constitute a complementary diagnostic tool in these tumors and additionally may assist in choosing an adequate treatment. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundEndosonography has been successfully used in staging gastrointestinal cancer, but its value is as yet undetermined in laryngology.MethodsThis prospective study includes 84 patients undergoing microlaryngoscopy for laryngeal cancer. The results of endosonography were compared with those of CT and MRI in the 76 surgical cases.ResultsIn the assessment of laryngal cancer, endosonography was superior to current imaging techniques, whereas CT and MRI showed similar results (accuracy of 89% vs 77% and 77%, respectively).ConclusionsThis study confirms that endosonography is highly effective in staging laryngeal cancer. Therefore, the latter may constitute a complementary diagnostic tool in these tumors and additionally may assist in choosing an adequate treatment. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22952" xmlns="http://purl.org/rss/1.0/"><title>AlloDerm and DermaMatrix implants for parotidectomy reconstruction: A histologic study in the rat model</title><link>http://dx.doi.org/10.1002%2Fhed.22952</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">AlloDerm and DermaMatrix implants for parotidectomy reconstruction: A histologic study in the rat model</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sanjay M. Athavale</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sanjeet Rangarajan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Latif Dharamsi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sabrina Wentz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sharon Phillips</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Theodore McRackan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wendell G. Yarbrough</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:17:07.2148-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22952</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22952</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22952</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>We analyzed tissue incorporation, immune response, and neovascularization of AlloDerm and DermaMatrix in a rat model of postparotidectomy reconstruction.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>In 8 male Sprague–Dawley rats, 3-dimensionally folded AlloDerm implants were placed in the left postparotidectomy bed and 3 in the anterior dorsum as controls. The same was done for DermaMatrix on the right side and posterior dorsum. Two animals were euthanized at 4, 8, and 12 days. A blinded pathologist assessed the degree of fibroblast proliferation, neovascularization, and inflammation.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>When compared with the dorsum, DermaMatrix implants in the parotid bed had significantly higher numbers of inflammatory cells at 8 and 12 days (<em>p</em> = .049 and .0046). AlloDerm acted more consistently between the postparotidectomy bed and dorsum.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>AlloDerm reacts similarly when comparing the postparotidectomy bed to the dorsum. DermaMatrix induces a more marked inflammatory reaction in the postparotidectomy bed when compared with the dorsum. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundWe analyzed tissue incorporation, immune response, and neovascularization of AlloDerm and DermaMatrix in a rat model of postparotidectomy reconstruction.MethodsIn 8 male Sprague–Dawley rats, 3-dimensionally folded AlloDerm implants were placed in the left postparotidectomy bed and 3 in the anterior dorsum as controls. The same was done for DermaMatrix on the right side and posterior dorsum. Two animals were euthanized at 4, 8, and 12 days. A blinded pathologist assessed the degree of fibroblast proliferation, neovascularization, and inflammation.ResultsWhen compared with the dorsum, DermaMatrix implants in the parotid bed had significantly higher numbers of inflammatory cells at 8 and 12 days (p = .049 and .0046). AlloDerm acted more consistently between the postparotidectomy bed and dorsum.ConclusionsAlloDerm reacts similarly when comparing the postparotidectomy bed to the dorsum. DermaMatrix induces a more marked inflammatory reaction in the postparotidectomy bed when compared with the dorsum. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22954" xmlns="http://purl.org/rss/1.0/"><title>Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer</title><link>http://dx.doi.org/10.1002%2Fhed.22954</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Increased radioresistance via G12S K-Ras by compensatory upregulation of MAPK and PI3K pathways in epithelial cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Annette Affolter</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martynas Drigotas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kai Fruth</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Irene Schmidtmann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christoph Brochhausen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wolf J. Mann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jürgen Brieger</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:16:58.457036-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22954</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22954</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22954</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Irradiation-induced signaling via the 2 pathways, Raf-MEK-ERK and PI3K-Akt, is known to be closely associated with a limited response to radiotherapy. In the present study we analyzed the relevance of constitutively active K-Ras for postradiogenic pathway stimulation and the option of coordinated inhibition to overcome these rescue mechanisms.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We used 2 epithelial tumor cell lines as a model system, one of them harboring a G12S K-Ras mutation. Cells were irradiated and the effect of combined treatment with ionizing radiation and inhibitors on the expression of pERK and pAkt was determined by Western blotting. Additionally, clonogenic assays were performed to functionally analyze survival of the cell lines.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Compared with the nonmutated cells we observed the G12S cell line showing a clearly reduced response to inhibitor treatment under irradiation. In the case of pharmacologic inhibition of 1 of the pathways a compensatory upregulation of the second cascade leading to increased clonogenic survival seems feasible. However, there was a good functional response of this cell line to double inhibition with both compounds represented by minimized colony forming ability. The activation of ERK and Akt after irradiation was confirmed in xenotransplants showing elevated postradiogenic protein levels.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>With our data we confirmed our hypothesis of postradiogenic constitutive activation of the 2 pathways both required for Ras-mediated radioresistance in epithelial cells. If this effect should prove itself as a general mechanism in Ras-mutated tumors, application of specific inhibitors to block both cascades in parallel could contribute to enhance radiosensitivity in these types of cancer. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundIrradiation-induced signaling via the 2 pathways, Raf-MEK-ERK and PI3K-Akt, is known to be closely associated with a limited response to radiotherapy. In the present study we analyzed the relevance of constitutively active K-Ras for postradiogenic pathway stimulation and the option of coordinated inhibition to overcome these rescue mechanisms.MethodsWe used 2 epithelial tumor cell lines as a model system, one of them harboring a G12S K-Ras mutation. Cells were irradiated and the effect of combined treatment with ionizing radiation and inhibitors on the expression of pERK and pAkt was determined by Western blotting. Additionally, clonogenic assays were performed to functionally analyze survival of the cell lines.ResultsCompared with the nonmutated cells we observed the G12S cell line showing a clearly reduced response to inhibitor treatment under irradiation. In the case of pharmacologic inhibition of 1 of the pathways a compensatory upregulation of the second cascade leading to increased clonogenic survival seems feasible. However, there was a good functional response of this cell line to double inhibition with both compounds represented by minimized colony forming ability. The activation of ERK and Akt after irradiation was confirmed in xenotransplants showing elevated postradiogenic protein levels.ConclusionWith our data we confirmed our hypothesis of postradiogenic constitutive activation of the 2 pathways both required for Ras-mediated radioresistance in epithelial cells. If this effect should prove itself as a general mechanism in Ras-mutated tumors, application of specific inhibitors to block both cascades in parallel could contribute to enhance radiosensitivity in these types of cancer. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22956" xmlns="http://purl.org/rss/1.0/"><title>Mediastinal goiter presenting with ventricular tachycardia</title><link>http://dx.doi.org/10.1002%2Fhed.22956</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Mediastinal goiter presenting with ventricular tachycardia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kevin C. Gilbert</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Muthuswamy Dhiwakar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William S. Stevens</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">K. Thomas Robbins</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-02-02T06:16:49.009144-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22956</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22956</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22956</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>We report a rare case of a mediastinal goiter confined to the thoracic inlet and cavity presenting with ventricular tachycardia as the sole clinical manifestation.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>The patient did not have any of the typical features of a mediastinal goiter such as neck swelling, dysphagia, or respiratory difficulty, but instead had spontaneous onset of wide-complex tachycardia requiring emergency treatment. This atypical presentation led to initial misinterpretation of imaging studies and delayed diagnosis of the mediastinal mass. The large, completely intrathoracic thyroid goiter abutted the cardiac muscle and required a combined transcervical and median sternotomy approach for removal. The arrhythmia resolved postoperatively.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>To our knowledge, this case represents the first documented presentation of ventricular tachycardia as a unique and sole feature of mediastinal goiter. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundWe report a rare case of a mediastinal goiter confined to the thoracic inlet and cavity presenting with ventricular tachycardia as the sole clinical manifestation.Methods and ResultsThe patient did not have any of the typical features of a mediastinal goiter such as neck swelling, dysphagia, or respiratory difficulty, but instead had spontaneous onset of wide-complex tachycardia requiring emergency treatment. This atypical presentation led to initial misinterpretation of imaging studies and delayed diagnosis of the mediastinal mass. The large, completely intrathoracic thyroid goiter abutted the cardiac muscle and required a combined transcervical and median sternotomy approach for removal. The arrhythmia resolved postoperatively.ConclusionTo our knowledge, this case represents the first documented presentation of ventricular tachycardia as a unique and sole feature of mediastinal goiter. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22927" xmlns="http://purl.org/rss/1.0/"><title>Letter to the Editor: Lymph nodes thyroglobulin measurement after rhTSH stimulation</title><link>http://dx.doi.org/10.1002%2Fhed.22927</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Letter to the Editor: Lymph nodes thyroglobulin measurement after rhTSH stimulation</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luca Giovanella</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:14:57.815155-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22927</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22927</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22927</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Letter to the Editor</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22917" xmlns="http://purl.org/rss/1.0/"><title>Intraosseous carcinoma of the jaws—A clinicopathologic review. Part I: Metastatic and salivary-type carcinomas</title><link>http://dx.doi.org/10.1002%2Fhed.22917</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intraosseous carcinoma of the jaws—A clinicopathologic review. Part I: Metastatic and salivary-type carcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia A. Woolgar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Asterios Triantafyllou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfio Ferlito</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kenneth O. Devaney</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James S. Lewis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Rinaldo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pieter J. Slootweg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leon Barnes</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:13:52.889535-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22917</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22917</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22917</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>This is the first part of a 3-part comprehensive review of intraosseous carcinoma of the jaws. We have outlined 4 groups of intraosseous carcinoma of the jaws (metastatic, salivary-type, odontogenic, and primary intraosseous carcinoma), emphasizing the need for accurate diagnosis and the problems associated with changing classification systems, standardization of diagnostic criteria and nomenclature, and the accuracy of existing literature. In this first part, the features of metastatic and the very rare salivary-type carcinomas of the jaws are examined with particular emphasis on histologic and immunohistochemical characteristics, diagnostic difficulties, and uncertainties. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>]]></content:encoded><description>This is the first part of a 3-part comprehensive review of intraosseous carcinoma of the jaws. We have outlined 4 groups of intraosseous carcinoma of the jaws (metastatic, salivary-type, odontogenic, and primary intraosseous carcinoma), emphasizing the need for accurate diagnosis and the problems associated with changing classification systems, standardization of diagnostic criteria and nomenclature, and the accuracy of existing literature. In this first part, the features of metastatic and the very rare salivary-type carcinomas of the jaws are examined with particular emphasis on histologic and immunohistochemical characteristics, diagnostic difficulties, and uncertainties. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22922" xmlns="http://purl.org/rss/1.0/"><title>Intraosseous carcinoma of the jaws: A clinicopathologic review. Part III: Primary intraosseous squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.22922</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intraosseous carcinoma of the jaws: A clinicopathologic review. Part III: Primary intraosseous squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia A. Woolgar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Asterios Triantafyllou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfio Ferlito</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kenneth O. Devaney</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James S. Lewis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Rinaldo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pieter J. Slootweg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leon Barnes</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:13:34.023387-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22922</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22922</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22922</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>This is the third part of a review of the clinicopathologic features of intraosseous carcinoma of the jaws (IOCJ). In parts 1 and 2, we discussed metastatic and salivary-type and odontogenic carcinomas, respectively. This part deals with primary intraosseous squamous cell carcinoma. Again, based on a critical approach, we emphasize histopathologic features, diagnostic difficulties, discuss histogenesis, and highlight areas of uncertainty. The 3-part review also offers speculations on how future studies may refine our understanding of the unusual and interesting IOCJ. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>]]></content:encoded><description>This is the third part of a review of the clinicopathologic features of intraosseous carcinoma of the jaws (IOCJ). In parts 1 and 2, we discussed metastatic and salivary-type and odontogenic carcinomas, respectively. This part deals with primary intraosseous squamous cell carcinoma. Again, based on a critical approach, we emphasize histopathologic features, diagnostic difficulties, discuss histogenesis, and highlight areas of uncertainty. The 3-part review also offers speculations on how future studies may refine our understanding of the unusual and interesting IOCJ. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22923" xmlns="http://purl.org/rss/1.0/"><title>Intraosseous carcinoma of the jaws: A clinicopathologic review. part II: Odontogenic carcinomas</title><link>http://dx.doi.org/10.1002%2Fhed.22923</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Intraosseous carcinoma of the jaws: A clinicopathologic review. part II: Odontogenic carcinomas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia A. Woolgar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Asterios Triantafyllou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfio Ferlito</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kenneth O. Devaney</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James S. Lewis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Rinaldo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pieter J. Slootweg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Leon Barnes</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:13:26.296286-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22923</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22923</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22923</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>This is the second of a 3-part review of the clinicopathologic features of intraosseous carcinoma of the jaws (IOCJ). This part deals with odontogenic carcinomas, rare entities that are difficult to evaluate because of changes in classification/nomenclature, lack of standardized diagnostic criteria, and variable consistency of the existing literature. Endorsing a critical approach, problems are addressed and areas of uncertainty are highlighted. As in part I, we emphasize histopathologic features from a diagnostic point of view and also question the existence of some “distinct” entities. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>]]></content:encoded><description>This is the second of a 3-part review of the clinicopathologic features of intraosseous carcinoma of the jaws (IOCJ). This part deals with odontogenic carcinomas, rare entities that are difficult to evaluate because of changes in classification/nomenclature, lack of standardized diagnostic criteria, and variable consistency of the existing literature. Endorsing a critical approach, problems are addressed and areas of uncertainty are highlighted. As in part I, we emphasize histopathologic features from a diagnostic point of view and also question the existence of some “distinct” entities. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21973" xmlns="http://purl.org/rss/1.0/"><title>Implications of a positive sentinel node in oral squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21973</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Implications of a positive sentinel node in oral squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benjamin A. S. Gurney</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Clare Schilling</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Venkata Putcha</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lee W. Alkureishi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Amezaga J. Alvarez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vivi Bakholdt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luis Barbier Herrero</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luigi Barzan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anders Bilde</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elisabeth Bloemena</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carmen Camarero Salces</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paolo Dalla Palma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Remco de Bree</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Didier Dequanter</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gilles Dolivet</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Davide Donner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Geke B. Flach</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Manuel Fresno</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cesare Grandi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephan Haerle</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gerhard F. Huber</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Keith Hunter</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">George Lawson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Agnes Leroux</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Phillippe H. Lothaire</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gerard Mamelle</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Enrico M. Silini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Romina Mastronicola</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edward W. Odell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael J. O'Doherty</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tito Poli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Siavash Rahimi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gary L. Ross</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">J. Santamaria Zuazua</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simone Santini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lars Sebbesen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Taimur Shoaib</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philip Sloan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jens Ahm Sorensen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David S. Soutar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marianne H. Therkildsen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maurizio Giovanni Vigili</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pedro M. Villarreal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christian von Buchwald</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jochen A. Werner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Susanne Wiegand</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark McGurk</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:12:59.769235-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21973</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21973</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21973</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The role of sentinel node biopsy in head and neck cancer is currently being explored. Patients with positive sentinel nodes were investigated to establish if additional metastases were present in the neck, their distribution, and their impact on outcome.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>In all, 109 patients (<em>n</em> = 109) from 15 European centers, with cT1/2,N0 tumors, and a positive sentinel lymph node were identified. Kaplan–Meier and univariate and multivariate logistic regression analysis were used to identify variables that predicted for additional positive nodes and their position within the neck.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>A total of 122 neck dissections were performed in 109 patients. Additional positive nodes were found in 34.4% of cases (42/122: 18 same, 21 adjacent, and 3 nonadjacent neck level). Additional nodes, especially if outside the sentinel node basin, had an impact on outcome.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>The results are preliminary but suggest that both the number and the position of positive sentinel nodes may identify different prognostic groups that may allow further tailoring of management plans. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe role of sentinel node biopsy in head and neck cancer is currently being explored. Patients with positive sentinel nodes were investigated to establish if additional metastases were present in the neck, their distribution, and their impact on outcome.MethodsIn all, 109 patients (n = 109) from 15 European centers, with cT1/2,N0 tumors, and a positive sentinel lymph node were identified. Kaplan–Meier and univariate and multivariate logistic regression analysis were used to identify variables that predicted for additional positive nodes and their position within the neck.ResultsA total of 122 neck dissections were performed in 109 patients. Additional positive nodes were found in 34.4% of cases (42/122: 18 same, 21 adjacent, and 3 nonadjacent neck level). Additional nodes, especially if outside the sentinel node basin, had an impact on outcome.ConclusionsThe results are preliminary but suggest that both the number and the position of positive sentinel nodes may identify different prognostic groups that may allow further tailoring of management plans. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21978" xmlns="http://purl.org/rss/1.0/"><title>Acquired arteriovenous fistula associated with traumatic oroantral fistula: Endovascular treatment</title><link>http://dx.doi.org/10.1002%2Fhed.21978</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Acquired arteriovenous fistula associated with traumatic oroantral fistula: Endovascular treatment</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthew R. Sanborn</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ilya Nasrallah</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David C. Stanton</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael F. Stiefel</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert W. Hurst</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bryan A. Pukenas</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:12:45.387228-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21978</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21978</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21978</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background.</h3><div class="para"><p>Oroantral fistulas are pathologic connections between the oral cavity and the maxillary sinus. Arteriovenous fistulas are abnormal connections between an artery and a vein with no intervening capillary network.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We present an extremely rare case of barotrauma-related oroantral fistula with an associated arteriovenous fistula between the internal maxillary artery and the ophthalmic venous system.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The patient developed an oroantral fistula from barometric pressure changes in the setting of sinusitis. After closure and revision of the oroantral fistula, he developed proptosis and chemosis. Angiography revealed an arteriovenous fistula between the internal maxillary artery and the ophthalmic venous drainage system in the area of the oroantral fistula, which was treated with endovascular embolization.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Arteriovenous fistulas may accompany oroantral fistulas created by trauma or surgery and should be considered in patients presenting with chemosis and proptosis. Treatment with embolization should be performed before surgical intervention. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>Background.Oroantral fistulas are pathologic connections between the oral cavity and the maxillary sinus. Arteriovenous fistulas are abnormal connections between an artery and a vein with no intervening capillary network.MethodsWe present an extremely rare case of barotrauma-related oroantral fistula with an associated arteriovenous fistula between the internal maxillary artery and the ophthalmic venous system.ResultsThe patient developed an oroantral fistula from barometric pressure changes in the setting of sinusitis. After closure and revision of the oroantral fistula, he developed proptosis and chemosis. Angiography revealed an arteriovenous fistula between the internal maxillary artery and the ophthalmic venous drainage system in the area of the oroantral fistula, which was treated with endovascular embolization.ConclusionsArteriovenous fistulas may accompany oroantral fistulas created by trauma or surgery and should be considered in patients presenting with chemosis and proptosis. Treatment with embolization should be performed before surgical intervention. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21988" xmlns="http://purl.org/rss/1.0/"><title>Minor salivary gland tumors of the sinonasal region: Results of a retrospective analysis with review of literature</title><link>http://dx.doi.org/10.1002%2Fhed.21988</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Minor salivary gland tumors of the sinonasal region: Results of a retrospective analysis with review of literature</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gouri H. Pantvaidya</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Abhishek D. Vaidya</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rajendra Metgudmath</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shubhada V. Kane</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anil K. D'Cruz</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:12:28.413424-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21988</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21988</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21988</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Minor salivary gland tumors of the sinonasal region are rare. Minor salivary gland tumors of this region behave differently from other subsites in the head and neck. The objective of our study was to analyze the survival and prognostic factors in patients with minor salivary gland tumors of the sinonasal region.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We carried out a retrospective review of patients with minor salivary gland tumors of the sinonasal region. All slides were reviewed by an independent pathologist. Survival was analyzed using the Kaplan–Meier method and Cox multivariate regression to identify prognostic factors.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>In all, 163 patients were identified from our registry. The 5-year disease-free and overall survival rates were 48.3% and 83.3%, respectively. Tumor grade, nodal status, and adjuvant radiotherapy were significant predictors of disease-free survival (DFS), on multivariate analysis.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Minor salivary gland tumors have a good overall survival in spite of high recurrence rates. Tumor grade, nodal status, and adjuvant radiotherapy are independent predictors of DFS. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundMinor salivary gland tumors of the sinonasal region are rare. Minor salivary gland tumors of this region behave differently from other subsites in the head and neck. The objective of our study was to analyze the survival and prognostic factors in patients with minor salivary gland tumors of the sinonasal region.MethodsWe carried out a retrospective review of patients with minor salivary gland tumors of the sinonasal region. All slides were reviewed by an independent pathologist. Survival was analyzed using the Kaplan–Meier method and Cox multivariate regression to identify prognostic factors.ResultsIn all, 163 patients were identified from our registry. The 5-year disease-free and overall survival rates were 48.3% and 83.3%, respectively. Tumor grade, nodal status, and adjuvant radiotherapy were significant predictors of disease-free survival (DFS), on multivariate analysis.ConclusionsMinor salivary gland tumors have a good overall survival in spite of high recurrence rates. Tumor grade, nodal status, and adjuvant radiotherapy are independent predictors of DFS. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21989" xmlns="http://purl.org/rss/1.0/"><title>Ent—head and neck surgery: Essential procedures</title><link>http://dx.doi.org/10.1002%2Fhed.21989</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Ent—head and neck surgery: Essential procedures</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yelizaveta Shnayder</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:12:09.069853-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21989</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21989</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21989</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21990" xmlns="http://purl.org/rss/1.0/"><title>Diagnostic imaging: Head and neck, 2nd edition</title><link>http://dx.doi.org/10.1002%2Fhed.21990</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Diagnostic imaging: Head and neck, 2nd edition</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ashley H. Aiken</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:11:47.171427-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21990</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21990</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21990</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21995" xmlns="http://purl.org/rss/1.0/"><title>Imaging for otolaryngologists</title><link>http://dx.doi.org/10.1002%2Fhed.21995</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Imaging for otolaryngologists</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jenny K. Hoang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:10:20.760868-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21995</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21995</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21995</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22931" xmlns="http://purl.org/rss/1.0/"><title>Cricotracheal reconstruction with free radial forearm flap and titanium mesh</title><link>http://dx.doi.org/10.1002%2Fhed.22931</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cricotracheal reconstruction with free radial forearm flap and titanium mesh</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Deepak Balasubramanian</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Krishnakumar Thankappan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sharankumar Shetty</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kiran Jayaprasad</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jimmy Mathew</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Subramania Iyer</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:09:56.38966-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22931</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22931</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22931</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Reconstruction after partial cricotracheal resection is technically demanding and is seldom reported in literature. The purpose of this study was to report a technique of reconstruction of such a defect with a radial forearm flap supported by a titanium mesh.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A 75-year-old man who was diagnosed with a case of papillary carcinoma thyroid, underwent excision of the tumor with a partial cricotracheal resection. The defect was reconstructed with a free radial forearm flap with fascia suspended on a titanium mesh.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>At a follow-up of 6 months after treatment, the patient has normal nasal breathing and an acceptable voice.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>This reconstructive technique enabled us to maintain the integrity of the subglottic airway. Our technique was unique in that we used the skin-lined part of the radial forearm flap to line the airway and the fascia to cover the titanium mesh outside, thereby preventing plate exposure. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundReconstruction after partial cricotracheal resection is technically demanding and is seldom reported in literature. The purpose of this study was to report a technique of reconstruction of such a defect with a radial forearm flap supported by a titanium mesh.MethodsA 75-year-old man who was diagnosed with a case of papillary carcinoma thyroid, underwent excision of the tumor with a partial cricotracheal resection. The defect was reconstructed with a free radial forearm flap with fascia suspended on a titanium mesh.ResultsAt a follow-up of 6 months after treatment, the patient has normal nasal breathing and an acceptable voice.ConclusionThis reconstructive technique enabled us to maintain the integrity of the subglottic airway. Our technique was unique in that we used the skin-lined part of the radial forearm flap to line the airway and the fascia to cover the titanium mesh outside, thereby preventing plate exposure. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22933" xmlns="http://purl.org/rss/1.0/"><title>Cheek mucosa: A versatile donor site of myomucosal flaps. Technical and functional considerations</title><link>http://dx.doi.org/10.1002%2Fhed.22933</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cheek mucosa: A versatile donor site of myomucosal flaps. Technical and functional considerations</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Olindo Massarelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandro Baj</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roberta Gobbi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Damiano Soma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefano Marelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giacomo De Riu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antonio Tullio</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aldo B. Giannì</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:09:45.642271-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22933</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22933</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22933</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Reconstruction of moderate-sized mucosal defects of the oral cavity/oropharynx represents a surgical challenge. The most widely used reconstructive techniques are skin grafts, local or regional pedicled flaps, and free flaps, but they do not provide mucosal sensitivity, mobility, volume, or texture similar to that of native tissue. The cheek myomucosal flaps seem to provide “ideal reconstruction” because they carry a thin, mobile, well-vascularized, and sensitive tissue, like those excised or lost. The purpose of this retrospective analysis was to evaluate the indications for the advantages and disadvantages of 6 types of buccinator myomucosal flaps which are possible to raise from the cheek mucosa.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Sixty-nine buccinator myomucosal flaps were performed on 66 patients with moderate-sized postoncologic and posttraumatic oral and oropharyngeal defects.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>In all cases except 1, flaps were successfully used with excellent oncological and functional results.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Buccinator myomucosal flaps can be considered “ideal flaps” for three-dimensional oral and oropharyngeal reconstructions. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundReconstruction of moderate-sized mucosal defects of the oral cavity/oropharynx represents a surgical challenge. The most widely used reconstructive techniques are skin grafts, local or regional pedicled flaps, and free flaps, but they do not provide mucosal sensitivity, mobility, volume, or texture similar to that of native tissue. The cheek myomucosal flaps seem to provide “ideal reconstruction” because they carry a thin, mobile, well-vascularized, and sensitive tissue, like those excised or lost. The purpose of this retrospective analysis was to evaluate the indications for the advantages and disadvantages of 6 types of buccinator myomucosal flaps which are possible to raise from the cheek mucosa.MethodsSixty-nine buccinator myomucosal flaps were performed on 66 patients with moderate-sized postoncologic and posttraumatic oral and oropharyngeal defects.ResultsIn all cases except 1, flaps were successfully used with excellent oncological and functional results.ConclusionBuccinator myomucosal flaps can be considered “ideal flaps” for three-dimensional oral and oropharyngeal reconstructions. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22937" xmlns="http://purl.org/rss/1.0/"><title>Head and neck pathology (Consultant Pathology)</title><link>http://dx.doi.org/10.1002%2Fhed.22937</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Head and neck pathology (Consultant Pathology)</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Diana Bell</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:09:27.731303-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22937</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22937</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22937</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22938" xmlns="http://purl.org/rss/1.0/"><title>Cutaneous malignancy of the head and neck: A multidisciplinary approach</title><link>http://dx.doi.org/10.1002%2Fhed.22938</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cutaneous malignancy of the head and neck: A multidisciplinary approach</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephan Haerle</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan C. Irish</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:09:11.573374-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22938</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22938</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22938</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22939" xmlns="http://purl.org/rss/1.0/"><title>Atlas of head and neck surgery: Expert consult</title><link>http://dx.doi.org/10.1002%2Fhed.22939</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Atlas of head and neck surgery: Expert consult</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard Wein</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:08:54.215979-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22939</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22939</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22939</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22944" xmlns="http://purl.org/rss/1.0/"><title>Abstracts</title><link>http://dx.doi.org/10.1002%2Fhed.22944</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Abstracts</dc:title><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:08:25.643406-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22944</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22944</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22944</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Abstract</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22948" xmlns="http://purl.org/rss/1.0/"><title>Assessment of second tier lymph nodes in melanoma and implications for extent of elective neck dissection in metastatic cutaneous malignancy of the parotid</title><link>http://dx.doi.org/10.1002%2Fhed.22948</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Assessment of second tier lymph nodes in melanoma and implications for extent of elective neck dissection in metastatic cutaneous malignancy of the parotid</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sydney Ch'ng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Audrey Pinna</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kim Ioannou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karolina Juszczyk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kerwin Shannon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anthony Clifford</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roger Uren</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan R. Clark</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:08:12.438084-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22948</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22948</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22948</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The parotid is the commonest site of cutaneous metastases in the head and neck. The role and extent of neck dissection in patients with parotid metastatic cutaneous malignancy remains controversial.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We reviewed the lymphoscintigraphy and single photon emission CT (SPECT) of patients with melanoma who had a sentinel node in the parotid to determine the second tier cervical lymph nodes.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Levels II and III cervical nodes make up 82% of second tier lymph nodes for the parotid, and levels IV and V, 12% and 4%, respectively. Second tier lymph nodes isolated to levels I, IV, or V, bypassing levels II and III, occurred in only 2% of cases.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The risk of harboring occult metastasis in levels I, IV, and V when levels II and III are negative is low. Levels II and III neck dissection is likely to be an effective staging procedure in patients with isolated parotid metastases. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe parotid is the commonest site of cutaneous metastases in the head and neck. The role and extent of neck dissection in patients with parotid metastatic cutaneous malignancy remains controversial.MethodsWe reviewed the lymphoscintigraphy and single photon emission CT (SPECT) of patients with melanoma who had a sentinel node in the parotid to determine the second tier cervical lymph nodes.ResultsLevels II and III cervical nodes make up 82% of second tier lymph nodes for the parotid, and levels IV and V, 12% and 4%, respectively. Second tier lymph nodes isolated to levels I, IV, or V, bypassing levels II and III, occurred in only 2% of cases.ConclusionThe risk of harboring occult metastasis in levels I, IV, and V when levels II and III are negative is low. Levels II and III neck dissection is likely to be an effective staging procedure in patients with isolated parotid metastases. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21996" xmlns="http://purl.org/rss/1.0/"><title>Skull base surgery: Basic techniques</title><link>http://dx.doi.org/10.1002%2Fhed.21996</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Skull base surgery: Basic techniques</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alec E. Vaezi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:08:02.281557-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21996</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21996</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21996</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Book Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22908" xmlns="http://purl.org/rss/1.0/"><title>Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital</title><link>http://dx.doi.org/10.1002%2Fhed.22908</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Parathyroid cancer: Outcome analysis of 16 patients treated at the princess margaret hospital</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Boban M. Erovic</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David P. Goldstein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dae Kim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ozgur Mete</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James Brierley</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard Tsang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeremy L. Freeman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sylvia L. Asa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lorne Rotstein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan C. Irish</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:07:48.811321-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22908</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22908</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22908</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to discuss the appropriate management options for parathyroid carcinomas, which is still a subject of controversy.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A retrospective chart review of 16 patients with parathyroid carcinoma was undertaken to determine the clinical outcome.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>All patients were initially treated with surgery, and 11 patients received adjuvant radiotherapy. The 5- and 10-year disease-specific survival rates were 100% and 80%, respectively; the 5- and 10-year disease-free survival rates were 69% and 43%, respectively. The 5- and 10-year locoregional control rates were 69% and 52%, respectively; the 5- and 10-year distant control rates were 89% and 74%, respectively. In this cohort, none of the clinicopathologic parameters could be defined as a predictor.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>In patients with parathyroid carcinoma, definition of prognostic factors and the role of adjuvant radiation treatment has still to be elucidated. Nevertheless, angioinvasion and positive resection margins are critical factors regarding disease-free survival in patients with parathyroid carcinomas. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to discuss the appropriate management options for parathyroid carcinomas, which is still a subject of controversy.MethodsA retrospective chart review of 16 patients with parathyroid carcinoma was undertaken to determine the clinical outcome.ResultsAll patients were initially treated with surgery, and 11 patients received adjuvant radiotherapy. The 5- and 10-year disease-specific survival rates were 100% and 80%, respectively; the 5- and 10-year disease-free survival rates were 69% and 43%, respectively. The 5- and 10-year locoregional control rates were 69% and 52%, respectively; the 5- and 10-year distant control rates were 89% and 74%, respectively. In this cohort, none of the clinicopathologic parameters could be defined as a predictor.ConclusionIn patients with parathyroid carcinoma, definition of prognostic factors and the role of adjuvant radiation treatment has still to be elucidated. Nevertheless, angioinvasion and positive resection margins are critical factors regarding disease-free survival in patients with parathyroid carcinomas. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22910" xmlns="http://purl.org/rss/1.0/"><title>Sporadic or familial head neck paragangliomas enrolled in a single center: Clinical presentation and genotype/phenotype correlations</title><link>http://dx.doi.org/10.1002%2Fhed.22910</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Sporadic or familial head neck paragangliomas enrolled in a single center: Clinical presentation and genotype/phenotype correlations</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Bacca</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefano Sellari Franceschini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Davide Carrara</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matteo Bernini</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Virna Zampa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefano Taddei</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paolo Miccoli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Caterina Congregati</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paolo Simi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauro Ferrari</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giampaolo Bernini</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:07:38.325798-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22910</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22910</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22910</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to investigate clinical features and prevalence of germline mutations of patients with head/neck paragangliomas.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Genetic analysis on known susceptibility genes for paragangliomas (<em>VHL</em>, <em>RET</em>, <em>SDHB</em>, <em>SDHC</em>, <em>SDHD</em>, and <em>SDHAF2</em>) was performed in 17 consecutive patients with head/neck paraganglioma (age range, 14–82 years) and 17 relatives.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Head/neck paragangliomas were usually symptomatic with “mass effect” (88.2%), without family history (82.3%), often multifocal (41.2%), never functioning, and malignant. Germline mutations were detected in 7 of 17 patients (41%; 6 <em>SDHD</em> and 1 <em>SDHB</em>). Patients with mutations were younger, with head/neck paragangliomas usually multifocal and with higher biologic aggressiveness than wild-type subjects. To date, 4 families have been studied and the prevalence of carriers was elevated (58.8%). These mutated relatives (age range, 17–71 years) were disease-free, except 4 patients in whom multiple head/neck paragangliomas were detected.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Adequate morpho-functional screening and follow-up and, if possible, genetic testing is advisable in patients with head/neck paraganglioma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to investigate clinical features and prevalence of germline mutations of patients with head/neck paragangliomas.MethodsGenetic analysis on known susceptibility genes for paragangliomas (VHL, RET, SDHB, SDHC, SDHD, and SDHAF2) was performed in 17 consecutive patients with head/neck paraganglioma (age range, 14–82 years) and 17 relatives.ResultsHead/neck paragangliomas were usually symptomatic with “mass effect” (88.2%), without family history (82.3%), often multifocal (41.2%), never functioning, and malignant. Germline mutations were detected in 7 of 17 patients (41%; 6 SDHD and 1 SDHB). Patients with mutations were younger, with head/neck paragangliomas usually multifocal and with higher biologic aggressiveness than wild-type subjects. To date, 4 families have been studied and the prevalence of carriers was elevated (58.8%). These mutated relatives (age range, 17–71 years) were disease-free, except 4 patients in whom multiple head/neck paragangliomas were detected.ConclusionAdequate morpho-functional screening and follow-up and, if possible, genetic testing is advisable in patients with head/neck paraganglioma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22915" xmlns="http://purl.org/rss/1.0/"><title>Use of an intraoperative shunt for easy resection of complicated carotid body tumors</title><link>http://dx.doi.org/10.1002%2Fhed.22915</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Use of an intraoperative shunt for easy resection of complicated carotid body tumors</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Guojun Zeng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jichun Zhao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yukui Ma</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bin Huang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:04:26.277634-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22915</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22915</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22915</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>This study was carried out to explore the use of an intraoperative shunt during surgical resection of complicated carotid body tumors (CBTs).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Of the 47 patients who underwent surgical resection for CBT, an intraoperative shunt was performed in 10 patients with complicated CBTs involving the carotid artery wall between January 2005 and August 2010, and their clinical materials were respectively reviewed.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>No severe complications occurred intraoperatively and postoperatively in all the 10 patients with complicated CBTs involving the carotid artery wall. No recurrence and metastasis occurred during follow-up period for a mean of 35.3 months (range, 12–60 months).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>An intraoperative shunt maintained cerebral circulation, decreased the size of tumor by excluding the vascular supply of the external carotid artery, and guided the resection of CBT. The intraoperative shunt was a safe and effective way during surgical resection of complicated CBTs. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThis study was carried out to explore the use of an intraoperative shunt during surgical resection of complicated carotid body tumors (CBTs).MethodsOf the 47 patients who underwent surgical resection for CBT, an intraoperative shunt was performed in 10 patients with complicated CBTs involving the carotid artery wall between January 2005 and August 2010, and their clinical materials were respectively reviewed.ResultsNo severe complications occurred intraoperatively and postoperatively in all the 10 patients with complicated CBTs involving the carotid artery wall. No recurrence and metastasis occurred during follow-up period for a mean of 35.3 months (range, 12–60 months).ConclusionsAn intraoperative shunt maintained cerebral circulation, decreased the size of tumor by excluding the vascular supply of the external carotid artery, and guided the resection of CBT. The intraoperative shunt was a safe and effective way during surgical resection of complicated CBTs. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22925" xmlns="http://purl.org/rss/1.0/"><title>Reply to Letter to the Editor</title><link>http://dx.doi.org/10.1002%2Fhed.22925</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Reply to Letter to the Editor</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carlo Cappelli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:02:00.325031-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22925</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22925</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22925</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Letter to the Editor</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[]]></content:encoded><description/></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21956" xmlns="http://purl.org/rss/1.0/"><title>Abdominal compression: A new intraoperative maneuver to detect chyle fistulas during left neck dissections that include level IV</title><link>http://dx.doi.org/10.1002%2Fhed.21956</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Abdominal compression: A new intraoperative maneuver to detect chyle fistulas during left neck dissections that include level IV</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Claudio R. Cernea</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Flavio C. Hojaij</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dorival De Carlucci</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marcos R. Tavares</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vergilius J. Araújo–Filho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gilberto Britto e Silva–Filho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lenine G. Brandão</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:01:37.141629-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21956</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21956</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21956</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Chyle fistulas may occur after left neck dissections that include level IV, due to injury of the thoracic duct or of 1 of its major branches. Despite being unusual, this complication carries substantial postoperative morbidity and even mortality. So far, no effective intraoperative maneuver has been reported to detect this fistula at the end of a neck dissection. In this cohort study, we sought to describe a simple new maneuver, intraoperative abdominal compression, which can effectively help to identify an open major lymphatic duct on level IV at the end of a neck dissection.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Patients and Methods</h3><div class="para"><p>From March 1989 to September 2010, 206 patients underwent neck dissections involving left level IV, and underwent intraoperative abdominal compression. There were 119 men and 87 women, with ages ranging from 18 to 81 years (median, 52 years). One hundred forty-four patients had squamous cell carcinomas, 54 had thyroid carcinomas, 5 had malignant melanomas, and 3 had salivary cancers. Distribution by type of left neck dissection was: selective including levels II, III, and IV (73 cases; 35.4%), selective including levels II, III, IV, and V (55 cases; 26.6%), selective including levels I, II, III, and IV (12 cases; 5.8%), modified radical (47 cases; 22.8%), and radical (19 cases; 9.2%). In all cases, at the end of the procedure, the endotracheal tube was temporarily disconnected from the ventilator. Keeping the dissected level IV area under clear visualization, an abdominal compression was performed. At this moment, any detected lymphatic leak was carefully clamped and tied with nonabsorbable sutures. After ventilating the patient, the intraoperative abdominal compression was repeated to reassure complete occlusion of the lymphatic vessel.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>In 13 cases (6.3%), a chyle leak was detected after performing the intraoperative abdominal compression. All leaks except for 2 were successfully controlled after 1 attempt. In these 2 patients, a patch of muscle and fat tissue was applied with fibrin glue on the top. In 1 of these patients, another chyle leak in a different location was detected only at the second intraoperative abdominal compression, and was also effectively closed. Postoperatively, there were 2 (1%) chyle fistulas, both among these 13 cases, and all were successfully managed with clinical measures only. No fistulas occurred among the remaining 193 patients in whom intraoperative abdominal compression did not demonstrate lymphatic leak.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>To our knowledge, this is the first description of a specific maneuver to actively detect a lymphatic fistula at the end of a left neck dissection involving level IV. In this study, intraoperative abdominal compression was able to detect an open lymphatic vessel in 6.3% of the cases, as well as to assure its effective sealing in the remaining 93.7% of the patients. Moreover, no life-threatening high-volume fistula was noted in this study. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundChyle fistulas may occur after left neck dissections that include level IV, due to injury of the thoracic duct or of 1 of its major branches. Despite being unusual, this complication carries substantial postoperative morbidity and even mortality. So far, no effective intraoperative maneuver has been reported to detect this fistula at the end of a neck dissection. In this cohort study, we sought to describe a simple new maneuver, intraoperative abdominal compression, which can effectively help to identify an open major lymphatic duct on level IV at the end of a neck dissection.Patients and MethodsFrom March 1989 to September 2010, 206 patients underwent neck dissections involving left level IV, and underwent intraoperative abdominal compression. There were 119 men and 87 women, with ages ranging from 18 to 81 years (median, 52 years). One hundred forty-four patients had squamous cell carcinomas, 54 had thyroid carcinomas, 5 had malignant melanomas, and 3 had salivary cancers. Distribution by type of left neck dissection was: selective including levels II, III, and IV (73 cases; 35.4%), selective including levels II, III, IV, and V (55 cases; 26.6%), selective including levels I, II, III, and IV (12 cases; 5.8%), modified radical (47 cases; 22.8%), and radical (19 cases; 9.2%). In all cases, at the end of the procedure, the endotracheal tube was temporarily disconnected from the ventilator. Keeping the dissected level IV area under clear visualization, an abdominal compression was performed. At this moment, any detected lymphatic leak was carefully clamped and tied with nonabsorbable sutures. After ventilating the patient, the intraoperative abdominal compression was repeated to reassure complete occlusion of the lymphatic vessel.ResultsIn 13 cases (6.3%), a chyle leak was detected after performing the intraoperative abdominal compression. All leaks except for 2 were successfully controlled after 1 attempt. In these 2 patients, a patch of muscle and fat tissue was applied with fibrin glue on the top. In 1 of these patients, another chyle leak in a different location was detected only at the second intraoperative abdominal compression, and was also effectively closed. Postoperatively, there were 2 (1%) chyle fistulas, both among these 13 cases, and all were successfully managed with clinical measures only. No fistulas occurred among the remaining 193 patients in whom intraoperative abdominal compression did not demonstrate lymphatic leak.ConclusionTo our knowledge, this is the first description of a specific maneuver to actively detect a lymphatic fistula at the end of a left neck dissection involving level IV. In this study, intraoperative abdominal compression was able to detect an open lymphatic vessel in 6.3% of the cases, as well as to assure its effective sealing in the remaining 93.7% of the patients. Moreover, no life-threatening high-volume fistula was noted in this study. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21964" xmlns="http://purl.org/rss/1.0/"><title>Value of narrow band imaging endoscopy in early mucosal head and neck cancer</title><link>http://dx.doi.org/10.1002%2Fhed.21964</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Value of narrow band imaging endoscopy in early mucosal head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yen–Chun Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wen–Hung Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kam–Fai Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wan–Chi Tsai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hsu–Huei Weng</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T04:01:12.124053-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21964</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21964</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21964</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to show the investigated prevalence rate of brownish spots of early cancer under narrow band imaging (NBI) in different sites/types of the epithelium.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>In all, 125 adults with early mucosal cancer underwent NBI examination. Four types of epithelium were categorized: keratinized thick stratified squamous (type 1), nonkeratinized thin (type 2a) or very thick (type 2b) stratified squamous, and pseudo-stratified ciliated columnar epithelium (type 3).</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The prevalence rate of brownish spots in early cancer of the nasopharynx, oral cavity, oropharynx, hypopharynx, and epiglottis were 11.1%, 15.9%, 21.4%, 100%, and 100%, respectively. Type 2a epithelium (odds ratio [OR], 76.45; 95% confidence interval [CI], 9.26–631.14) was a significant predictive factor for the brownish spots.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The brownish spots have higher reliability for screening in early cancer of the mouth floor, hypopharynx, and epiglottis, but not in other mucosal sites. Mucosal sites with type 2a epithelium have a higher tendency of demonstrating brownish spots. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to show the investigated prevalence rate of brownish spots of early cancer under narrow band imaging (NBI) in different sites/types of the epithelium.MethodsIn all, 125 adults with early mucosal cancer underwent NBI examination. Four types of epithelium were categorized: keratinized thick stratified squamous (type 1), nonkeratinized thin (type 2a) or very thick (type 2b) stratified squamous, and pseudo-stratified ciliated columnar epithelium (type 3).ResultsThe prevalence rate of brownish spots in early cancer of the nasopharynx, oral cavity, oropharynx, hypopharynx, and epiglottis were 11.1%, 15.9%, 21.4%, 100%, and 100%, respectively. Type 2a epithelium (odds ratio [OR], 76.45; 95% confidence interval [CI], 9.26–631.14) was a significant predictive factor for the brownish spots.ConclusionThe brownish spots have higher reliability for screening in early cancer of the mouth floor, hypopharynx, and epiglottis, but not in other mucosal sites. Mucosal sites with type 2a epithelium have a higher tendency of demonstrating brownish spots. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21966" xmlns="http://purl.org/rss/1.0/"><title>Anti-proliferative effect of glucocorticoids on mesenchymal cells in juvenile angiofibromas</title><link>http://dx.doi.org/10.1002%2Fhed.21966</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Anti-proliferative effect of glucocorticoids on mesenchymal cells in juvenile angiofibromas</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Olaf Wendler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Julia Dlugaiczyk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephanie Birk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bernhard Schick</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T03:59:50.007394-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21966</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21966</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21966</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Glucocorticoids (GCs) not only regulate metabolic and inflammatory mechanisms, but also are known to suppress tumor growth. Despite previous detection of glucocorticoid receptors (GRs) in juvenile angiofibromas, their distribution and function have not further been studied.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Juvenile angiofibroma tissue (<em>n</em> = 30), nasal mucosa specimens (<em>n</em> = 10), subepithelial stroma of nasal mucosa (<em>n</em> = 20), and primary fibroblasts from juvenile angiofibroma (<em>n</em> = 6) and nasal mucosa samples (<em>n</em> = 6) were analyzed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and immunofluorescence staining. The antiproliferative effect of GCs (dexamethasone, prednisolone, and hydrocortisone) in vitro was assessed using a bromdeoxyuridine (BrdU) assay.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>An upregulation of GR transcripts and protein was shown in juvenile angiofibroma tissue and primary mesenchymal cells compared to nasal mucosa. Application of GCs resulted in a significantly higher antiproliferative effect on juvenile angiofibroma versus nasal mucosa fibroblasts in vitro.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Expression of GRs and antiproliferative effects of GCs on juvenile angiofibroma fibroblasts offer novel options for the treatment of this unique fibrovascular tumor. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundGlucocorticoids (GCs) not only regulate metabolic and inflammatory mechanisms, but also are known to suppress tumor growth. Despite previous detection of glucocorticoid receptors (GRs) in juvenile angiofibromas, their distribution and function have not further been studied.MethodsJuvenile angiofibroma tissue (n = 30), nasal mucosa specimens (n = 10), subepithelial stroma of nasal mucosa (n = 20), and primary fibroblasts from juvenile angiofibroma (n = 6) and nasal mucosa samples (n = 6) were analyzed by quantitative reverse transcriptase-polymerase chain reaction (RT-PCR) and immunofluorescence staining. The antiproliferative effect of GCs (dexamethasone, prednisolone, and hydrocortisone) in vitro was assessed using a bromdeoxyuridine (BrdU) assay.ResultsAn upregulation of GR transcripts and protein was shown in juvenile angiofibroma tissue and primary mesenchymal cells compared to nasal mucosa. Application of GCs resulted in a significantly higher antiproliferative effect on juvenile angiofibroma versus nasal mucosa fibroblasts in vitro.ConclusionExpression of GRs and antiproliferative effects of GCs on juvenile angiofibroma fibroblasts offer novel options for the treatment of this unique fibrovascular tumor. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21967" xmlns="http://purl.org/rss/1.0/"><title>Cephalometric analysis for microvascular head and neck reconstruction</title><link>http://dx.doi.org/10.1002%2Fhed.21967</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cephalometric analysis for microvascular head and neck reconstruction</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Edward I. Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark W. Clemens</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Patrick B. Garvey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roman J. Skoracki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthew M. Hanasono</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T03:59:22.9441-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21967</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21967</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21967</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>While a large body of literature exists involving normative measurements for the craniofacial skeleton, few have analyzed the necessary dimensions that are pertinent in reconstruction using microvascular free flaps.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Cephalometric analysis was performed using 3-dimensional CT scans from 70 adults. Relevant dimensions of the fibula were obtained from a subset of 20 patients.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Normative cephalometric values, including various distances and angles, for the mandible and maxilla were obtained and compared to the dimensions of the fibula. Comparisons were made between measurements from men and women, and patients with full dentition and edentulous patients. Schematics for designing mandibular and maxillary reconstructions are presented.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>When premorbid craniofacial anatomy cannot be discerned in the setting of extensive trauma or tumor involvement, normative dimensions may be a helpful guide for flap design and should be in the armamentarium of surgeons engaged in complex head and heck reconstruction. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundWhile a large body of literature exists involving normative measurements for the craniofacial skeleton, few have analyzed the necessary dimensions that are pertinent in reconstruction using microvascular free flaps.MethodsCephalometric analysis was performed using 3-dimensional CT scans from 70 adults. Relevant dimensions of the fibula were obtained from a subset of 20 patients.ResultsNormative cephalometric values, including various distances and angles, for the mandible and maxilla were obtained and compared to the dimensions of the fibula. Comparisons were made between measurements from men and women, and patients with full dentition and edentulous patients. Schematics for designing mandibular and maxillary reconstructions are presented.ConclusionWhen premorbid craniofacial anatomy cannot be discerned in the setting of extensive trauma or tumor involvement, normative dimensions may be a helpful guide for flap design and should be in the armamentarium of surgeons engaged in complex head and heck reconstruction. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21969" xmlns="http://purl.org/rss/1.0/"><title>mTHPC mediated interstitial photodynamic therapy of recurrent nonmetastatic base of tongue cancers: Development of a new method</title><link>http://dx.doi.org/10.1002%2Fhed.21969</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">mTHPC mediated interstitial photodynamic therapy of recurrent nonmetastatic base of tongue cancers: Development of a new method</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Baris Karakullukcu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Heike J. Nyst</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert L. van Veen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Frank J. P. Hoebers</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Olga Hamming–Vrieze</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Max J. H. Witjes</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sebastiaan A. H. J. de Visscher</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Fred R. Burlage</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter C. Levendag</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Henricus J. C. M. Sterenborg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">I. Bing Tan</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-31T03:56:37.32999-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21969</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21969</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21969</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Interstitial photodynamic therapy (iPDT) can be an option in the management of locally recurrent base of tongue cancer after (chemo)radiation treatment. The purpose of the current study was to develop a technique to implant light sources into the tumor tissue.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Twenty patients with previously irradiated locally recurrent base of tongue cancers who were not candidates for salvage surgery or reirradiation or refused these therapies were included in this study. The treatment planning was done on MRI. The light sources were implanted using modified brachytherapy techniques.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The iPDT could be conducted in all patients without short-term complications. At 6 months, 9 patients had complete response with 4 patients still free of disease (46–80 months). Long-term complications included pharyngocutaneous fistula in 6 patients, serious bleeding in 1 patient, and cutaneous metastasis in 2 patients.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The initial results are encouraging. There is room for improvement to control the destructive potential of iPDT through planning and monitoring tools. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundInterstitial photodynamic therapy (iPDT) can be an option in the management of locally recurrent base of tongue cancer after (chemo)radiation treatment. The purpose of the current study was to develop a technique to implant light sources into the tumor tissue.MethodsTwenty patients with previously irradiated locally recurrent base of tongue cancers who were not candidates for salvage surgery or reirradiation or refused these therapies were included in this study. The treatment planning was done on MRI. The light sources were implanted using modified brachytherapy techniques.ResultsThe iPDT could be conducted in all patients without short-term complications. At 6 months, 9 patients had complete response with 4 patients still free of disease (46–80 months). Long-term complications included pharyngocutaneous fistula in 6 patients, serious bleeding in 1 patient, and cutaneous metastasis in 2 patients.ConclusionThe initial results are encouraging. There is room for improvement to control the destructive potential of iPDT through planning and monitoring tools. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21953" xmlns="http://purl.org/rss/1.0/"><title>Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21953</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Clinical significance of elevated spleen tyrosine kinase expression in nasopharyngeal carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zi–Ming Du</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chang–Wei Kou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hai–Yun Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ma–Yan Huang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ding–Zhun Liao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chun–Fang Hu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jing Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Li–Xu Yan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Li–Fu Hu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ingemar Ernberg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi–Xin Zeng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jian–Yong Shao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T07:01:01.00028-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21953</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21953</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21953</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Spleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase and often aberrantly expressed in human cancers. However, Syk expression pattern has not yet been investigated in nasopharyngeal carcinoma (NPC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Samples of 223 NPC tissues were immunohistochemically stained for Syk expression and survival analysis was then performed. Interaction and co-localization of Syk with Epstein–Barr virus encoded latent membrane protein 2A (LMP2A) was explored.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>High expression of Syk was detected in 24% of NPC cases, and correlated significantly with T classification, local recurrence, a lower 5-year survival rate, and a lower 5-year disease-free survival (DFS) rate. Syk expression was a significant, independent prognosis predictor for patients with NPC. LMP2A induced Syk expression in NPC and LMP2A high expression correlated with Syk high expression in NPC clinical samples.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>High expression of Syk, which results partly from LMP2A expression in NPC, is associated with tumor recurrence and poor prognosis of patients with NPC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundSpleen tyrosine kinase (Syk) is a nonreceptor tyrosine kinase and often aberrantly expressed in human cancers. However, Syk expression pattern has not yet been investigated in nasopharyngeal carcinoma (NPC).MethodsSamples of 223 NPC tissues were immunohistochemically stained for Syk expression and survival analysis was then performed. Interaction and co-localization of Syk with Epstein–Barr virus encoded latent membrane protein 2A (LMP2A) was explored.ResultsHigh expression of Syk was detected in 24% of NPC cases, and correlated significantly with T classification, local recurrence, a lower 5-year survival rate, and a lower 5-year disease-free survival (DFS) rate. Syk expression was a significant, independent prognosis predictor for patients with NPC. LMP2A induced Syk expression in NPC and LMP2A high expression correlated with Syk high expression in NPC clinical samples.ConclusionHigh expression of Syk, which results partly from LMP2A expression in NPC, is associated with tumor recurrence and poor prognosis of patients with NPC. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21952" xmlns="http://purl.org/rss/1.0/"><title>Level V in therapeutic neck dissections for papillary thyroid carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21952</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Level V in therapeutic neck dissections for papillary thyroid carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Avi Khafif</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jesus E. Medina</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">K.Thomas Robbins</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carl E. Silver</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Randal S. Weber</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alessandra Rinaldo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Randall P. Owen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ashok R. Shaha</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfio Ferlito</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:57:19.067452-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21952</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21952</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21952</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Neck dissection for papillary thyroid carcinoma (PTC) is the standard of care for patients with clinical evidence of regional metastases. However, the extent of neck dissection is debatable. The purpose of the current study was to develop evidence-based recommendations for when to include level V, or 1 of its sublevels, among patients with PTC undergoing neck dissection. A literature review of all studies evaluating the occurrence of metastases in level V in patients with regional metastases from PTC undergoing neck dissection was performed. Occurrence of metastases at level V is low in most series (5% to 10%), although a wide range was noticed. In cases in which metastases were found at level V, they occurred almost exclusively at sublevel VB. Sublevel VA was rarely, if ever, involved with metastatic lymph nodes. However, only recently have investigators begun to specify which sublevels of level V are at risk. Therapeutic dissection of level V is indicated when there is clinical evidence of disease involving this zone. Elective dissection of sublevel VB is indicated when there is involvement of level IV, or possibly multiple nodes at levels II and III. Under these circumstances, dissection of sublevel VB is indicated but sublevel VA may be spared. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>]]></content:encoded><description>Neck dissection for papillary thyroid carcinoma (PTC) is the standard of care for patients with clinical evidence of regional metastases. However, the extent of neck dissection is debatable. The purpose of the current study was to develop evidence-based recommendations for when to include level V, or 1 of its sublevels, among patients with PTC undergoing neck dissection. A literature review of all studies evaluating the occurrence of metastases in level V in patients with regional metastases from PTC undergoing neck dissection was performed. Occurrence of metastases at level V is low in most series (5% to 10%), although a wide range was noticed. In cases in which metastases were found at level V, they occurred almost exclusively at sublevel VB. Sublevel VA was rarely, if ever, involved with metastatic lymph nodes. However, only recently have investigators begun to specify which sublevels of level V are at risk. Therapeutic dissection of level V is indicated when there is clinical evidence of disease involving this zone. Elective dissection of sublevel VB is indicated when there is involvement of level IV, or possibly multiple nodes at levels II and III. Under these circumstances, dissection of sublevel VB is indicated but sublevel VA may be spared. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21954" xmlns="http://purl.org/rss/1.0/"><title>High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis</title><link>http://dx.doi.org/10.1002%2Fhed.21954</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">High prevalence of vitamin D insufficiency in patients with head and neck cancer at diagnosis</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Helena Orell–Kotikangas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ursula Schwab</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pia Österlund</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kauko Saarilahti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Outi Mäkitie</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Antti A. Mäkitie</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:57:07.068032-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21954</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21954</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21954</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Low serum levels of vitamin D, measured as serum 25-hydroxy-vitamin D (S-25-OHD), have been observed in several cancers.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Sixty-five adult patients with head and neck cancer, 50 men, median age 61 years (range, 33–77 years), were enrolled in this prospective cohort study. Concentrations of S-25-OHD and plasma calcium (Ca) and phosphate (Pi) were measured before cancer treatment.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The mean S-25-OHD was 42.0 (SD 22) nmol/L. Hypovitaminosis D (37.5–50 nmol/L) was found in 20% of the patients and vitamin D deficiency (&lt;37.5 nmol/L) in 45% of the patients. No seasonal variation was seen. Subnormal plasma Ca and Pi levels were found in 11% and 9% of the patients, respectively.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Subnormal vitamin D levels were found in a significant proportion of the patients. Because vitamin D deficiency may pose these patients to increased risk of therapy-related morbidity, special attention should be paid to correction of this nutritional deficiency. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundLow serum levels of vitamin D, measured as serum 25-hydroxy-vitamin D (S-25-OHD), have been observed in several cancers.MethodsSixty-five adult patients with head and neck cancer, 50 men, median age 61 years (range, 33–77 years), were enrolled in this prospective cohort study. Concentrations of S-25-OHD and plasma calcium (Ca) and phosphate (Pi) were measured before cancer treatment.ResultsThe mean S-25-OHD was 42.0 (SD 22) nmol/L. Hypovitaminosis D (37.5–50 nmol/L) was found in 20% of the patients and vitamin D deficiency (&lt;37.5 nmol/L) in 45% of the patients. No seasonal variation was seen. Subnormal plasma Ca and Pi levels were found in 11% and 9% of the patients, respectively.ConclusionSubnormal vitamin D levels were found in a significant proportion of the patients. Because vitamin D deficiency may pose these patients to increased risk of therapy-related morbidity, special attention should be paid to correction of this nutritional deficiency. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21958" xmlns="http://purl.org/rss/1.0/"><title>Expression of hedgehog signaling molecules as a prognostic indicator of oral squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21958</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Expression of hedgehog signaling molecules as a prognostic indicator of oral squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi–Fen Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chun–Ju Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chin–Ping Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shyue–Yih Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pen–Yuan Chu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shyh–Kuan Tai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wing–Yin Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">K.S. Clifford Chao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu–Jen Chen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:56:55.622562-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21958</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21958</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21958</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Recent studies have indicated hedgehog pathway plays a role in carcinogenesis of certain cancers. We investigated the clinical significance of its signaling components, including Sonic hedgehog (Shh), Patched (Ptch), and Gli-1, in oral squamous cell carcinoma (OSCC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>By immunohistochemistry, we determined Shh, Ptch, and Gli-1 expression in surgical specimens from 40 patients with OSCC. The relationship between expression of these molecules and clinicopathologic variables were assessed by chi-square analysis. Statistical difference of survival was compared using log-rank test.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Ptch overexpression was associated with lymphatic metastasis (<em>p</em> = .028). Nuclear Gli-1 overexpression correlated with primary tumor size (<em>p</em> = .001), lymphatic metastasis (<em>p</em> = .011), and tumor recurrence (<em>p</em> = .008). Overexpression of Ptch (<em>p</em> = .020) or Gli-1 (<em>p</em> = .002) in OSCC indicated poor prognosis in the univariate survival analysis.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Our results suggest sonic hedgehog (Shh) pathway plays an important role in OSCC progression and should be considered a potential therapeutic target. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundRecent studies have indicated hedgehog pathway plays a role in carcinogenesis of certain cancers. We investigated the clinical significance of its signaling components, including Sonic hedgehog (Shh), Patched (Ptch), and Gli-1, in oral squamous cell carcinoma (OSCC).MethodsBy immunohistochemistry, we determined Shh, Ptch, and Gli-1 expression in surgical specimens from 40 patients with OSCC. The relationship between expression of these molecules and clinicopathologic variables were assessed by chi-square analysis. Statistical difference of survival was compared using log-rank test.ResultsPtch overexpression was associated with lymphatic metastasis (p = .028). Nuclear Gli-1 overexpression correlated with primary tumor size (p = .001), lymphatic metastasis (p = .011), and tumor recurrence (p = .008). Overexpression of Ptch (p = .020) or Gli-1 (p = .002) in OSCC indicated poor prognosis in the univariate survival analysis.ConclusionOur results suggest sonic hedgehog (Shh) pathway plays an important role in OSCC progression and should be considered a potential therapeutic target. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21946" xmlns="http://purl.org/rss/1.0/"><title>Maxillary reconstruction using the scapular tip free flap: A radiologic comparison of 3D morphology</title><link>http://dx.doi.org/10.1002%2Fhed.21946</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Maxillary reconstruction using the scapular tip free flap: A radiologic comparison of 3D morphology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nitin A. Pagedar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ralph W. Gilbert</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Harley Chan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael J. Daly</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan C. Irish</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeffrey H. Siewerdsen</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:56:41.55331-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21946</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21946</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21946</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Scapular tip osteomyogenous free flaps have been described for complex palate reconstruction. Minimal osteotomies are needed because of the similar shapes of the scapula and palate. We compared the bony morphology of the palate and scapular tip to determine the suitability of the scapular tip for palate reconstruction.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We analyzed facial and chest CT images of 10 patients, comparing the morphology of 3 simulated palate resection specimens (total palate, subtotal palate, and hemipalate) with corresponding simulated scapular tip bone flaps from the same patient.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Conformance distances between palates and simulated flaps were small, indicating close shape similarity. Median conformance distances were 3.44 mm for hemipalatectomy, 3.56 mm for subtotal palatectomy, and 3.71 mm for total palatectomy. Six outlier observations accrued from 2 patients.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Based on this analysis, there is close similarity between the shapes of the palate and the scapular tip. This similarity supports use of the scapular tip flap for selected palate defects. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundScapular tip osteomyogenous free flaps have been described for complex palate reconstruction. Minimal osteotomies are needed because of the similar shapes of the scapula and palate. We compared the bony morphology of the palate and scapular tip to determine the suitability of the scapular tip for palate reconstruction.MethodsWe analyzed facial and chest CT images of 10 patients, comparing the morphology of 3 simulated palate resection specimens (total palate, subtotal palate, and hemipalate) with corresponding simulated scapular tip bone flaps from the same patient.ResultsConformance distances between palates and simulated flaps were small, indicating close shape similarity. Median conformance distances were 3.44 mm for hemipalatectomy, 3.56 mm for subtotal palatectomy, and 3.71 mm for total palatectomy. Six outlier observations accrued from 2 patients.ConclusionsBased on this analysis, there is close similarity between the shapes of the palate and the scapular tip. This similarity supports use of the scapular tip flap for selected palate defects. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21975" xmlns="http://purl.org/rss/1.0/"><title>Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment</title><link>http://dx.doi.org/10.1002%2Fhed.21975</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Opportunities and challenges facing biomarker development for personalized head and neck cancer treatment</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alexandra V. Lucs</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benjamin Saltman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christine H. Chung</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bettie M. Steinberg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David L. Schwartz</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:56:24.21934-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21975</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21975</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21975</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Basic Science Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Head and neck oncologists have traditionally relied on clinical tumor features and patient characteristics to guide care of individual patients. As surgical, radiotherapeutic, and systemic treatments have evolved to become more anatomically precise and mechanistically specific, the opportunity for improved cure and functional patient recovery has never been more promising for this historically debilitating cancer. However, personalized treatment must be accompanied by sophisticated patient selection to triage the application of advanced therapies toward ideal patient candidates. In this monograph, we review current progress, investigative themes, and key challenges facing head and neck cancer biomarker development intended to make personalized head and neck cancer treatment a clinical reality. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div>]]></content:encoded><description>Head and neck oncologists have traditionally relied on clinical tumor features and patient characteristics to guide care of individual patients. As surgical, radiotherapeutic, and systemic treatments have evolved to become more anatomically precise and mechanistically specific, the opportunity for improved cure and functional patient recovery has never been more promising for this historically debilitating cancer. However, personalized treatment must be accompanied by sophisticated patient selection to triage the application of advanced therapies toward ideal patient candidates. In this monograph, we review current progress, investigative themes, and key challenges facing head and neck cancer biomarker development intended to make personalized head and neck cancer treatment a clinical reality. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21998" xmlns="http://purl.org/rss/1.0/"><title>Emergency airway management: Training and experience of chief residents in otolaryngology and anesthesiology</title><link>http://dx.doi.org/10.1002%2Fhed.21998</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Emergency airway management: Training and experience of chief residents in otolaryngology and anesthesiology</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James D. Andrews</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cheryl C. Nocon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stephen M. Small</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jayant M. Pinto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Elizabeth A. Blair</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:54:46.273936-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21998</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21998</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21998</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Resident training in emergency airway management is not well described. We quantified training and exposure to airway emergencies among graduating Otolaryngology–Head and Neck Surgery and Anesthesiology residents.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>The methods used for this study were a national web-based survey of chief residents.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The response rate was 52% (otolaryngology) and 60% (anesthesiology). More otolaryngology residents rotated on anesthesiology than anesthesia residents on otolaryngology (33% vs 8%). More anesthesiology chiefs never performed an emergency surgical airway than otolaryngology (92% vs 18%). The most common self-rating of competency was “9,” with 82% overall self-rating “8” or higher (10 = “totally competent”).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Otolaryngology and anesthesiology emergency airway management experience/training is heterogeneous and nonstandardized. Many chief residents graduate with little exposure to airway emergencies, especially surgical airways. Resident confidence levels are high despite minimal experience. This high confidence-low experience dichotomy may reflect novice overconfidence and suggests the need for improved training methods. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundResident training in emergency airway management is not well described. We quantified training and exposure to airway emergencies among graduating Otolaryngology–Head and Neck Surgery and Anesthesiology residents.MethodsThe methods used for this study were a national web-based survey of chief residents.ResultsThe response rate was 52% (otolaryngology) and 60% (anesthesiology). More otolaryngology residents rotated on anesthesiology than anesthesia residents on otolaryngology (33% vs 8%). More anesthesiology chiefs never performed an emergency surgical airway than otolaryngology (92% vs 18%). The most common self-rating of competency was “9,” with 82% overall self-rating “8” or higher (10 = “totally competent”).ConclusionOtolaryngology and anesthesiology emergency airway management experience/training is heterogeneous and nonstandardized. Many chief residents graduate with little exposure to airway emergencies, especially surgical airways. Resident confidence levels are high despite minimal experience. This high confidence-low experience dichotomy may reflect novice overconfidence and suggests the need for improved training methods. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22004" xmlns="http://purl.org/rss/1.0/"><title>inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.22004</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">inducTION of mage-A3 and HPV-16 immunity by Trojan vaccines in patients with head and neck carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Caroline J. Voskens</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Duane Sewell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ronna Hertzano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jennifer DeSanto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sandra Rollins</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Myounghee Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rodney Taylor</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeffrey Wolf</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mohan Suntharalingam</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Brian Gastman</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John C. Papadimitriou</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Changwan Lu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ming Tan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert Morales</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kevin Cullen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Esteban Celis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dean Mann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Scott E. Strome</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:54:36.832651-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22004</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22004</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22004</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>We performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a “penetrin” peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Enrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Following vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>This treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundWe performed a pilot study using Trojan vaccines in patients with advanced squamous cell carcinoma of the head and neck (SCCHN). These vaccines are composed of HLA-I and HLA-II restricted melanoma antigen E (MAGE)-A3 or human papillomavirus (HPV)-16 derived peptides, joined by furin-cleavable linkers, and linked to a “penetrin” peptide sequence derived from HIV-TAT. Thirty-one patients with SCCHN were screened for the trial and 5 were enrolled.MethodsEnrolled patients were treated with 300 μg of Trojan peptide supplemented with Montanide and granulocyte-macrophage colony-stimulating factor (GM-CSF) at 4-week intervals for up to 4 injections.ResultsFollowing vaccination, peripheral blood mononuclear cells (PBMCs) from 4 of 5 patients recognized both the full Trojan constructs and constituent HLA-II peptides, whereas responses to HLA-I restricted peptides were less pronounced.ConclusionThis treatment regimen seems to have acceptable toxicity and elicits measurable systemic immune responses against HLA-II restricted epitopes in a subset of patients with advanced SCCHN. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22926" xmlns="http://purl.org/rss/1.0/"><title>t(3;8) as the sole chromosomal abnormality in a myoepithelial carcinoma ex pleomorphic adenoma: A putative progression event</title><link>http://dx.doi.org/10.1002%2Fhed.22926</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">t(3;8) as the sole chromosomal abnormality in a myoepithelial carcinoma ex pleomorphic adenoma: A putative progression event</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Diana Bell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeffrey N. Myers</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Pulivarthi H. Rao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adel K. El-Naggar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:54:20.121148-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22926</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22926</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22926</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Carcinoma ex pleomorphic adenoma (Ca ex-PA) is defined as a carcinoma arising from a primary (de novo) or recurrent benign pleomorphic adenoma (PA).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We present a parotid myoepithelial carcinoma ex pleomorphic adenoma in a 38-year-old man with a t(3;8)(p21;q13) as the only chromosomal alteration by cytogenetic and spectral karyotypic analysis (SKY).</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The finding of this translocation in a subset of PA and in the present case suggests a critical role for this event in the malignant transformation of PA.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Collectively, both the cytogenetic and the molecular studies suggest the concept that PA lacking alterations pursue a benign behavior, whereas those with the t(3;8) translocation may progress to carcinoma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundCarcinoma ex pleomorphic adenoma (Ca ex-PA) is defined as a carcinoma arising from a primary (de novo) or recurrent benign pleomorphic adenoma (PA).MethodsWe present a parotid myoepithelial carcinoma ex pleomorphic adenoma in a 38-year-old man with a t(3;8)(p21;q13) as the only chromosomal alteration by cytogenetic and spectral karyotypic analysis (SKY).ResultsThe finding of this translocation in a subset of PA and in the present case suggests a critical role for this event in the malignant transformation of PA.ConclusionsCollectively, both the cytogenetic and the molecular studies suggest the concept that PA lacking alterations pursue a benign behavior, whereas those with the t(3;8) translocation may progress to carcinoma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22934" xmlns="http://purl.org/rss/1.0/"><title>Viability of full-thickness skin grafts used for correction of cicatricial ectropion of lower eyelid in previously irradiated field in the periocular region</title><link>http://dx.doi.org/10.1002%2Fhed.22934</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Viability of full-thickness skin grafts used for correction of cicatricial ectropion of lower eyelid in previously irradiated field in the periocular region</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hee Joon Kim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Brent Hayek</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Qasiem Nasser</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Bita Esmaeli</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-27T06:54:09.618219-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22934</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22934</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22934</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to evaluate the viability of skin grafts used for correction of cicatricial ectropion resulting from previous ablative surgery and radiotherapy for head and neck cancer and to report overall outcomes of cicatricial ectropion repair.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This is a retrospective, noncomparative case series of all consecutive patients with head and neck cancer who had been exposed to high-dose radiation therapy in their periocular region and had surgical correction of their lower eyelid cicatricial ectropion through placement of a full-thickness skin graft and a lower eyelid tightening procedure by the same surgeon. The primary outcome measure was skin graft viability. Secondary outcome measures comprised postoperative complications, the overall outcome of ectropion repair as judged by improvement in symptoms of exposure keratopathy, and dependence on lubricating eye drops and ointments, as well as cosmetic improvement measured through a grading scale based on the degree of inferior scleral show and/or tarsal conjunctival eversion.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Twenty-five patients were eligible for the study. Nineteen men and 6 women had a median age of 63 years (range, 20–84 years). All 25 patients had high-dose radiation therapy for their head and neck cancer. All but 1 patient had major cancer ablative surgery performed before radiation therapy. Thirteen of 25 patients also received chemotherapy. There was 100% viability of the skin grafts used for the repair of lower eyelid cicatricial ectropion. There were a few postoperative complications including the need for revision surgery to correct residual ectropion in the lower eyelid in 2 patients, and a third patient required a revision surgery due to upper eyelid retraction and lagophthalmos after harvest of skin graft from the upper eyelid. Improvement was noted in the subjective symptoms in 22 of 25 patients (88%), whereas 17 patients (68%) were noted to have improvement in their clinical findings on slit lamp examination. All 20 patients, for whom good quality photos were available, had improvement in the degree of cicatricial lower eyelid ectropion as measured by the amount of inferior scleral show and tarsal conjunctival eversion, although 11 patients had some residual ectropion. All 20 had either good or excellent results in the appearance of their skin grafts.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Our findings suggest that full-thickness skin grafts are a nice option for correction of cicatricial lower eyelid ectropion in a previously radiated field; 100% of the grafts survived. The majority of patients had improvement of ocular surface damage and symptoms, with a decreased dependence on topical lubricants. All evaluable patients had improvement in the degree of cicatricial lower eyelid ectropion, although close to one-half of patients had some mild residual ectropion. The majority of patients had excellent appearance of the skin graft. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to evaluate the viability of skin grafts used for correction of cicatricial ectropion resulting from previous ablative surgery and radiotherapy for head and neck cancer and to report overall outcomes of cicatricial ectropion repair.MethodsThis is a retrospective, noncomparative case series of all consecutive patients with head and neck cancer who had been exposed to high-dose radiation therapy in their periocular region and had surgical correction of their lower eyelid cicatricial ectropion through placement of a full-thickness skin graft and a lower eyelid tightening procedure by the same surgeon. The primary outcome measure was skin graft viability. Secondary outcome measures comprised postoperative complications, the overall outcome of ectropion repair as judged by improvement in symptoms of exposure keratopathy, and dependence on lubricating eye drops and ointments, as well as cosmetic improvement measured through a grading scale based on the degree of inferior scleral show and/or tarsal conjunctival eversion.ResultsTwenty-five patients were eligible for the study. Nineteen men and 6 women had a median age of 63 years (range, 20–84 years). All 25 patients had high-dose radiation therapy for their head and neck cancer. All but 1 patient had major cancer ablative surgery performed before radiation therapy. Thirteen of 25 patients also received chemotherapy. There was 100% viability of the skin grafts used for the repair of lower eyelid cicatricial ectropion. There were a few postoperative complications including the need for revision surgery to correct residual ectropion in the lower eyelid in 2 patients, and a third patient required a revision surgery due to upper eyelid retraction and lagophthalmos after harvest of skin graft from the upper eyelid. Improvement was noted in the subjective symptoms in 22 of 25 patients (88%), whereas 17 patients (68%) were noted to have improvement in their clinical findings on slit lamp examination. All 20 patients, for whom good quality photos were available, had improvement in the degree of cicatricial lower eyelid ectropion as measured by the amount of inferior scleral show and tarsal conjunctival eversion, although 11 patients had some residual ectropion. All 20 had either good or excellent results in the appearance of their skin grafts.ConclusionOur findings suggest that full-thickness skin grafts are a nice option for correction of cicatricial lower eyelid ectropion in a previously radiated field; 100% of the grafts survived. The majority of patients had improvement of ocular surface damage and symptoms, with a decreased dependence on topical lubricants. All evaluable patients had improvement in the degree of cicatricial lower eyelid ectropion, although close to one-half of patients had some mild residual ectropion. The majority of patients had excellent appearance of the skin graft. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22924" xmlns="http://purl.org/rss/1.0/"><title>Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.22924</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Alterations of Smad expression and activation in defining 2 subtypes of human head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wen Xie</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Seena Aisner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Soly Baredes</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gangadhar Sreepada</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rasesh Shah</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Reiss</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-24T09:16:32.461057-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22924</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22924</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22924</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>We postulated that disruptions of the canonical transforming growth factor-beta (TGF-β)/Smad signaling pathway might contribute to the development of head and neck squamous cell carcinoma (HNSCC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A cohort of 798 HNSCC tumor samples from 346 patients were analyzed by immunohistochemistry (IHC) to define the pattern of expression of (phospho)Smad2, (phospho)Smad3, and Smad4.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>We found that 19%, 40%, and 12% of HNSCC specimens failed to express pSmad2, pSmad3, or Smad4, respectively. Loss of Smad2/3 activation was observed in 8.5% of specimens. In addition, 4% of specimens failed to express only Smad4. Moreover, patients with pSmad2/3-negative tumors had a significantly better overall survival than that of those whose tumors expressed activated Smad2/3. In contrast, loss of Smad4 expression did not have prognostic significance.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Our results indicate that HNSCC in which Smad2/3 are inactivated or in which Smad4 expression is lost represent 2 distinct tumor subtypes with different clinical outcomes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundWe postulated that disruptions of the canonical transforming growth factor-beta (TGF-β)/Smad signaling pathway might contribute to the development of head and neck squamous cell carcinoma (HNSCC).MethodsA cohort of 798 HNSCC tumor samples from 346 patients were analyzed by immunohistochemistry (IHC) to define the pattern of expression of (phospho)Smad2, (phospho)Smad3, and Smad4.ResultsWe found that 19%, 40%, and 12% of HNSCC specimens failed to express pSmad2, pSmad3, or Smad4, respectively. Loss of Smad2/3 activation was observed in 8.5% of specimens. In addition, 4% of specimens failed to express only Smad4. Moreover, patients with pSmad2/3-negative tumors had a significantly better overall survival than that of those whose tumors expressed activated Smad2/3. In contrast, loss of Smad4 expression did not have prognostic significance.ConclusionOur results indicate that HNSCC in which Smad2/3 are inactivated or in which Smad4 expression is lost represent 2 distinct tumor subtypes with different clinical outcomes. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22903" xmlns="http://purl.org/rss/1.0/"><title>Pattern and predictive factors of regional lymph node metastasis in papillary thyroid carcinoma: A prospective study</title><link>http://dx.doi.org/10.1002%2Fhed.22903</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Pattern and predictive factors of regional lymph node metastasis in papillary thyroid carcinoma: A prospective study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Inn Chul Nam</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jun Ook Park</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Young Hoon Joo</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kwang Jae Cho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Min Sik Kim</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:15:36.512459-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22903</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22903</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22903</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Most of the reports about lymph node (LN) metastasis in papillary thyroid carcinoma (PTC) are retrospective studies.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We prospectively evaluated the pattern and predictive factors of LN metastasis of 176 patients with PTC who underwent total thyroidectomy and bilateral central LN dissection with or without therapeutic lateral LN dissection.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Ipsilateral central LNs were involved even in early T classification, and contralateral central LNs were infrequently involved even in late T classification. Most of the lateral LN metastases were in levels II, III, and IV. Male sex was predictive of LN metastasis. Ipsilateral central LN metastasis and central LN metastasis were associated with contralateral central LN metastasis and lateral LN metastasis, respectively.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Ipsilateral central neck dissection is recommended for all PTC patients. Careful inspection for LN metastasis should be performed when evaluating male patients with PTC, and if central LNs are involved, carefully inspect lateral LNs. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundMost of the reports about lymph node (LN) metastasis in papillary thyroid carcinoma (PTC) are retrospective studies.MethodsWe prospectively evaluated the pattern and predictive factors of LN metastasis of 176 patients with PTC who underwent total thyroidectomy and bilateral central LN dissection with or without therapeutic lateral LN dissection.ResultsIpsilateral central LNs were involved even in early T classification, and contralateral central LNs were infrequently involved even in late T classification. Most of the lateral LN metastases were in levels II, III, and IV. Male sex was predictive of LN metastasis. Ipsilateral central LN metastasis and central LN metastasis were associated with contralateral central LN metastasis and lateral LN metastasis, respectively.ConclusionsIpsilateral central neck dissection is recommended for all PTC patients. Careful inspection for LN metastasis should be performed when evaluating male patients with PTC, and if central LNs are involved, carefully inspect lateral LNs. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22907" xmlns="http://purl.org/rss/1.0/"><title>CO2 laser surgery in elderly patients with glottic carcinoma: Univariate and multivariate analyses of results</title><link>http://dx.doi.org/10.1002%2Fhed.22907</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">CO2 laser surgery in elderly patients with glottic carcinoma: Univariate and multivariate analyses of results</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Marco Lucioni</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andy Bertolin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Rizzotto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daria Accordi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Luciano Giacomelli</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gino Marioni</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:14:56.814579-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22907</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22907</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22907</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>There are limited data on the role of laser-assisted surgery for early glottic cancer in elderly patients.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This retrospective study was conducted on a series of 130 consecutive cases of early glottic carcinoma occurring in elderly patients (&gt;65 years old) treated with CO<sub>2</sub> laser surgery.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The overall and disease-specific survival rates were 87.7% and 99.2%, respectively. The rates of local disease control after primary laser surgery, ultimate local control with laser alone, and laryngeal preservation were 84.6%, 93.8%, and 96.9%, respectively. A shorter disease-free survival (DFS) was associated with the involvement of 1 or more specific laryngeal regions (arytenoids, ventricle, anterior commissure, vocal muscle, subglottis) (<em>p</em> = .01) and the status of the surgical margins (<em>p</em> = .002); on multivariate analysis, only the latter remained prognostically significant vis-à-vis the DFS (<em>p</em> = .002).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Even in elderly patients with early glottic carcinoma, endoscopic laser surgery is an effective treatment. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThere are limited data on the role of laser-assisted surgery for early glottic cancer in elderly patients.MethodsThis retrospective study was conducted on a series of 130 consecutive cases of early glottic carcinoma occurring in elderly patients (&gt;65 years old) treated with CO2 laser surgery.ResultsThe overall and disease-specific survival rates were 87.7% and 99.2%, respectively. The rates of local disease control after primary laser surgery, ultimate local control with laser alone, and laryngeal preservation were 84.6%, 93.8%, and 96.9%, respectively. A shorter disease-free survival (DFS) was associated with the involvement of 1 or more specific laryngeal regions (arytenoids, ventricle, anterior commissure, vocal muscle, subglottis) (p = .01) and the status of the surgical margins (p = .002); on multivariate analysis, only the latter remained prognostically significant vis-à-vis the DFS (p = .002).ConclusionsEven in elderly patients with early glottic carcinoma, endoscopic laser surgery is an effective treatment. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22913" xmlns="http://purl.org/rss/1.0/"><title>Distant metastases from cutaneous squamous cell carcinoma—analysis of AJCC stage IV</title><link>http://dx.doi.org/10.1002%2Fhed.22913</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Distant metastases from cutaneous squamous cell carcinoma—analysis of AJCC stage IV</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Markus Brunner</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael J. Veness</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sydney Ch'ng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Elliott</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan R. Clark</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:14:39.623092-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22913</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22913</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22913</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The seventh edition of the American Joint Committee on Cancer (AJCC) Staging Manual introduced a more detailed system to stage regional lymph node metastases for disease with cutaneous squamous cell carcinoma (SCC). The purpose of this study was to determine if the inclusion of disease staged N2 and N3 together with disease staged M1 is an appropriate grouping within stage IV.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A retrospective multicenter analysis was conducted of 603 patients with metastatic cutaneous SCC to compare survival data for regional (N2 and N3) versus distant metastases.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Disease specific survival (DSS) and overall survival (OS) were much poorer for patients with distant disease compared to those with different stages of regional disease. After 5 years, only 25% of patients with N2 disease and 35% of patients with N3 disease died from their cancer compared with 89% of patients with distant metastases.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Our results indicate that in cutaneous SCC, stage IV represents a very heterogeneous group. Therefore, N2 and N3 disease should not be grouped with M1 together within AJCC stage IV. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe seventh edition of the American Joint Committee on Cancer (AJCC) Staging Manual introduced a more detailed system to stage regional lymph node metastases for disease with cutaneous squamous cell carcinoma (SCC). The purpose of this study was to determine if the inclusion of disease staged N2 and N3 together with disease staged M1 is an appropriate grouping within stage IV.MethodsA retrospective multicenter analysis was conducted of 603 patients with metastatic cutaneous SCC to compare survival data for regional (N2 and N3) versus distant metastases.ResultsDisease specific survival (DSS) and overall survival (OS) were much poorer for patients with distant disease compared to those with different stages of regional disease. After 5 years, only 25% of patients with N2 disease and 35% of patients with N3 disease died from their cancer compared with 89% of patients with distant metastases.ConclusionOur results indicate that in cutaneous SCC, stage IV represents a very heterogeneous group. Therefore, N2 and N3 disease should not be grouped with M1 together within AJCC stage IV. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22916" xmlns="http://purl.org/rss/1.0/"><title>Improved outcomes in buccal squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.22916</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Improved outcomes in buccal squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chun–Shu Lin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yee–Min Jen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Woei–Yau Kao</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ching–Liang Ho</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ming–Shen Dai</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chia–Lin Shih</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jen–Chan Cheng</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ping–Ying Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wen–Yen Huang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yu–Fu Su</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:14:20.390187-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22916</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22916</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22916</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The treatment results of buccal squamous cell carcinoma before and after 2002 were compared.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Two hundred forty-five patients with buccal cancer who underwent curative treatment were retrospectively reviewed.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The 5-year overall survival rate was 30.0% before 2002 and 53.5% after 2002 (<em>p</em> = .004). On multivariate analysis, T classification, surgical margins, and treatment modality significantly affected overall survival, and N classification and histologic grade had trends to affect it. Invasion depth had a trend to influence locoregional control. For patients with early-stage disease without adverse factors, the locoregional control was similar between surgery alone group and surgery + radiotherapy group.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The survival of patients with buccal cancer was improved after 2002, which represented the start of intensity-modulated radiotherapy (IMRT) in our institute. Ipsilateral neck alone irradiation was recommended for T1-2N0-1 and small T3N0 disease, and bilateral neck irradiation could be reserved for advanced disease. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe treatment results of buccal squamous cell carcinoma before and after 2002 were compared.MethodsTwo hundred forty-five patients with buccal cancer who underwent curative treatment were retrospectively reviewed.ResultsThe 5-year overall survival rate was 30.0% before 2002 and 53.5% after 2002 (p = .004). On multivariate analysis, T classification, surgical margins, and treatment modality significantly affected overall survival, and N classification and histologic grade had trends to affect it. Invasion depth had a trend to influence locoregional control. For patients with early-stage disease without adverse factors, the locoregional control was similar between surgery alone group and surgery + radiotherapy group.ConclusionThe survival of patients with buccal cancer was improved after 2002, which represented the start of intensity-modulated radiotherapy (IMRT) in our institute. Ipsilateral neck alone irradiation was recommended for T1-2N0-1 and small T3N0 disease, and bilateral neck irradiation could be reserved for advanced disease. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22919" xmlns="http://purl.org/rss/1.0/"><title>Outcomes of combined oncologic resection and carotid endarterectomy in patients with head and neck cancer</title><link>http://dx.doi.org/10.1002%2Fhed.22919</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Outcomes of combined oncologic resection and carotid endarterectomy in patients with head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Teresa R. Kroeker</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John C. O'Brien</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:13:57.883975-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22919</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22919</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22919</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Patients with head and neck cancer have similar risk factors to patients with carotid disease. Patients with head and neck cancer should be screened with vascular consultations obtained as indicated. Identification of significant carotid artery disease before surgical treatment of head and neck cancer is important in order to prevent perioperative and future strokes.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Eleven patients underwent carotid duplex ultrasound followed by vascular consultation for significant asymptomatic and symptomatic carotid stenosis. Carotid endarterectomy was performed during an oncologic resection of head and neck cancer between the years of 1996 and 2011.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>There were no local or regional recurrences. There were no perioperative deaths or strokes. Two-year and 5-year survival were 70% and 29%, respectively, with a median survival of 51 months.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Collaboration of head and neck surgeons with vascular surgeons provides the patient with an oncologic resection and revascularization with a low perioperative risk of stroke. This improves the patient's quality of life by lessening the possibility of a stroke postoperatively. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundPatients with head and neck cancer have similar risk factors to patients with carotid disease. Patients with head and neck cancer should be screened with vascular consultations obtained as indicated. Identification of significant carotid artery disease before surgical treatment of head and neck cancer is important in order to prevent perioperative and future strokes.MethodsEleven patients underwent carotid duplex ultrasound followed by vascular consultation for significant asymptomatic and symptomatic carotid stenosis. Carotid endarterectomy was performed during an oncologic resection of head and neck cancer between the years of 1996 and 2011.ResultsThere were no local or regional recurrences. There were no perioperative deaths or strokes. Two-year and 5-year survival were 70% and 29%, respectively, with a median survival of 51 months.ConclusionCollaboration of head and neck surgeons with vascular surgeons provides the patient with an oncologic resection and revascularization with a low perioperative risk of stroke. This improves the patient's quality of life by lessening the possibility of a stroke postoperatively. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22921" xmlns="http://purl.org/rss/1.0/"><title>Relation between the dimensions and intraluminal pressure of the pharyngoesophageal segment and tracheoesophageal voice and speech proficiency</title><link>http://dx.doi.org/10.1002%2Fhed.22921</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Relation between the dimensions and intraluminal pressure of the pharyngoesophageal segment and tracheoesophageal voice and speech proficiency</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Telma Kioko Takeshita</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Henrique Ceretta Zozolotto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eduardo Alvarez Ribeiro</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hilton Ricz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Paulo Mazzoncini de Azevedo-Marques</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Roberto Oliveira Dantas</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lílian Aguiar-Ricz</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:13:39.128745-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22921</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22921</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22921</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The objective of the present study was to relate the dimensions and the intraluminal pressure of the pharyngoesophageal segment (PES) to the voice and speech proficiency of total laryngectomees with a tracheoesophageal prosthesis (TEP).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Twenty total laryngectomees with secondary TEP insertion underwent evaluation of voice and speech, manometry, and videofluoroscopy.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Most laryngectomees (65%) were moderate speakers. The poorer speakers presented a lower intraluminal pressure in the PES at rest (4.44 mmHg) and a higher value (40.46 mmHg) during phonation. Good speakers presented a significant difference in the anteroposterior distance between prominence of the PES and the posterior pharyngeal wall (PPES-PPW) in the rest (6.09 mm) to phonation (3.24 mm).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>The poorer speakers presented a lower intraluminal pressure in the PES at rest and a higher value during phonation compared with moderate speakers. Good speakers showed a significant difference in the PPES-PPW dimension. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe objective of the present study was to relate the dimensions and the intraluminal pressure of the pharyngoesophageal segment (PES) to the voice and speech proficiency of total laryngectomees with a tracheoesophageal prosthesis (TEP).MethodsTwenty total laryngectomees with secondary TEP insertion underwent evaluation of voice and speech, manometry, and videofluoroscopy.ResultsMost laryngectomees (65%) were moderate speakers. The poorer speakers presented a lower intraluminal pressure in the PES at rest (4.44 mmHg) and a higher value (40.46 mmHg) during phonation. Good speakers presented a significant difference in the anteroposterior distance between prominence of the PES and the posterior pharyngeal wall (PPES-PPW) in the rest (6.09 mm) to phonation (3.24 mm).ConclusionsThe poorer speakers presented a lower intraluminal pressure in the PES at rest and a higher value during phonation compared with moderate speakers. Good speakers showed a significant difference in the PPES-PPW dimension. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21874" xmlns="http://purl.org/rss/1.0/"><title>Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer</title><link>http://dx.doi.org/10.1002%2Fhed.21874</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Comparison of limited-volume perioperative high-dose-rate brachytherapy and wide-field external irradiation in resected head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miren Gaztañaga</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">María Pagola</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mauricio Cambeiro</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Maria E. Rodriguez Ruiz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Javier Aristu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Néstor Montesdeoca</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juan Alcalde</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rafael Martínez-Monge</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:13:26.422817-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21874</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21874</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21874</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>This study aimed to test the safety of using perioperative high-dose-rate brachytherapy (PHDRB) in resected head and neck cancer.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>From 2000 to 2008, 97 patients received PHDRB after complete macroscopic resection. Group 1 (previously irradiated patients) received 32 to 40 Gray (Gy) of PHDRB in 8 to 10 twice-daily (bid) treatments (R0–R1 resections). Group 2 (unirradiated patients) received 16 to 24 Gy of PHDRB in 4 to 6 bid treatments (R0–R1 resections) followed by external beam irradiation (EBRT) of 45 Gy/25 daily fractions ± concomitant chemotherapy.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The median follow-up was 4.3 years. The cumulative hazard of 2-year grade ≥ 3 complications in group 1 was 45.9%, and the rate of grade ≥ 3 complications in group 2 was 24.6%. Actuarial locoregional control at 2 and 5 years for group 1 was 60.9% and for group 2, 84.1% and 79.4%.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Complications and locoregional failure rates were similar to those reported in the reference standards despite a much smaller treatment volume. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThis study aimed to test the safety of using perioperative high-dose-rate brachytherapy (PHDRB) in resected head and neck cancer.MethodsFrom 2000 to 2008, 97 patients received PHDRB after complete macroscopic resection. Group 1 (previously irradiated patients) received 32 to 40 Gray (Gy) of PHDRB in 8 to 10 twice-daily (bid) treatments (R0–R1 resections). Group 2 (unirradiated patients) received 16 to 24 Gy of PHDRB in 4 to 6 bid treatments (R0–R1 resections) followed by external beam irradiation (EBRT) of 45 Gy/25 daily fractions ± concomitant chemotherapy.ResultsThe median follow-up was 4.3 years. The cumulative hazard of 2-year grade ≥ 3 complications in group 1 was 45.9%, and the rate of grade ≥ 3 complications in group 2 was 24.6%. Actuarial locoregional control at 2 and 5 years for group 1 was 60.9% and for group 2, 84.1% and 79.4%.ConclusionsComplications and locoregional failure rates were similar to those reported in the reference standards despite a much smaller treatment volume. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21980" xmlns="http://purl.org/rss/1.0/"><title>Minor salivary gland malignancies in the pediatric population</title><link>http://dx.doi.org/10.1002%2Fhed.21980</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Minor salivary gland malignancies in the pediatric population</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chad Galer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfredo A. Santillan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Daniel Chelius</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Winston Huh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adel El-Naggar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ehab. Hanna</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Randal S. Weber</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael E. Kupferman</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:13:11.214189-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21980</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21980</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21980</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Minor salivary gland malignancies in children are rare and data on treatment and outcomes are limited.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>A retrospective chart review of all pediatric patients with the pathologic diagnosis of minor salivary gland malignancy at a tertiary care cancer hospital was used to conduct this review.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>From 1952 to 2006, 35 children with minor salivary gland cancers were treated at The University of Texas MD Anderson Cancer Center. Mean age was 15.2 +/- 2.9 years with a slight female predominance. Recurrence occurred in 4 patients and was significantly associated with positive margins, advanced stage, and high histologic grade. Overall survival (OS) and disease-specific survival (DSS) were 89.3% and 88.4%, respectively, at 5 years. Advanced stage, positive margins, and high grade were associated with adverse survival.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Minor salivary gland malignancies in children are rare. Surgical resection with clear margins yields excellent outcomes in patients with low-intermediate grade and early stage tumors. Patients with high-grade malignancies do poorly despite multimodality therapy. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundMinor salivary gland malignancies in children are rare and data on treatment and outcomes are limited.MethodsA retrospective chart review of all pediatric patients with the pathologic diagnosis of minor salivary gland malignancy at a tertiary care cancer hospital was used to conduct this review.ResultsFrom 1952 to 2006, 35 children with minor salivary gland cancers were treated at The University of Texas MD Anderson Cancer Center. Mean age was 15.2 +/- 2.9 years with a slight female predominance. Recurrence occurred in 4 patients and was significantly associated with positive margins, advanced stage, and high histologic grade. Overall survival (OS) and disease-specific survival (DSS) were 89.3% and 88.4%, respectively, at 5 years. Advanced stage, positive margins, and high grade were associated with adverse survival.ConclusionMinor salivary gland malignancies in children are rare. Surgical resection with clear margins yields excellent outcomes in patients with low-intermediate grade and early stage tumors. Patients with high-grade malignancies do poorly despite multimodality therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21981" xmlns="http://purl.org/rss/1.0/"><title>Volumetric change of human papillomavirus–related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy</title><link>http://dx.doi.org/10.1002%2Fhed.21981</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Volumetric change of human papillomavirus–related neck lymph nodes before, during, and shortly after intensity-modulated radiation therapy</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Giuseppe Sanguineti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francesco Ricchetti</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Binbin Wu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nishant Agrawal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christine Gourin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Harold Agbahiwe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shanthi Marur</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Stefania Clemente</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Todd McNutt</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Arlene Forastiere</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:12:52.049966-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21981</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21981</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21981</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>To assess volumetric changes of human papillomavirus (HPV)-related lymph nodes (LN) before, during, and after a course of intensity-modulated radiation therapy (IMRT) ± chemotherapy.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Each “pathologic” LN (≥1 cm) was contoured on the available diagnostic/planning CTs before, during each week, and after treatment.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Seventy-nine LNs in 50 patients were identified. Beyond the first week of treatment, 3 patterns of LN change were recorded: consistently shrinking LN (<em>n</em> = 33; 41.8%), inconsistently shrinking LN with temporary enlargement limited to the first week (<em>n</em> = 14; 17.7%), or also during the subsequent weeks (<em>n</em> = 32; 40.5%). Nodal density at planning is highly predictive of group assignment, with a larger mean density for consistently over inconsistently shrinking LNs (<em>p</em> = .009). Also, this grouping predicts the response at the end of treatment.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>HPV-related LN behavior during IMRT is extremely variable but somewhat predictable on the basis of nodal density at planning. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundTo assess volumetric changes of human papillomavirus (HPV)-related lymph nodes (LN) before, during, and after a course of intensity-modulated radiation therapy (IMRT) ± chemotherapy.MethodsEach “pathologic” LN (≥1 cm) was contoured on the available diagnostic/planning CTs before, during each week, and after treatment.ResultsSeventy-nine LNs in 50 patients were identified. Beyond the first week of treatment, 3 patterns of LN change were recorded: consistently shrinking LN (n = 33; 41.8%), inconsistently shrinking LN with temporary enlargement limited to the first week (n = 14; 17.7%), or also during the subsequent weeks (n = 32; 40.5%). Nodal density at planning is highly predictive of group assignment, with a larger mean density for consistently over inconsistently shrinking LNs (p = .009). Also, this grouping predicts the response at the end of treatment.ConclusionHPV-related LN behavior during IMRT is extremely variable but somewhat predictable on the basis of nodal density at planning. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21985" xmlns="http://purl.org/rss/1.0/"><title>Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand </title><link>http://dx.doi.org/10.1002%2Fhed.21985</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand </dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Haili Sun</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yuhe Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Dingfang Bu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiang Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">James S. Norris</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shuifang Xiao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:12:36.224553-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21985</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21985</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21985</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Apoptosis induced by Fas/FasL system has been proposed as a gene therapy methold for various cancers.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We used adeno-associated virus–expressing enhanced green fluorescent protein (EGFP)-human FasL (AAV-EGFP-hFasL) to deliver FasL into Hep-2 cells, cytotoxicity was detected by MTS assay , apoptosis was confirmed by flow cytometry. We also treated the xenograft of Hep-2 tumor in nude mice with intratumoral injection of AAV-EGFP-hFasL. The size of the xenograft, the apoptosis in the xenograft, and the survival rate of the inoculated mice were then evaluated.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Hep-2 cells infected with AAV-EGFP-hFasL showed increased apoptosis rate and killing effect compared with AAV-EGFP–infected cells. In addition intratumoral injections of AAV-EGFP-hFasL into Hep-2 xenografts induced significant growth suppression of tumors.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Our findings suggest that the introduction of FasL into head and neck squamous cell carcinoma may induce significant apoptosis, and adeno-associated virus may be a useful vehicle for gene therapy. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundApoptosis induced by Fas/FasL system has been proposed as a gene therapy methold for various cancers.MethodsWe used adeno-associated virus–expressing enhanced green fluorescent protein (EGFP)-human FasL (AAV-EGFP-hFasL) to deliver FasL into Hep-2 cells, cytotoxicity was detected by MTS assay , apoptosis was confirmed by flow cytometry. We also treated the xenograft of Hep-2 tumor in nude mice with intratumoral injection of AAV-EGFP-hFasL. The size of the xenograft, the apoptosis in the xenograft, and the survival rate of the inoculated mice were then evaluated.ResultsHep-2 cells infected with AAV-EGFP-hFasL showed increased apoptosis rate and killing effect compared with AAV-EGFP–infected cells. In addition intratumoral injections of AAV-EGFP-hFasL into Hep-2 xenografts induced significant growth suppression of tumors.ConclusionOur findings suggest that the introduction of FasL into head and neck squamous cell carcinoma may induce significant apoptosis, and adeno-associated virus may be a useful vehicle for gene therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22002" xmlns="http://purl.org/rss/1.0/"><title>Plastic cordotomy in the treatment of bilateral vocal fold immobility</title><link>http://dx.doi.org/10.1002%2Fhed.22002</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Plastic cordotomy in the treatment of bilateral vocal fold immobility</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ramil K. Yagudin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Valentin R. Demenkov</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kamil F. Yagudin</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:11:20.87865-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22002</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22002</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22002</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to evaluate a new surgical method, plastic cordotomy for treatment of bilateral vocal fold immobility.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We used cadaver experiments on 20 larynges to measure the widening of the glottis after bilateral plastic cordotomy. We conducted a prospective study of 21 female patients operated on with bilateral plastic cordotomy.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Bilateral plastic cordotomy enlarged the width of glottis to 9.55 (range, 8.3–10) mm in men and 8.5 (range, 7.4–8.8) mm in women and the area of glottis to 110.5 mm<sup>2</sup> (range, 88–149 mm<sup>2</sup>) in men and to 84.5 mm<sup>2</sup> (range, 59–107 mm<sup>2</sup>) in women. Clinical study revealed that the mean of peak inspiratory flow increased from 1.09 (0.41) L/seconds before surgery to 2.85 (0.67) L/seconds in long-term.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Plastic cordotomy is an effective, anatomically based method to alleviate obstruction in bilateral vocal fold immobility patients. The main advantage of plastic cordotomy is long-term stability of results due to prevention of restenosis. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to evaluate a new surgical method, plastic cordotomy for treatment of bilateral vocal fold immobility.MethodsWe used cadaver experiments on 20 larynges to measure the widening of the glottis after bilateral plastic cordotomy. We conducted a prospective study of 21 female patients operated on with bilateral plastic cordotomy.ResultsBilateral plastic cordotomy enlarged the width of glottis to 9.55 (range, 8.3–10) mm in men and 8.5 (range, 7.4–8.8) mm in women and the area of glottis to 110.5 mm2 (range, 88–149 mm2) in men and to 84.5 mm2 (range, 59–107 mm2) in women. Clinical study revealed that the mean of peak inspiratory flow increased from 1.09 (0.41) L/seconds before surgery to 2.85 (0.67) L/seconds in long-term.ConclusionPlastic cordotomy is an effective, anatomically based method to alleviate obstruction in bilateral vocal fold immobility patients. The main advantage of plastic cordotomy is long-term stability of results due to prevention of restenosis. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22009" xmlns="http://purl.org/rss/1.0/"><title>Epidemiology of sebaceous carcinoma of the head and neck: Implications for lymph node management</title><link>http://dx.doi.org/10.1002%2Fhed.22009</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Epidemiology of sebaceous carcinoma of the head and neck: Implications for lymph node management</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Geir Tryggvason</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rodrigo Bayon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nitin A. Pagedar</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:11:06.092172-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22009</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22009</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22009</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to describe the incidence of nodal disease in sebaceous carcinoma and its impact on survival.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Data from the 17 registries of the Surveillance, Epidemiology, and End Results (SEER) database was retrospectively collected for sebaceous carcinoma from 1973 to 2007. Information on location, histologic grade, stage of disease, and survival was gathered.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>One thousand eight hundred thirty-six sebaceous carcinomas were diagnosed during the time period: 633 (34.5%) in the eyelid and 786 (42.8%) in the extraocular head and neck skin. Eyelid sebaceous carcinomas had higher histologic grade compared with tumors in extraocular sites (<em>p</em> &lt; .001). Ocular sebaceous carcinomas had a higher incidence of regional or distant metastases at presentation (4.4%) compared with extraocular head and neck sites (0.9%; <em>p</em> = .03). There was a high incidence of N+ disease in poorly differentiated ocular sebaceous carcinomas (15.2%).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The incidence of nodal disease was higher with eyelid tumors. Sentinel lymph node biopsy can be considered for eyelid tumors, but not for non-eyelid head and neck tumors. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to describe the incidence of nodal disease in sebaceous carcinoma and its impact on survival.MethodsData from the 17 registries of the Surveillance, Epidemiology, and End Results (SEER) database was retrospectively collected for sebaceous carcinoma from 1973 to 2007. Information on location, histologic grade, stage of disease, and survival was gathered.ResultsOne thousand eight hundred thirty-six sebaceous carcinomas were diagnosed during the time period: 633 (34.5%) in the eyelid and 786 (42.8%) in the extraocular head and neck skin. Eyelid sebaceous carcinomas had higher histologic grade compared with tumors in extraocular sites (p &lt; .001). Ocular sebaceous carcinomas had a higher incidence of regional or distant metastases at presentation (4.4%) compared with extraocular head and neck sites (0.9%; p = .03). There was a high incidence of N+ disease in poorly differentiated ocular sebaceous carcinomas (15.2%).ConclusionThe incidence of nodal disease was higher with eyelid tumors. Sentinel lymph node biopsy can be considered for eyelid tumors, but not for non-eyelid head and neck tumors. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22012" xmlns="http://purl.org/rss/1.0/"><title>Molecular targeting agents in the context of primary chemoradiation strategies</title><link>http://dx.doi.org/10.1002%2Fhed.22012</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Molecular targeting agents in the context of primary chemoradiation strategies</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Simon Laban</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chia Jung Wang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adrian Münscher</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Silke Tribius</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Philippe Schafhausen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rainald Knecht</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:10:43.52484-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22012</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22012</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22012</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Demands for organ preservation and increasing knowledge in molecular tumor biology have lead to the development of molecular targeting agents. These substances have also been incorporated into concomitant and sequential chemoradiation protocols.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This study was conducted using a systematic literature review.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>In head and neck squamous cell carcinoma (HNSCC), the inhibition of epidermal growth factor receptor (EGFR) signaling as a central step in carcinogenesis, progression, and metastasis is the predominant approach. Although EGFR targeting substances are commonly used, the specific influence of molecular targeting therapies on patient outcome remains unclear. In this review, results from recent clinical trials in the area of primary chemoradiation in the combination with EGFR targeting agents are discussed.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Encouraging results from recent trials need to be confirmed in larger patient cohorts and cost-effectiveness analyses have to be undertaken. Phase III studies need to confirm these results before, time and again, new phase II studies are initiated. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundDemands for organ preservation and increasing knowledge in molecular tumor biology have lead to the development of molecular targeting agents. These substances have also been incorporated into concomitant and sequential chemoradiation protocols.MethodsThis study was conducted using a systematic literature review.ResultsIn head and neck squamous cell carcinoma (HNSCC), the inhibition of epidermal growth factor receptor (EGFR) signaling as a central step in carcinogenesis, progression, and metastasis is the predominant approach. Although EGFR targeting substances are commonly used, the specific influence of molecular targeting therapies on patient outcome remains unclear. In this review, results from recent clinical trials in the area of primary chemoradiation in the combination with EGFR targeting agents are discussed.ConclusionEncouraging results from recent trials need to be confirmed in larger patient cohorts and cost-effectiveness analyses have to be undertaken. Phase III studies need to confirm these results before, time and again, new phase II studies are initiated. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22015" xmlns="http://purl.org/rss/1.0/"><title>Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region</title><link>http://dx.doi.org/10.1002%2Fhed.22015</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prevalence of human papillomavirus in oropharyngeal and nonoropharyngeal head and neck cancer—systematic review and meta-analysis of trends by time and region</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hisham Mehanna</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tom Beech</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tom Nicholson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Iman El-Hariry</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Christopher McConkey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vinidh Paleri</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sally Roberts</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-20T23:09:57.777191-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22015</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22015</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22015</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Clinical Review</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Little information has been reported on regional and time trends of human papillomavirus (HPV) prevalence rates of oropharyngeal cancer (OPC) and non-OPC.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>The study consisted of a systematic review and meta-analysis using random effects logistic regression models.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Overall HPV prevalence in OPC (47.7%; 95% confidence interval [CI], 42.9–52.5%) increased significantly over time: from 40.5% (95% CI, 35.1–46.1) before 2000, to 64.3% (95% CI, 56.7–71.3) between 2000 and 2004, and 72.2% (95% CI, 52.9–85.7) between 2005 and 2009 (<em>p</em> &lt; .001). Prevalence increased significantly in North America and Europe, and the significant gap between them that existed before 2000 (50.7% vs 35.3%, respectively, <em>p</em> = .008) has now disappeared (69.7% vs 73.1%, respectively, <em>p</em> = .8). Prevalence in non-OPC (21.8%; 95% CI, 18.9–25.1%) has not increased over time (<em>p</em> = .97)</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>The sharp increase in the proportion of HPV-positive OPC over the last decade has occurred at a faster rate in Europe compared with that in North America. In contrast, the relatively low prevalence of HPV in non-OPC remains unchanged. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundLittle information has been reported on regional and time trends of human papillomavirus (HPV) prevalence rates of oropharyngeal cancer (OPC) and non-OPC.MethodsThe study consisted of a systematic review and meta-analysis using random effects logistic regression models.ResultsOverall HPV prevalence in OPC (47.7%; 95% confidence interval [CI], 42.9–52.5%) increased significantly over time: from 40.5% (95% CI, 35.1–46.1) before 2000, to 64.3% (95% CI, 56.7–71.3) between 2000 and 2004, and 72.2% (95% CI, 52.9–85.7) between 2005 and 2009 (p &lt; .001). Prevalence increased significantly in North America and Europe, and the significant gap between them that existed before 2000 (50.7% vs 35.3%, respectively, p = .008) has now disappeared (69.7% vs 73.1%, respectively, p = .8). Prevalence in non-OPC (21.8%; 95% CI, 18.9–25.1%) has not increased over time (p = .97)ConclusionsThe sharp increase in the proportion of HPV-positive OPC over the last decade has occurred at a faster rate in Europe compared with that in North America. In contrast, the relatively low prevalence of HPV in non-OPC remains unchanged. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21987" xmlns="http://purl.org/rss/1.0/"><title>Preoperative imaging and surgical margins in maxillectomy patients</title><link>http://dx.doi.org/10.1002%2Fhed.21987</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Preoperative imaging and surgical margins in maxillectomy patients</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anne Marijn Kreeft</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ludwig E. Smeele</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Coen R. N. Rasch</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Hauptmann</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Derk H. F. Rietveld</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. René Leemans</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alfons J. M. Balm</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T06:24:20.165058-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21987</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21987</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21987</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>High rates of positive surgical margins are reported after a maxillectomy. A large part of tumors that are preoperatively considered “operable” can thus not be resected with tumor-free margins.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>This was a retrospective study on medical files of 69 patients that underwent maxillectomy as primary treatment for a squamous cell carcinoma.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>More than one third (39%) of all resections performed is incomplete, with dorsal or dorsocranial-positive surgical margins in two thirds. Correlation of tumor extension on preoperative imaging to surgical margins status revealed that dorsal and cranial tumor extension were significant prognostic factors for tumor positive surgical margins (<em>p</em> = .006 and <em>p</em> = .031, respectively). Positive margins were associated with a 2-fold increased risk of death (hazard ratio, 2.4; 95% confidence interval, 1.2–4.9).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Cranial or dorsal tumor extension on preoperative imaging was a significant risk factor for positive surgical margins after maxillectomy with significant negative influence on overall survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundHigh rates of positive surgical margins are reported after a maxillectomy. A large part of tumors that are preoperatively considered “operable” can thus not be resected with tumor-free margins.MethodsThis was a retrospective study on medical files of 69 patients that underwent maxillectomy as primary treatment for a squamous cell carcinoma.ResultsMore than one third (39%) of all resections performed is incomplete, with dorsal or dorsocranial-positive surgical margins in two thirds. Correlation of tumor extension on preoperative imaging to surgical margins status revealed that dorsal and cranial tumor extension were significant prognostic factors for tumor positive surgical margins (p = .006 and p = .031, respectively). Positive margins were associated with a 2-fold increased risk of death (hazard ratio, 2.4; 95% confidence interval, 1.2–4.9).ConclusionCranial or dorsal tumor extension on preoperative imaging was a significant risk factor for positive surgical margins after maxillectomy with significant negative influence on overall survival. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21993" xmlns="http://purl.org/rss/1.0/"><title>ACR appropriateness criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil</title><link>http://dx.doi.org/10.1002%2Fhed.21993</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">ACR appropriateness criteria® ipsilateral radiation for squamous cell carcinoma of the tonsil</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Anamaria Reyna Yeung</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Madhur Kumar Garg</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joshua Lawson</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark W. McDonald</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Harry Quon</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John A. Ridge</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nabil Saba</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joseph K. Salama</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Richard V. Smith</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sue S. Yom</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan J. Beitler</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-17T04:02:38.377027-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21993</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21993</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21993</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">ACR Appropriateness Criteria</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Controversy exists as to the criteria for selecting patients with carcinoma of the tonsil for treatment with ipsilateral radiotherapy (RT).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>The American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of treatment procedures by the panel. In those instances where evidence is not definitive, expert opinion may be used to recommend treatment.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The ACR Expert Panel on Radiation Oncology – Head and Neck Cancer developed consensus recommendations for selecting patients with tonsillar carcinoma for ipsilateral RT.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Patients that are appropriate for ipsilateral RT have less than 1 cm of tumor invasion into the soft palate or base of tongue, and nodal stage of N0 to 1. © 2012 American College of Radiology. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundControversy exists as to the criteria for selecting patients with carcinoma of the tonsil for treatment with ipsilateral radiotherapy (RT).MethodsThe American College of Radiology (ACR) Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current literature from peer reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of treatment procedures by the panel. In those instances where evidence is not definitive, expert opinion may be used to recommend treatment.ResultsThe ACR Expert Panel on Radiation Oncology – Head and Neck Cancer developed consensus recommendations for selecting patients with tonsillar carcinoma for ipsilateral RT.ConclusionPatients that are appropriate for ipsilateral RT have less than 1 cm of tumor invasion into the soft palate or base of tongue, and nodal stage of N0 to 1. © 2012 American College of Radiology. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21997" xmlns="http://purl.org/rss/1.0/"><title>Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status</title><link>http://dx.doi.org/10.1002%2Fhed.21997</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Matted nodes: Poor prognostic marker in oropharyngeal squamous cell carcinoma independent of HPV and EGFR status</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Matthew E. Spector</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">K. Kelly Gallagher</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Emily Light</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mohannad Ibrahim</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Eric J. Chanowski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jeffrey S. Moyer</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark E. Prince</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gregory T. Wolf</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carol R. Bradford</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kitrina Cordell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan B. McHugh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas Carey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Francis P. Worden</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Avraham Eisbruch</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Douglas B. Chepeha</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-13T08:03:12.539131-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21997</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21997</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21997</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Despite better prognosis, there is a group of oropharyngeal squamous cell carcinoma (SCC) human papillomavirus (HPV)+ patients who experience treatment failure and succumb to distant metastasis.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Seventy-eight previously untreated patients nested in a concurrent chemoradiation protocol were reviewed to correlate patterns of local-regional tumor extent to distant metastasis. Biomarker assessment was: HPV in situ hybridization and epidermal growth factor receptor (EGFR) immunointensity.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>The 3-year disease-specific survival (DSS) for patients presenting with and without matted nodes was 69% and 94%, respectively (<em>p</em> = .003). Matted nodes were a poor prognostic factor independent of T classification, HPV, EGFR, and smoking status. For patients who were HPV+, 7 of 11 died of distant metastasis and 6 of 7 with distant metastasis had matted nodes.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Matted nodes are a novel marker of poor prognosis in oropharyngeal SCC independent of established prognostic factors. Matted nodes may identify patients at risk for the development of distant metastasis who could benefit from systemic therapy, whereas patients without matted nodes may be candidates for de-escalation of therapy. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundDespite better prognosis, there is a group of oropharyngeal squamous cell carcinoma (SCC) human papillomavirus (HPV)+ patients who experience treatment failure and succumb to distant metastasis.MethodsSeventy-eight previously untreated patients nested in a concurrent chemoradiation protocol were reviewed to correlate patterns of local-regional tumor extent to distant metastasis. Biomarker assessment was: HPV in situ hybridization and epidermal growth factor receptor (EGFR) immunointensity.ResultsThe 3-year disease-specific survival (DSS) for patients presenting with and without matted nodes was 69% and 94%, respectively (p = .003). Matted nodes were a poor prognostic factor independent of T classification, HPV, EGFR, and smoking status. For patients who were HPV+, 7 of 11 died of distant metastasis and 6 of 7 with distant metastasis had matted nodes.ConclusionMatted nodes are a novel marker of poor prognosis in oropharyngeal SCC independent of established prognostic factors. Matted nodes may identify patients at risk for the development of distant metastasis who could benefit from systemic therapy, whereas patients without matted nodes may be candidates for de-escalation of therapy. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22909" xmlns="http://purl.org/rss/1.0/"><title>Preoperative prediction of papillary thyroid carcinoma prognosis with the assistance of computerized morphometry of cytology samples obtained by fine-needle aspiration: Preliminary report</title><link>http://dx.doi.org/10.1002%2Fhed.22909</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Preoperative prediction of papillary thyroid carcinoma prognosis with the assistance of computerized morphometry of cytology samples obtained by fine-needle aspiration: Preliminary report</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shyang–Rong Shih</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi–Cheng Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hung–Yuan Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jau–Yu Liau</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chia–Yen Lee</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chung–Ming Chen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tien–Chun Chang</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-13T08:03:00.030243-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22909</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22909</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22909</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The purpose of this study was to analyze the relationship between cytologic features, clinical features, and recurrence of papillary thyroid cancer (PTC). We hoped to predict prognosis preoperatively.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We retrospectively studied cytologic features by using computerized morphometry and clinical data of 118 patients with usual-type PTC without initial metastasis, including 34 patients with cancer recurrence in 10 years after surgery and 84 patients who did not have recurrence for more than 10 years after surgery. Another 24 patients were recruited for validation.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Multivariate logistic analysis indicated that nucleus-to-cell ratio, variation of nuclear area, tumor size, and patient age were significantly related to recurrence. Cox regression analysis showed that hazard ratios were 3.34, 1.53, 1.77, and 2.6, respectively.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Cytologic features of PTC analyzed with computerized morphometry significantly correlated with recurrence. It helped to predict prognosis preoperatively and may be helpful for planning further treatment. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe purpose of this study was to analyze the relationship between cytologic features, clinical features, and recurrence of papillary thyroid cancer (PTC). We hoped to predict prognosis preoperatively.MethodsWe retrospectively studied cytologic features by using computerized morphometry and clinical data of 118 patients with usual-type PTC without initial metastasis, including 34 patients with cancer recurrence in 10 years after surgery and 84 patients who did not have recurrence for more than 10 years after surgery. Another 24 patients were recruited for validation.ResultsMultivariate logistic analysis indicated that nucleus-to-cell ratio, variation of nuclear area, tumor size, and patient age were significantly related to recurrence. Cox regression analysis showed that hazard ratios were 3.34, 1.53, 1.77, and 2.6, respectively.ConclusionCytologic features of PTC analyzed with computerized morphometry significantly correlated with recurrence. It helped to predict prognosis preoperatively and may be helpful for planning further treatment. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22911" xmlns="http://purl.org/rss/1.0/"><title>Cyclooxygenase-2 expression and clinical parameters in laryngeal squamous cell carcinoma, vocal fold nodule, and laryngeal atypical hyperplasia</title><link>http://dx.doi.org/10.1002%2Fhed.22911</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Cyclooxygenase-2 expression and clinical parameters in laryngeal squamous cell carcinoma, vocal fold nodule, and laryngeal atypical hyperplasia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cağdaş Sayar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hamide Sayar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Süleyman Özdemir</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tahsin Selçuk</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Orhan Görgülü</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yücel Akbaş</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mustafa Kemal Olgun</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-13T08:02:48.265341-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22911</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22911</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22911</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The diagnostic role of cyclooxygenase-2 (COX-2) expression in laryngeal atypical hyperplasia, vocal fold nodule, and laryngeal squamous cell carcinoma was examined.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Specimens obtained from patients diagnosed with vocal fold nodule (<em>n</em> = 35), atypical hyperplasia (<em>n</em> = 35), laryngeal squamous cell carcinoma (<em>n</em> = 35), and clinical parameters were evaluated retrospectively.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Although no staining was observed in patients with vocal fold nodules, staining was noted in laryngeal atypical hyperplasia and squamous cell carcinoma. The percentage of COX-2 staining was the highest in the carcinoma group.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>It was determined that COX-2 staining was significantly associated with laryngeal squamous cell carcinoma. It should be noted that overexpression of COX-2, a potentially important factor in the evolution of carcinogenesis in precancerous lesions, might be an indicator of the development of carcinoma. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundThe diagnostic role of cyclooxygenase-2 (COX-2) expression in laryngeal atypical hyperplasia, vocal fold nodule, and laryngeal squamous cell carcinoma was examined.MethodsSpecimens obtained from patients diagnosed with vocal fold nodule (n = 35), atypical hyperplasia (n = 35), laryngeal squamous cell carcinoma (n = 35), and clinical parameters were evaluated retrospectively.ResultsAlthough no staining was observed in patients with vocal fold nodules, staining was noted in laryngeal atypical hyperplasia and squamous cell carcinoma. The percentage of COX-2 staining was the highest in the carcinoma group.ConclusionIt was determined that COX-2 staining was significantly associated with laryngeal squamous cell carcinoma. It should be noted that overexpression of COX-2, a potentially important factor in the evolution of carcinogenesis in precancerous lesions, might be an indicator of the development of carcinoma. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21894" xmlns="http://purl.org/rss/1.0/"><title>Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia</title><link>http://dx.doi.org/10.1002%2Fhed.21894</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Effectiveness of cevimeline to improve oral health in patients with postradiation xerostomia</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David L. Witsell</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Sandra Stinnett</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark S. Chambers</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-09T06:32:34.890802-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21894</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21894</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21894</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>We assessed the effectiveness of cevimeline 30 mg 3 times daily in patient-reported oral health (Oral Health Impact Profile [OHIP-49]) and quality of life (QOL) in patients with xerostomia.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>In our investigator-initiated, multicenter, randomized, double-blind, placebo-controlled study, patients who received &gt;40 Gy of radiation therapy to the head and neck including at least 3 major salivary glands were randomized to cevimeline 30 mg or placebo orally 3 times daily for 6 weeks. Patients had to have grade 1 or 2 xerostomia and be &gt;16 weeks posttreatment. Clinical data were collected and questionnaires administered at baseline and week 6. The primary outcome was change in OHIP-49 total score from baseline to week 6.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>No statistically significant differences in oral health or QOL were observed. During the 6 weeks of the study, the severity of xerostomia decreased from baseline.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Xerostomia is a significant sequela of treatment of head and neck cancer that may improve with time. The role of oral parasympathetic muscarinic secretogogues in alleviating patient symptoms and complaints remains unclear. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</p></div></div>]]></content:encoded><description>BackgroundWe assessed the effectiveness of cevimeline 30 mg 3 times daily in patient-reported oral health (Oral Health Impact Profile [OHIP-49]) and quality of life (QOL) in patients with xerostomia.MethodsIn our investigator-initiated, multicenter, randomized, double-blind, placebo-controlled study, patients who received &gt;40 Gy of radiation therapy to the head and neck including at least 3 major salivary glands were randomized to cevimeline 30 mg or placebo orally 3 times daily for 6 weeks. Patients had to have grade 1 or 2 xerostomia and be &gt;16 weeks posttreatment. Clinical data were collected and questionnaires administered at baseline and week 6. The primary outcome was change in OHIP-49 total score from baseline to week 6.ResultsNo statistically significant differences in oral health or QOL were observed. During the 6 weeks of the study, the severity of xerostomia decreased from baseline.ConclusionsXerostomia is a significant sequela of treatment of head and neck cancer that may improve with time. The role of oral parasympathetic muscarinic secretogogues in alleviating patient symptoms and complaints remains unclear. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21948" xmlns="http://purl.org/rss/1.0/"><title>Topographic description of an alternative insertion technique for percutaneous approach of cricopharyngeus muscle electromyography: A cadaveric and clinical study</title><link>http://dx.doi.org/10.1002%2Fhed.21948</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Topographic description of an alternative insertion technique for percutaneous approach of cricopharyngeus muscle electromyography: A cadaveric and clinical study</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Salih Murat Akkin</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zeynep Alkan</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ozgür Yigit</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Turgut Adatepe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mehmet Selman Demirci</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juergen Koebke</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nurten Uzun</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-03T01:18:42.841246-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21948</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21948</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21948</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Cricopharyngeus is the only muscle for which electromyography is used in the differential diagnosis of swallowing disorders. Because of some practical difficulties, electrophysiologic tests for this muscle are not performed routinely. Thus we aimed to describe an alternative topographic way to reach the muscle easily.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>On 10 cadavers, a spinal needle (20 G) and on 37 patients a concentric needle electrode (26 G) were used. The needle was inserted percutaneous at the level of the superior border of the cricoid cartilage, anterior to the anterior border of the sternocleidomastoid muscle at 60 degrees angle to the frontal plane in the posteromedial direction.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>We reached the muscle in all cadavers. In all of the patients, the needle entered the muscle on the first attempt; that was confirmed by electromyographic responses.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Our results show that this method can be useful for the practical application of cricopharyngeus muscle electromyography. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundCricopharyngeus is the only muscle for which electromyography is used in the differential diagnosis of swallowing disorders. Because of some practical difficulties, electrophysiologic tests for this muscle are not performed routinely. Thus we aimed to describe an alternative topographic way to reach the muscle easily.MethodsOn 10 cadavers, a spinal needle (20 G) and on 37 patients a concentric needle electrode (26 G) were used. The needle was inserted percutaneous at the level of the superior border of the cricoid cartilage, anterior to the anterior border of the sternocleidomastoid muscle at 60 degrees angle to the frontal plane in the posteromedial direction.ResultsWe reached the muscle in all cadavers. In all of the patients, the needle entered the muscle on the first attempt; that was confirmed by electromyographic responses.ConclusionOur results show that this method can be useful for the practical application of cricopharyngeus muscle electromyography. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21982" xmlns="http://purl.org/rss/1.0/"><title>Tissue imprint for molecular mapping of deep surgical margins in patients with head and neck squamous cell carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21982</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Tissue imprint for molecular mapping of deep surgical margins in patients with head and neck squamous cell carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jong–Lyel Roh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William H. Westra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joseph A. Califano</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David Sidransky</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wayne M. Koch</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2012-01-03T01:18:14.671821-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21982</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21982</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21982</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Tissue imprinting can generate molecular marker maps of tumor cells at deep surgical margins. The purpose of this study was to evaluate the feasibility of this method for detection of residual head and neck squamous cell carcinoma (HNSCC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Paired fresh tissue and nitrocellulose membrane imprints of tumor and deep margins were collected from 17 HNSCC resections. DNA was amplified using quantitative methylation-specific polymerase chain reaction (qMSP) for <em>p16</em>, <em>DCC</em>, <em>KIF1A</em>, and <em>EDNRB</em>. Levels of methylation in tumors and deep margins were compared.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>DNA from imprints was adequate for qMSP. Hypermethylation of target genes was present in 12 of 17 tumors and in 8 deep margins. Methylation level was better from margin imprints than tissue. During follow-up (median, 13 months), local or regional recurrences occurred in 6 cases of which 5 had molecularly positive margins.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Tissue imprinting is feasible for molecular detection of residual tumor at deep surgical margins and may correlate with locoregional recurrence. © 2012 Wiley Periodicals, Inc. <em>Head Neck</em>, 2012</p></div></div>]]></content:encoded><description>BackgroundTissue imprinting can generate molecular marker maps of tumor cells at deep surgical margins. The purpose of this study was to evaluate the feasibility of this method for detection of residual head and neck squamous cell carcinoma (HNSCC).MethodsPaired fresh tissue and nitrocellulose membrane imprints of tumor and deep margins were collected from 17 HNSCC resections. DNA was amplified using quantitative methylation-specific polymerase chain reaction (qMSP) for p16, DCC, KIF1A, and EDNRB. Levels of methylation in tumors and deep margins were compared.ResultsDNA from imprints was adequate for qMSP. Hypermethylation of target genes was present in 12 of 17 tumors and in 8 deep margins. Methylation level was better from margin imprints than tissue. During follow-up (median, 13 months), local or regional recurrences occurred in 6 cases of which 5 had molecularly positive margins.ConclusionTissue imprinting is feasible for molecular detection of residual tumor at deep surgical margins and may correlate with locoregional recurrence. © 2012 Wiley Periodicals, Inc. Head Neck, 2012</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21986" xmlns="http://purl.org/rss/1.0/"><title>Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck</title><link>http://dx.doi.org/10.1002%2Fhed.21986</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Surgical resection for clinical perineural invasion from cutaneous squamous cell carcinoma of the head and neck</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benedict Panizza</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">C. Arturo Solares</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael Redmond</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Priya Parmar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Peter O'Rourke</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-23T06:29:19.451225-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21986</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21986</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21986</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Perineural invasion (PNI) in cutaneous squamous cell carcinoma of the head and neck (SCCHN) is associated with decreased survival. Patients with large nerve or clinical PNI present with clinical signs and symptoms or MRI evidence of cranial nerve involvement. These patients often succumb to disease that spreads into the brainstem. In our experience, when the disease extends up to the Gasserian or Geniculate ganglion, surgical resection with negative margins provides the best chance for cure. Herein we review our experience to validate our clinical observations.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We identified patients with large nerve PNI from cutaneous SCCHN between January 1996 and 2006 from a prospectively collected database. Patients who underwent surgical resection as their primary mode of therapy were included. Clinical and demographic variables were recorded. Survival analysis was performed with Kaplan-Meier curves, and the log-rank test was used for significance testing between groups.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Twenty-one patients were identified. The mean age was 60 (range, 38–86) years, with 15 men and 6 women. Nineteen patients had a formal skull base resection, whereas 2 patients had a subcranial resection. We had 3 complications in our series: extradural hemorrhage (<em>n</em> = 1), cerebrospinal fluid leak (<em>n</em> = 1), and wound infection (<em>n</em> = 1). None of the patients who underwent a formal skull base resection to include the lateral cavernous sinus (ie, Gasserian ganglion) suffered ocular palsies or permanent morbidity when the orbit was preserved (<em>n</em> = 11). We had no surgical deaths. The average length of stay was 9 days (SD 6.3 days). The 5-year disease specific survival rate for the entire group was 64.3%. V3 involvement resulted in lower, although not significant, 5-year disease-free survival rates— 0% for those patients with involvement (<em>n</em> = 4) versus 66.8% for no involvement of V3 (<em>n</em> = 17).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Appropriately planned surgical resection of PNI in cutaneous SCCHN up to the ganglion as dictated by the disease extent may improve survival without significant added morbidity. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em> 2011</p></div></div>]]></content:encoded><description>BackgroundPerineural invasion (PNI) in cutaneous squamous cell carcinoma of the head and neck (SCCHN) is associated with decreased survival. Patients with large nerve or clinical PNI present with clinical signs and symptoms or MRI evidence of cranial nerve involvement. These patients often succumb to disease that spreads into the brainstem. In our experience, when the disease extends up to the Gasserian or Geniculate ganglion, surgical resection with negative margins provides the best chance for cure. Herein we review our experience to validate our clinical observations.MethodsWe identified patients with large nerve PNI from cutaneous SCCHN between January 1996 and 2006 from a prospectively collected database. Patients who underwent surgical resection as their primary mode of therapy were included. Clinical and demographic variables were recorded. Survival analysis was performed with Kaplan-Meier curves, and the log-rank test was used for significance testing between groups.ResultsTwenty-one patients were identified. The mean age was 60 (range, 38–86) years, with 15 men and 6 women. Nineteen patients had a formal skull base resection, whereas 2 patients had a subcranial resection. We had 3 complications in our series: extradural hemorrhage (n = 1), cerebrospinal fluid leak (n = 1), and wound infection (n = 1). None of the patients who underwent a formal skull base resection to include the lateral cavernous sinus (ie, Gasserian ganglion) suffered ocular palsies or permanent morbidity when the orbit was preserved (n = 11). We had no surgical deaths. The average length of stay was 9 days (SD 6.3 days). The 5-year disease specific survival rate for the entire group was 64.3%. V3 involvement resulted in lower, although not significant, 5-year disease-free survival rates— 0% for those patients with involvement (n = 4) versus 66.8% for no involvement of V3 (n = 17).ConclusionAppropriately planned surgical resection of PNI in cutaneous SCCHN up to the ganglion as dictated by the disease extent may improve survival without significant added morbidity. © 2011 Wiley Periodicals, Inc. Head Neck 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21968" xmlns="http://purl.org/rss/1.0/"><title>Transoral robotic biopsy of the tongue base: A novel paradigm in the evaluation of unknown primary tumors of the head and neck</title><link>http://dx.doi.org/10.1002%2Fhed.21968</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Transoral robotic biopsy of the tongue base: A novel paradigm in the evaluation of unknown primary tumors of the head and neck</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Waleed M. Abuzeid</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carol R. Bradford</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Vasu Divi</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:25:44.743324-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21968</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21968</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21968</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Squamous cell carcinoma of the head and neck can present as a cervical metastasis from an unknown primary site. The standard diagnostic workup includes panendoscopy and directed biopsies but this will fail to identify a portion of unknown primary tumors.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Herein, we present a case report of a male patient with an unknown primary tumor in which the da Vinci surgical robot was used to evaluate the tongue base.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Clinical evaluation, imaging, and panendoscopy with directed biopsies failed to detect the primary tumor site. Robot-assisted biopsy of a broad area of the tongue base, incorporating submucosal tissue, identified the primary tumor with minimal postoperative morbidity.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Failure to localize an unknown primary tumor often results in widespread irradiation of the upper aerodigestive tract, inducing significant morbidity. Robot-assisted biopsies of the tongue base may identify unknown primaries that would otherwise have been missed through standard directed biopsy techniques. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundSquamous cell carcinoma of the head and neck can present as a cervical metastasis from an unknown primary site. The standard diagnostic workup includes panendoscopy and directed biopsies but this will fail to identify a portion of unknown primary tumors.MethodsHerein, we present a case report of a male patient with an unknown primary tumor in which the da Vinci surgical robot was used to evaluate the tongue base.ResultsClinical evaluation, imaging, and panendoscopy with directed biopsies failed to detect the primary tumor site. Robot-assisted biopsy of a broad area of the tongue base, incorporating submucosal tissue, identified the primary tumor with minimal postoperative morbidity.ConclusionFailure to localize an unknown primary tumor often results in widespread irradiation of the upper aerodigestive tract, inducing significant morbidity. Robot-assisted biopsies of the tongue base may identify unknown primaries that would otherwise have been missed through standard directed biopsy techniques. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21972" xmlns="http://purl.org/rss/1.0/"><title>Thyroid gland involvement in advanced laryngeal cancer: Association with clinical and pathologic characteristics</title><link>http://dx.doi.org/10.1002%2Fhed.21972</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Thyroid gland involvement in advanced laryngeal cancer: Association with clinical and pathologic characteristics</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Ohad Hilly</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Raanan Raz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yona Vaisbuch</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yulia Strenov</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Karl Segal</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Rumelia Koren</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jacob Shvero</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:25:32.698515-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21972</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21972</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21972</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Indications for thyroidectomy during laryngectomy are controversial. We examined whether clinicopathologic features can predict thyroid gland involvement, and the prognostic effect of thyroid gland involvement in patients undergoing total laryngectomy.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>The study set out to review preoperative assessment, operation findings, pathologic findings, and follow-up data.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Thyroid gland involvement was found in 11 of 53 patients (21%) undergoing total laryngectomy and thyroidectomy. Preoperative work-up failed to predict thyroid gland involvement. Thyroid gland involvement was associated with salvage procedures (<em>p</em> = .025), paratracheal metastases (<em>p</em> = .003), and poor overall survival (hazard ratio = 2.74, <em>p</em> = .008).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Thyroid gland involvement in patients undergoing total laryngectomy is frequent and is associated with poor prognosis. Preoperative assessment failed to predict thyroid gland involvement. We believe that thyroidectomy should be considered in cases with paratracheal lymphatic spread irrespective of tumor location within the larynx. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundIndications for thyroidectomy during laryngectomy are controversial. We examined whether clinicopathologic features can predict thyroid gland involvement, and the prognostic effect of thyroid gland involvement in patients undergoing total laryngectomy.MethodsThe study set out to review preoperative assessment, operation findings, pathologic findings, and follow-up data.ResultsThyroid gland involvement was found in 11 of 53 patients (21%) undergoing total laryngectomy and thyroidectomy. Preoperative work-up failed to predict thyroid gland involvement. Thyroid gland involvement was associated with salvage procedures (p = .025), paratracheal metastases (p = .003), and poor overall survival (hazard ratio = 2.74, p = .008).ConclusionsThyroid gland involvement in patients undergoing total laryngectomy is frequent and is associated with poor prognosis. Preoperative assessment failed to predict thyroid gland involvement. We believe that thyroidectomy should be considered in cases with paratracheal lymphatic spread irrespective of tumor location within the larynx. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21976" xmlns="http://purl.org/rss/1.0/"><title>Response to intra-arterial cisplatin and concurrent radiotherapy in a patient with primary mucosal malignant melanoma of the nasal cavity</title><link>http://dx.doi.org/10.1002%2Fhed.21976</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Response to intra-arterial cisplatin and concurrent radiotherapy in a patient with primary mucosal malignant melanoma of the nasal cavity</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hideo Shojaku</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hiromasa Takakura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hirohiko Tachino</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michiro Fujisaka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yukio Watanabe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gakuto Tomizawa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hideto Kawabe</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hiroko Shojaku</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Hikaru Seto</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Shigeharu Miwa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Junya Fukuoka</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Masashi Shimizu</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:25:02.54766-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21976</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21976</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21976</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>The prognosis for patients with mucosal malignant melanoma (MMM) of the nasal cavity is very poor because of the radioresistance of melanoma cells.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We present the first case report of the efficacy of superselective intra-arterial cisplatin (CDDP) infusion concurrent with hypofractionated radiotherapy (RT) for MMM of the nasal cavity.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>A pink, polypoid mass, histopathologically diagnosed as an amelanostic melanoma, occupied the right nasal cavity. After the treatment, a nasal tumor disappeared, leaving only a small bulge in the medial wall of the middle turbinate. Histopathologic examination revealed scattered degenerated melanoma cells, remaining only in the small restricted area in the medial surface of the excised middle turbinate. Twelve months after the treatment, the patient has not experienced any local recurrence or regional and distant metastasis.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>The superselective intra-arterial CDDP infusion concurrent with hypofractionated RT might be useful for the management of nasal MMM. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundThe prognosis for patients with mucosal malignant melanoma (MMM) of the nasal cavity is very poor because of the radioresistance of melanoma cells.MethodsWe present the first case report of the efficacy of superselective intra-arterial cisplatin (CDDP) infusion concurrent with hypofractionated radiotherapy (RT) for MMM of the nasal cavity.ResultsA pink, polypoid mass, histopathologically diagnosed as an amelanostic melanoma, occupied the right nasal cavity. After the treatment, a nasal tumor disappeared, leaving only a small bulge in the medial wall of the middle turbinate. Histopathologic examination revealed scattered degenerated melanoma cells, remaining only in the small restricted area in the medial surface of the excised middle turbinate. Twelve months after the treatment, the patient has not experienced any local recurrence or regional and distant metastasis.ConclusionsThe superselective intra-arterial CDDP infusion concurrent with hypofractionated RT might be useful for the management of nasal MMM. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21983" xmlns="http://purl.org/rss/1.0/"><title>Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer</title><link>http://dx.doi.org/10.1002%2Fhed.21983</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Phase I study of weekly docetaxel and cisplatin arterial infusion for recurrent head and neck cancer</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Tatsuya Nakamura</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Nobukazu Fuwa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kanako Takayama</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Haruo Inokuchi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Takuya Tomoda</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Akinori Takada</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chiyoko Makita</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miho Shiomi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jun–ichi Yokouchi</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Kazuo Watanabe</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:21:48.649566-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21983</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21983</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21983</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>We planned a phase I study of weekly arterial infusion of docetaxel and cisplatin via a superficial temporal artery for recurrent head and neck cancer to determine the optimal dose.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>The dose of cisplatin was fixed and the dose of docetaxel was escalated from 8 mg/m<sup>2</sup>, with an increase of 2 mg/m<sup>2</sup> per step, to identify the maximum tolerated dose (MTD). In total, 4 courses of weekly chemotherapy were administered.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Twelve patients were recruited to this trial. The MTD of docetaxel was 14 mg/m<sup>2</sup>. At this dose level, dose-limiting toxicity was observed in 2 of 3 patients. One patient experienced grade 3 leukopenia, while the other experienced grade 3 leukopenia. Myelosuppression was the dose-limiting toxicity for this regimen.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>The recommended dose for weekly arterial infusion of docetaxel was identified as 12 mg/m<sup>2</sup> combined with weekly cisplatin at 40 mg/m<sup>2</sup>, with 4 courses of each. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundWe planned a phase I study of weekly arterial infusion of docetaxel and cisplatin via a superficial temporal artery for recurrent head and neck cancer to determine the optimal dose.MethodsThe dose of cisplatin was fixed and the dose of docetaxel was escalated from 8 mg/m2, with an increase of 2 mg/m2 per step, to identify the maximum tolerated dose (MTD). In total, 4 courses of weekly chemotherapy were administered.ResultsTwelve patients were recruited to this trial. The MTD of docetaxel was 14 mg/m2. At this dose level, dose-limiting toxicity was observed in 2 of 3 patients. One patient experienced grade 3 leukopenia, while the other experienced grade 3 leukopenia. Myelosuppression was the dose-limiting toxicity for this regimen.ConclusionThe recommended dose for weekly arterial infusion of docetaxel was identified as 12 mg/m2 combined with weekly cisplatin at 40 mg/m2, with 4 courses of each. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21971" xmlns="http://purl.org/rss/1.0/"><title>Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck</title><link>http://dx.doi.org/10.1002%2Fhed.21971</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Single-arm phase II study of multiagent concurrent chemoradiotherapy and gefitinib in locoregionally advanced squamous cell carcinoma of the head and neck</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Cristina P. Rodriguez</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">David J. Adelstein</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Lisa A. Rybicki</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jerrold P. Saxton</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Robert R. Lorenz</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Benjamin G. Wood</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Joseph Scharpf</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Denise I. Ives</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:21:22.82196-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21971</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21971</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21971</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>This phase II study tested the addition of the oral epidermal growth factor receptor gefitinib to multiagent concurrent chemoradiotherapy regimen in head and neck squamous cell cancer (HNSCC).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Patients with stage III–IV HNSCC received hyperfractionated radiation (72–74.4 Gy at 120 cGy twice daily), with concurrent 96-hour infusions of cisplatin 20 mg/m<sup>2</sup>/day and fluorouracil 1000 mg/m<sup>2</sup>/day given during weeks 1 and 4. Daily gefitinib 250 mg was started on day 1 of radiation and continued for 2 years. Results were retrospectively compared with our previous study using identical chemoradiotherapy without gefitinib.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Sixty patients were enrolled in the study; 80% had stage IV disease and 68% had oropharyngeal primary tumors. The full course of gefitinib was not tolerated by 42%; there were 5 treatment-related deaths (8%). With a median follow-up of 54 months, 2- and 3-year overall survival estimates were 80% and 71%, respectively. Projected distant metastatic control at 2 and 3 years was 88%. When compared with our historical cohort, acute toxicities including renal dysfunction and unplanned rehospitalization were worse in the study patients. Projected outcome estimates did not differ between the 2 cohorts.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Addition of gefitinib to concurrent chemoradiotherapy was difficult to complete, did not improve outcomes, and increased toxicity. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundThis phase II study tested the addition of the oral epidermal growth factor receptor gefitinib to multiagent concurrent chemoradiotherapy regimen in head and neck squamous cell cancer (HNSCC).MethodsPatients with stage III–IV HNSCC received hyperfractionated radiation (72–74.4 Gy at 120 cGy twice daily), with concurrent 96-hour infusions of cisplatin 20 mg/m2/day and fluorouracil 1000 mg/m2/day given during weeks 1 and 4. Daily gefitinib 250 mg was started on day 1 of radiation and continued for 2 years. Results were retrospectively compared with our previous study using identical chemoradiotherapy without gefitinib.ResultsSixty patients were enrolled in the study; 80% had stage IV disease and 68% had oropharyngeal primary tumors. The full course of gefitinib was not tolerated by 42%; there were 5 treatment-related deaths (8%). With a median follow-up of 54 months, 2- and 3-year overall survival estimates were 80% and 71%, respectively. Projected distant metastatic control at 2 and 3 years was 88%. When compared with our historical cohort, acute toxicities including renal dysfunction and unplanned rehospitalization were worse in the study patients. Projected outcome estimates did not differ between the 2 cohorts.ConclusionsAddition of gefitinib to concurrent chemoradiotherapy was difficult to complete, did not improve outcomes, and increased toxicity. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21974" xmlns="http://purl.org/rss/1.0/"><title>p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency</title><link>http://dx.doi.org/10.1002%2Fhed.21974</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">p16 expression as a surrogate marker for HPV-related oropharyngeal carcinoma: A guide for interpretative relevance and consistency</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Adel K. El-Naggar</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">William H. Westra</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:21:04.378833-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21974</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21974</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21974</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Commentary</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="para" xmlns="http://www.w3.org/1999/xhtml"><p>Recent studies of oropharyngeal carcinoma have reported remarkable correlation between integrated human papillomavirus (HPV) viral detection and p16 protein overexpression in tumor cells. These findings led to calls for the substitution of p16 expression for the more demanding HPV testing in clinical practice. The rationale for such practice is largely driven by the simplicity, low cost, and the feasibility of the immunohistochemical (IHC) analysis. There are, however, several caveats that need to be fully considered. These include the subjective nature of IHC evaluation, the variable mechanisms of p16 expression in head and neck squamous cell carcinoma, and the lack of scoring and interpretive criteria. This perspective addresses the conceptual and practical issues associated with the p16 expression analysis and provides a broad outline for its application and evaluation in patients with oropharyngeal carcinoma. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div>]]></content:encoded><description>Recent studies of oropharyngeal carcinoma have reported remarkable correlation between integrated human papillomavirus (HPV) viral detection and p16 protein overexpression in tumor cells. These findings led to calls for the substitution of p16 expression for the more demanding HPV testing in clinical practice. The rationale for such practice is largely driven by the simplicity, low cost, and the feasibility of the immunohistochemical (IHC) analysis. There are, however, several caveats that need to be fully considered. These include the subjective nature of IHC evaluation, the variable mechanisms of p16 expression in head and neck squamous cell carcinoma, and the lack of scoring and interpretive criteria. This perspective addresses the conceptual and practical issues associated with the p16 expression analysis and provides a broad outline for its application and evaluation in patients with oropharyngeal carcinoma. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21979" xmlns="http://purl.org/rss/1.0/"><title>Prospective randomized trial of high versus low negative pressure suction in management of chyle fistula after neck dissection for metastatic thyroid carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21979</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Prospective randomized trial of high versus low negative pressure suction in management of chyle fistula after neck dissection for metastatic thyroid carcinoma</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Gaosong Wu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Xiaofei Chang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yun Xia</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wei Huang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Wayne M. Koch</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:20:54.911057-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21979</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21979</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21979</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Negative pressure drainage has been shown to be an effective treatment of chyle fistula. However, the optimal level of negative pressure has not been determined. We therefore conducted a prospective randomized trial to address this issue.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>In all, 21 patients with chyle fistula were randomly assigned to a high negative pressure suction (HNPS) group (−600 mmHg, <em>n</em> = 10) or low negative pressure suction (LNPS) group (−125 mmHg, <em>n</em> = 11). The duration of drain leakage and hospital stay, and the incidence of complications were compared between the 2 groups.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>All patients were successfully treated with conservative management without surgical intervention. The median durations of chyle leakage and hospital stay were significantly shorter in the HNPS group compared with the LNPS group: 4 versus 7 days (<em>p</em> = .0048) and 5 versus 11 days (<em>p</em> = .0107), respectively.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusions</h3><div class="para"><p>Negative suction was demonstrated to be highly effective in the management of chyle fistula, and HNPS appeared to be more efficient than LNPS. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundNegative pressure drainage has been shown to be an effective treatment of chyle fistula. However, the optimal level of negative pressure has not been determined. We therefore conducted a prospective randomized trial to address this issue.MethodsIn all, 21 patients with chyle fistula were randomly assigned to a high negative pressure suction (HNPS) group (−600 mmHg, n = 10) or low negative pressure suction (LNPS) group (−125 mmHg, n = 11). The duration of drain leakage and hospital stay, and the incidence of complications were compared between the 2 groups.ResultsAll patients were successfully treated with conservative management without surgical intervention. The median durations of chyle leakage and hospital stay were significantly shorter in the HNPS group compared with the LNPS group: 4 versus 7 days (p = .0048) and 5 versus 11 days (p = .0107), respectively.ConclusionsNegative suction was demonstrated to be highly effective in the management of chyle fistula, and HNPS appeared to be more efficient than LNPS. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.22013" xmlns="http://purl.org/rss/1.0/"><title>Integrating multiple microarray datasets on oral squamous cell carcinoma to reveal dysregulated networks</title><link>http://dx.doi.org/10.1002%2Fhed.22013</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Integrating multiple microarray datasets on oral squamous cell carcinoma to reveal dysregulated networks</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Zhongyu Liu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yulong Niu</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chao Li</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Yi Yang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Chunfang Gao</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-16T09:20:40.61238-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.22013</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.22013</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.22013</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Oral squamous cell carcinoma (OSCC) is the sixth most common type of carcinoma worldwide. The pathogenic pathways involved in this cancer are mostly unknown; therefore, a better characterization of the OSCC gene expression profile would represent a considerable advance. The public availability of gene expression datasets was meant to obtain new insights on biological processes.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>We integrated 4 public microarray datasets on OSCC to evaluate the degree of consistency among the biological results obtained in these different studies and to identify common regulatory pathways that could be responsible for tumor growth.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>Twelve altered cellular pathways implicated in OSCC and 4 genes altered in the extracellular matrix (ECM) receptor pathway were validated by quantitative real-time polymerase chain reaction (qRT-PCR).</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>Using 4 expression array datasets, we have developed a robust method for analyzing pathways altered in OSCC. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundOral squamous cell carcinoma (OSCC) is the sixth most common type of carcinoma worldwide. The pathogenic pathways involved in this cancer are mostly unknown; therefore, a better characterization of the OSCC gene expression profile would represent a considerable advance. The public availability of gene expression datasets was meant to obtain new insights on biological processes.MethodsWe integrated 4 public microarray datasets on OSCC to evaluate the degree of consistency among the biological results obtained in these different studies and to identify common regulatory pathways that could be responsible for tumor growth.ResultsTwelve altered cellular pathways implicated in OSCC and 4 genes altered in the extracellular matrix (ECM) receptor pathway were validated by quantitative real-time polymerase chain reaction (qRT-PCR).ConclusionUsing 4 expression array datasets, we have developed a robust method for analyzing pathways altered in OSCC. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21962" xmlns="http://purl.org/rss/1.0/"><title>UM-SCC-104: A New human papillomavirus-16–positive cancer stem cell–containing head and neck squamous cell carcinoma cell line</title><link>http://dx.doi.org/10.1002%2Fhed.21962</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">UM-SCC-104: A New human papillomavirus-16–positive cancer stem cell–containing head and neck squamous cell carcinoma cell line</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Alice L. Tang</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Samantha J. Hauff</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">John H. Owen</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Martin P. Graham</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Michael J. Czerwinski</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jung Je Park</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Heather Walline</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Silvana Papagerakis</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jay Stoerker</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Jonathan B. McHugh</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Douglas B. Chepeha</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Carol R. Bradford</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Thomas E. Carey</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Mark E. Prince</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-13T03:02:28.930508-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21962</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21962</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21962</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Original Article</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Few human papillomavirus (HPV)(+) head and neck squamous cell carcinoma (HNSCC) cell lines exist. We established University of Michigan-squamous cell carcinoma-104 (UM-SCC-104), a new HPV(+) HNSCC cell line from a recurrent oral cavity tumor, and characterized it for the presence of cancer stem cells (CSCs).</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods</h3><div class="para"><p>Tumor cells were tested for biomarker expression by immunohistology, and the presence of HPV was assessed by several methods.</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Results</h3><div class="para"><p>UM-SCC-104 has a unique genotype, contains HPV-16, and expresses E6/E7. Inoculation of aldehyde dehydrogenase (ALDH)(+) and ALDH(−) cells in an immunocompromised mouse resulted in tumor growth from the ALDH(+) cells after 6 weeks that recapitulated the histology of the primary, whereas ALDH(−) cells did not produce tumors.</p></div></div><div class="section" id="abs1-4" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>UM-SCC-104, a new HPV-16, CSC-containing HNSCC cell line will aid in studying recurrent HPV(+) tumors. The aggressive nature of this tumor is consistent with high uniform expression of epidermal growth factor receptor (EGFR) and a functionally significant proportion of ALDH(+) CSCs. © 2011 Wiley Periodicals, Inc. <em>Head Neck</em>, 2011</p></div></div>]]></content:encoded><description>BackgroundFew human papillomavirus (HPV)(+) head and neck squamous cell carcinoma (HNSCC) cell lines exist. We established University of Michigan-squamous cell carcinoma-104 (UM-SCC-104), a new HPV(+) HNSCC cell line from a recurrent oral cavity tumor, and characterized it for the presence of cancer stem cells (CSCs).MethodsTumor cells were tested for biomarker expression by immunohistology, and the presence of HPV was assessed by several methods.ResultsUM-SCC-104 has a unique genotype, contains HPV-16, and expresses E6/E7. Inoculation of aldehyde dehydrogenase (ALDH)(+) and ALDH(−) cells in an immunocompromised mouse resulted in tumor growth from the ALDH(+) cells after 6 weeks that recapitulated the histology of the primary, whereas ALDH(−) cells did not produce tumors.ConclusionUM-SCC-104, a new HPV-16, CSC-containing HNSCC cell line will aid in studying recurrent HPV(+) tumors. The aggressive nature of this tumor is consistent with high uniform expression of epidermal growth factor receptor (EGFR) and a functionally significant proportion of ALDH(+) CSCs. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21870" xmlns="http://purl.org/rss/1.0/"><title>Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone</title><link>http://dx.doi.org/10.1002%2Fhed.21870</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Metastatic adenoid cystic carcinoma of the salivary gland responding to cetuximab plus weekly paclitaxel after no response to weekly paclitaxel alone</dc:title><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Miguel Caballero</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Aaron E. Sosa</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Andrea Tagliapietra</dc:creator><dc:creator xmlns:dc="http://purl.org/dc/elements/1.1/">Juan J. Grau</dc:creator><dc:date xmlns:dc="http://purl.org/dc/elements/1.1/">2011-12-05T07:05:56.561434-05:00</dc:date><dc:identifier xmlns:dc="http://purl.org/dc/elements/1.1/">doi:10.1002/hed.21870</dc:identifier><dc:rights xmlns:dc="http://purl.org/dc/elements/1.1/"/><dc:publisher xmlns:dc="http://purl.org/dc/elements/1.1/">John Wiley &amp; Sons, Inc.</dc:publisher><prism:doi xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">10.1002/hed.21870</prism:doi><prism:url xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">http://dx.doi.org/10.1002%2Fhed.21870</prism:url><prism:section xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">Case Report</prism:section><prism:startingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:startingPage><prism:endingPage xmlns:prism="http://prismstandard.org/namespaces/1.2/basic/">n/a</prism:endingPage><content:encoded xmlns:content="http://purl.org/rss/1.0/modules/content/"><![CDATA[<h3 xhtml="http://www.w3.org/1999/xhtml" xmlns:ol="http://www.wiley.com/namespaces/ol/xsl-lib">Abstract</h3><div class="section" id="abs1-1" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Background</h3><div class="para"><p>Adenoid cystic carcinoma (ACC) of the salivary gland frequently develops lung metastases. In cases in which chemotherapy is indicated, resistance is a common phenomenon. New drugs, such as cetuximab, have been chosen to avoid this chemoresistance.</p></div></div><div class="section" id="abs1-2" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Methods and Results</h3><div class="para"><p>A 54-year-old man was diagnosed with ACC of the right submandibular gland. He underwent a submandibular gland resection with adjuvant radiotherapy. Three years later, bilateral lung metastases were diagnosed and treated with various chemotherapy schedules, including paclitaxel without success. We obtained radiographic response, followed by disease stabilization for more than 1 year with the addition of cetuximab to paclitaxel administered at low weekly doses (metronomic schedule).</p></div></div><div class="section" id="abs1-3" xmlns="http://www.w3.org/1999/xhtml"><h3 xhtml="http://www.w3.org/1999/xhtml" xmlns="http://purl.org/rss/1.0/">Conclusion</h3><div class="para"><p>This case demonstrates for the first time a reversion of primary resistance to chemotherapy in ACC that is currently considered chemoresistant by use of a combination of metronomic chemotherapy with new targeted agents such as cetuximab. Metronomic chemotherapy was also well tolerated and achieved long-term response. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</p></div></div>]]></content:encoded><description>BackgroundAdenoid cystic carcinoma (ACC) of the salivary gland frequently develops lung metastases. In cases in which chemotherapy is indicated, resistance is a common phenomenon. New drugs, such as cetuximab, have been chosen to avoid this chemoresistance.Methods and ResultsA 54-year-old man was diagnosed with ACC of the right submandibular gland. He underwent a submandibular gland resection with adjuvant radiotherapy. Three years later, bilateral lung metastases were diagnosed and treated with various chemotherapy schedules, including paclitaxel without success. We obtained radiographic response, followed by disease stabilization for more than 1 year with the addition of cetuximab to paclitaxel administered at low weekly doses (metronomic schedule).ConclusionThis case demonstrates for the first time a reversion of primary resistance to chemotherapy in ACC that is currently considered chemoresistant by use of a combination of metronomic chemotherapy with new targeted agents such as cetuximab. Metronomic chemotherapy was also well tolerated and achieved long-term response. © 2011 Wiley Periodicals, Inc. Head Neck, 2011</description></item><item rdf:about="http://dx.doi.org/10.1002%2Fhed.21928" xmlns="http://purl.org/rss/1.0/"><title>Use of a posterior pedicle nasal septum and floor mucoperiosteum flap to resurface the nasopharynx after endoscopic nasopharyngectomy for recurrent nasopharyngeal carcinoma</title><link>http://dx.doi.org/10.1002%2Fhed.21928</link><dc:title xmlns:dc="http://purl.org/dc/elements/1.1/">Use of a posterior pedicle nasal septum and floor mucoperiosteum flap to resurface the nasopharynx after endoscopic nasopharyngectomy
